 
 Protocol I5F -MC-JSCB(d)  
  Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC -CS4) in Patients 
With Advanced, Refractory Breast or Prostate Cancer  
 
 
[STUDY_ID_REMOVED]   
Approval Date: 10- Nov-2016 
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 1
LY3022855 (IMC -CS4)1.Protocol I5F-MC-JSCB (d)
Phase 1 Study  to Identify  the Immunomodulatory  Activity  
of LY3022855 (IMC -CS4) in Patients with Advanced , 
Refractory Breast or Prostate Cancer
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_105304]3022855 (IMC -CS4) , unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries .  This document and its associated attachments 
are subject to [LOCATION_002] Freedom of Info rmation Act (FOIA) Exemption 4.
LY3022855 (IMC -CS4)
This Phase 1 study is a single -center, open -label, nonrandomized, noncontrolled study o f 
intravenous LY3022855 (IMC -CS4) in patients with advanced , refractory breast or prostate 
cancer .
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_11007]: 09 April 2014 .
Amendm ent (a) Electronically Signed and Approved by [CONTACT_229490] 05 September 2014.
Amendm ent (b) Electronically Signed and Approved by [CONTACT_229490] 18 Ma rch 2015 .
Amendm ent (c) Electronically Signed and Approved by [CONTACT_229490] 25 September 2015 .
Amendm ent (d) Electronically Signed and Approved by [CONTACT_82356].
Approval Date: 10-Nov-2016 GMT
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 2
LY3022855 (IMC -CS4)2.Synopsis
This Phase 1 study  is a single -center, open -label, nonrandomized, noncontrolled study  of
intravenous LY3022855 (IMC -CS4) in patients with advanced , refractory breast or prostate
cancer.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 3
LY3022855 (IMC -CS4)3.Table of Contents
Phase 1 Study  to Identify the Immunomodulatory  Activity  of 
LY3022855 (IMC -CS4) in Patients with Advanced , Refractory
Breast or Prostate Cancer
Section Page
1. Protocol  I5F-MC-JSCB(d)  Phase 1 Study  to Identi fy the 
Immunomodulatory  Activit y of LY3022855 (IMC -CS4) in Patients 
with Advanced, Refractory  Breast or Prostate Cancer ......................................................... [ADDRESS_753870] ives........................................................................................... 17
5.2.3. Exploratory  Objectives ......................................................................................... 17
5.3. General Introduction to LY3022855 ............................................................................. 17
5.3.1. Definit ion of Immunomodulatory  Change ............................................................ 18
5.4. LY3022855 –Nonclinical and Clinical Experience ...................................................... 18
5.4.1. Nonclinical Pharmacokinetics .............................................................................. 18
5.4.2. Nonclinical Pharmacokinetic/Pharmacodynamic Model ....................................... 19
5.4.3. Clinical Pharmacokinet ics.................................................................................... 19
5.4.4. Nonclinical Toxico logy........................................................................................ 21
[IP_ADDRESS]. Single-Dose Toxi city...................................................................................... 22
[IP_ADDRESS]. Repeat -Dose Toxicit y..................................................................................... [ADDRESS_753871] an........................................................................................................... 30
6.1. Study  Popul ation.......................................................................................................... 30
6.1.1. Inclusio n Cri teria.................................................................................................30
6.1.2. Exclusio n Cri teria................................................................................................ 33
6.2. Summary  of Study  Design ............................................................................................ 34
6.2.1. Study  Com pletion and End of Trial ...................................................................... 37
6.2.2. Continued Access Period ...................................................................................... 37
6.3. Discontinuati ons .......................................................................................................... 38
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 4
LY3022855 (IMC -CS4)6.3.1. Discontinuati on of  Patients................................................................................... 38
6.3.2. Discontinuati on of  Study  Sites............................................................................. 39
6.3.3. Discontinuati on of  the Study ................................................................................ 39
7. Treatment .......................................................................................................................... 40
7.1. Materi als and Supplies .................................................................................................40
7.2. Study  Drug Administration .......................................................................................... 40
7.2.1. Dose Adjustments and Delays .............................................................................. 41
[IP_ADDRESS]. Infusio n-Related Reactions ............................................................................. 42
[IP_ADDRESS]. Other Adverse Events ..................................................................................... 43
[IP_ADDRESS].1. Immune-Related Adverse Events (irAEs) .................................................. [ADDRESS_753872] ion......................................................................................................................... 46
8.1. Safety Evaluat ions........................................................................................................ 46
8.1.1. Safety Data Collection and Review ...................................................................... 46
8.1.2. Adverse Events .................................................................................................... 46
[IP_ADDRESS]. Serious Adverse Events .................................................................................. 48
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting ..................................... 49
[IP_ADDRESS].1. Prior to Administrati on of  Study  Drug(s) .................................................. 49
[IP_ADDRESS].2. On Therapy ............................................................................................... 49
[IP_ADDRESS].3. 30- Day Follow-Up Visi t........................................................................... 49
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 50
[IP_ADDRESS]. Summary  of AE/SAE Reporti ng Guidelines ................................................... 50
8.1.3. Other Safet y Measures ......................................................................................... 51
[IP_ADDRESS]. Electrocardiograms ......................................................................................... [ADDRESS_753873] ing..................................................................................... 53
8.2.1. Samples for Study  Qualificat ion and Healt h Monit oring ....................................... 53
8.2.2. Samples for Drug Concentration Measurements 
Pharmacokinet ics/Pharmacodynamics .................................................................. 54
[IP_ADDRESS]. Pharmacokinet ic Samples ............................................................................... 54
[IP_ADDRESS]. Pharmacodynamic Samples ............................................................................ 54
8.2.3. Samples for Tailoring Bio markers ........................................................................ 55
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 5
LY3022855 (IMC -CS4)8.2.4. Samples for Immunogenicit y Research .................................................................56
8.3. Efficacy Evaluation ...................................................................................................... 56
8.4. Procedure/Sampling Co mpliance .................................................................................. 58
9. Data Management Methods ............................................................................................... 59
9.1. Data Qualit y Assurance ................................................................................................ 59
9.2. Data Capture Systems .................................................................................................. 59
9.2.1. Case Report Form ................................................................................................ 59
9.2.2. Ancillary Data ...................................................................................................... 59
10. Data Analyses ................................................................................................................... 61
10.1. General Considerations ................................................................................................ 61
10.2. Patient Disposi tion....................................................................................................... 62
10.3. Patient Characteri stics.................................................................................................. 62
10.4. Safety Analyses ............................................................................................................ 62
10.5. Pharmacokinet ic Analyses ............................................................................................ 63
10.6. Pharmacodynamic Analyses ......................................................................................... 63
10.7. Pharmacokinet ic/Pharmacodynamic Analyses .............................................................. [ADDRESS_753874] igator Informat ion....................................................................................... 66
11.3.2. Protocol  Signatures .............................................................................................. 66
11.3.3. Final Report Signature ......................................................................................... 66
12. References ........................................................................................................................ 67
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 6
LY3022855 (IMC -CS4)Listof Table s
Table Page
Table JSCB.1. Summary  of LY3022855 Dosages in Study  JSCB .......................................... 28
Table JSCB.2. General Dose Reduction Guidelines ............................................................... 41
Table JSCB.3. Toxicit ies for Which Dose Adjustments and Delays Apply ............................ 42
Table JSCB.4. Adverse Event and Serious Adverse Reporting Guidelines for 
Study JSCB ................................................................................................... 51
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 7
LY3022855 (IMC -CS4)List of Figures
Figure Page
Figure JSCB.1. Individual observed clearance versus patient body  weight (upper panel ) 
and LY3022855 dose (lower panel) for Studies JSCA and JSCB. .................. 21
Figure JSCB.2. CD14dimCD16bright(relative percentage of CD45+HLA -DR+CD14+) in 
the blood of patients from Study  JSCA. ......................................................... 27
Figure JSCB.3. Study  JSCB study  design. .............................................................................. 35
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 8
LY3022855 (IMC -CS4)List of Attachments
List of Protocol Attachments
Attachment Page
Attachm ent 1. Protocol  JSCB Study  Schedules ..................................................................... [ADDRESS_753875] Criteria 1.1 ............................................................. 103
Attachm ent 10. Protocol  JSCB Gui delines for the Management of Immune -Related 
Adverse Events ............................................................................................ 110
Attachm ent 11. Protocol  JSCB Protocol  Amendment I5F -MC-JSCB(d) Summary  Phase 
1 Study  to Identify the Immunomodulatory  Activity of LY3022855 
(IMC -CS4) in Patients with Advanced, Refractory  Breast or Prostate 
Cancer ......................................................................................................... 115
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 9
LY3022855 (IMC -CS4)4.Abbreviations and Definitions
Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product thatdoes not necessarily have a causal 
relatio nship with this treatment.  An adverse event (AE) can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of medicina l (investigational) product, whether or not 
related to the medicinal (investigational) product.
ALT alanine aminotrans ferase (also known as alanine transaminase)
AP alkaline phosphatase
ASCO American Society of Clinical Oncology
assent Agreement from a minor or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and potential risks involved in 
participating in a study (required by [CONTACT_80522] [IRBs]/ethical 
revie w boards [ERBs]).
AST aspartate aminotrans ferase (also known as aspartate transaminase)
AUC (0-168hr) area under the plasma concentration -time curve from time zero to 168 hours
AUC 0-∞ area under the plasma concentration -time curve from time zero to infinity
audit A systematic and independent examination of the study -related activities and documents 
to determine whether the evaluated study -related activities were conducted, and the data 
were recorded, analyzed, and accurately reported according to th e protocol, applicable 
standard operating procedures (SOPs), good clinical practice (GCP), and the applicable 
regulato ry requirement(s).
BLQ below the quantifiable lower limit of the assay
CnWn Cycle and Week numbers
C168hr concentration at 168 hours
Ctrough trough concentration (predose concentration)
CA 15-
3 cancer antigen 15 -3
CBC complete blood count
CEA carcinoembryonic antigen
CK creatine kinase (also known as creatine phosphokinase)
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 10
LY3022855 (IMC -CS4)CL total body clearance
Cmax maximum plasma concentration
CNS central nervous system
collection database A computer database where clinical trial data are entered and validated.
companion 
diagnosticAn in vitro diagnostic device (assay or test) that provides information that is essential for 
the safe and effective use of a corresponding therapeutic product.
complaint Any written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, purity, durability, reliability, safety, effectiveness, or performance of a 
drug o r drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements 
defined by [CONTACT_480749].  Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time poi nt, depending on the steps 
required to obtain confirmed results.
continued access 
periodThe period between study completion and end of trial during which patients on study 
treatment who continue to experience clinical benefit and no undue risks may continue to 
receive study treatment until one of the criteria for discontinuation is met .
CR complete response
CRF/eCRF case report form/electronic case report form:  Sometimes referred to as clinical report 
form, a printed or electronic form for rec ording study participants’ data during a clinical 
study, as required by [CONTACT_760].
CRP clinical research physician
CRPC castrate -resistant prostate cancer
CRS clinical research scientist
CS7 A recombinant rat IgG1 antibody specific for murine CSF-1R, used as a surrogate 
antibody to evaluate the effects of targeting CSF -1R on macrophages in murine models of 
cancer.
CSF colony-stimulating factor
CSF-[ADDRESS_753876] computed tomography
CTCAE Common Terminology Criteria for Adverse Events
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 11
LY3022855 (IMC -CS4)DCR disease control rate
DLT dose-limiting toxicity
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
ELISA enzyme-linked immunosorbent assay
end of trial End of trial is the date of the last visit or last scheduled procedure for the last patient.
enroll Patients who are enrolled in the trial are those who have been assigned to a treatment and 
have received at least one dose of study treatment.
enter Patients who are ente red in the trial are those who have signed the informed consent form 
directly or through their legally acceptable representatives.
ERB/IRB ethical review board/institutional review board: A board or committee (institutional, 
regio nal, or national) composed of medical and nonmedical members whose 
responsibility is to verify that the safety, welfare, and human rights of the patients 
participating in a clinical study are protected.
FACS fluorescence -activated cell sorting (a type of flow cytometr y)
FOIA [LOCATION_002] Freedom of Information Act
GCP good clinical practice
GERD gastroesophageal reflux disease
GnRH gonadotropin -releasing hormone
HIV human immunodeficiency virus
IB Investigator’s Brochure
IC50 half maximal inhibitory concentration
ICF informed consent form
ICH International Conference on Harmonisation
IgG1 immunoglobulin G, subclass 1
IL interleukin
IMC-CS4 sponsor code name [CONTACT_574468] G, subclass 1 (IgG1) 
monoclonal antibody targeted to the colony -stimulating factor -1 receptor (CSF -1R); also 
known as LY3022855
INF interferon
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 12
LY3022855 (IMC -CS4)informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
patient’s decision to participate.  Informed consent is documente d by [CONTACT_3553] a written, 
signed and dated informed consent form (ICF) .
interim analysis An analy sis of clinical study data that is conducted before the final reporting database is 
autho rized for data lock .
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the inves tigator is the responsible 
leader of the team and may be called the principal investigator.
irAE immune- related adverse event
irRECIST immune- related RECIST (Response Evaluation Criteria in Solid Tumors)
I.V. intravenous(ly)
Kd dissociation constant
legal representative An individual, judicial, or other body authorized under applicable law to consent on 
behalf of a pros pective patient, to the patient’ s participation in the clinical study.
Lilly Safety S ystem Global safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system.
LDH lactate dehydrogenase
LY3022855 Lilly  code name [CONTACT_574468] G, subclass 1 (IgG1) 
monoclonal antibody targeted to the colony -stimulating factor -1 receptor (CSF -1R); also 
known as IMC -CS4
LVEF left ventricular ejection fraction
monitor A person responsible for ensuring the investigator site complies with the monitoring plan, 
applicable local standard operating procedures ( SOPs ), if any, and global Medical SOPs.  
Monitors are trained on the investigational product(s), the protocol, informed consent 
form (ICF) , any  other written information provided to subjects, relevant SOPs, 
International Conference on Harmonisation Good Clinical Practice guidelines (ICH -
GCP), and all applicable laws (for example, privacy and data protection) and regulations. 
MRI magnetic resonance imaging
MSD Meso Scale Discover y
NCI Natio nal Cancer Institute
NK natural killer (cells)
NOAEL no-observed -adverse -effect level
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 13
LY3022855 (IMC -CS4)NYHA [LOCATION_001] Heart Association
open-label A study  in which there are no restrictions on knowledge of treatment allocation ;therefore ,
the investigator and the study participants are aware of the drug therapy received during 
the study .
ORR overall response rate
OS overall survival
patient A subject with a defined disease.
PCWG2 Prostate Cancer Clinical Trials Working Group
PD pharmacodynamic or progressive disease
Note -“Pharmacodynamic” and “progressive disease” are spelled out throughout this 
protocol, except as follows:  The abbreviation “PD” appears only in the study design 
figure and in tables in the protocol attachments . In these locations, the abbreviation is 
clearly defined.
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic (s)
PR partial response
Q2W once every [ADDRESS_753877] of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial. In this study, screening 
involves invasive or diagnostic procedures and/or tests (for example, x -rays, blood 
draws).  For this type of screening, informed consent for these screening procedures 
and/o r tests shall be obtained; this consent may be separate from obtaining consent for the 
study.
screen failure A patient who does not meet one or more criteria required for participation in a trial .
sponsor The party who takes responsibility for the initiation, management and/or financing of a 
clinical study.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 14
LY3022855 (IMC -CS4)study completion This study will be considered compl etewhen 16 evaluable patients are attained .
S[LOCATION_003]R suspected unexpected serious adverse reactions
t1/[ADDRESS_753878] upper limit of normal
Vss volume of distribution at steady state
WOCBP women of childbearing potential
I5F - MC- JSCB (d)  Phase1  Onco logy  P ro toco l Page  15
LY3022855( IMC - CS4 )Phase  1  S tudy to  Iden t i fythe  Immunomodu la to ry  A c t iv i ty o f  
LY3022855  ( IMC - CS4 )  in  Pa t ien ts  w i th  Advanced,  Re f rac to ry
B reas t  o r  P ros ta te  Cance r
5 .In t roduc t ion
5 .1 .Ra t iona le  and  Jus t i f ica t ion  fo r  the  S tudy
CC ICo lony - s t im u l a t i n g  f a c t o r - 1  r e c e p t o r  (CSF - 1R )  i s  a  ty r o s i n e  k i n a s e  r e c e p t o r  e x p r e s s e d  
s e l e c t i v e l y  o n  m a c r o p h a g e  a n d  g r a n u l o c y t e  c e l l  l i n e a g e s  i n  n o rm a l  i n d i v i d u a l s  a n d  o n  s om e
tum o r  c e l l s  i n  c a n c e r  (K a c i n s k i  1 9 9 5 ;  S a sm on o  e t  a l .  2 0 0 3 ) .   U p o n  c o l o n y -s t im u l a t i n g  f a c t o r -1  
(CSF - 1 )  o r  i n te r l e u k i n - 34  ( IL -3 4 )  b i n d i n g  t o  CSF - 1R ,  CSF - 1R  a n d  d ow n s t r e am  s i g n a l i n g  
m ol e c u l e s  a r e  p h o s p h o r y l a t e d  a n d  a c t i v a t e d ,  r e s u l t i n g  i n  t h e  r e g u l a t i o n  o f  pr o l i f e r a t i o n ,  
d i f f e r e n ti a t i o n ,  s u r v i v a l ,a n d  m i g r a t i o n  o f  m ono cy t e s /m a c r o p h a g e s  (B o u r e t t e  a n d  R o h r s c h n e i d e r  
2 0 0 0 ;  P i x l e y  a n d  S t a n l e y  2 0 0 4 ;  L i n  e t  a l .  2 0 0 8 ) .   I n  c a n c e r ,  i n c r e a s e d  i n f i l t r a t i o n  o f  m a c r o p h a g e s  
w it h i n  a n d  s u r r o u n d i n g  t h e  t um o r  m a s s  c o r r e l a t e s  w ith  i n c r e a s e d  t um o r  i n v a s i v e n e s s  a n d  g r ow t h  
(Now i ck i  e t  a l .  1 9 9 6 ;  L ew i s  a n d  P o l l a r d  2 0 0 6 ) ,  a n d  d e p l e t i n g  t h e s e  t um o r - a s s o c i a t e d  
m a c r o p h a g e s  r e s u l t s  i n  d e c r e a s e d  g r ow t h  o f  e x p e r im e n t a l  t um o r s  i n  m i c e  (L i n  e t  a l .  2 0 0 1,2 0 0 6 ) .   
W h i l e  CSF- 1R  l e v e l s  a r e  i n f r e q u e n tl y  i n c r e a s e d  i n  t um o r s  c om p a r e d  w i t h  a n a l o g o u s  n o rm a l  
t i s su e s ,  in c r e a s ed  CSF -1  i n  s e r a  o f  c a n c e r  p a t i e n t s  i s  m o r e  f r e q u e n t l y  o b s e r v e d  a n d  i s  a s s o c i a t e d  
w ith  p o o r  p r o g n o s i s  a n d  s e v e r i t y  o f  d i s e a s e  i n  m u l t i p l e  c a n c e r s ,  i n  p a r t i c u l a r  p r o s t a t e  a n d  b r e a s t  
c a n c e r s  (L aw i c k i  e t  a l .  2 0 0 6 ;  M r o c z k o  e t  a l .  2 0 0 7 ;  I d e  e t  a l .  2 0 0 8 ;  Z h u  e t  a l .  2 0 0 8 ) .   T h e s e  d a t a  
s u g g e s t  t h a t  t a r g e t i n g  CSF - 1R  h a s  po t en t i a l  to  l im i t  c an c e r  p rog r e s s ion .
LY 3 0 2 2 8 5 5  (a l so  knowna sIMC - CS 4)i s  a  r e c om b i n a n t  h um a n  m o n o c l o n a l  a n t i b o dy  o f  th e  
im munog lo b u l i n  G ,  s u b c l a s s  1  ( I gG 1 )  t a r g e t i n g  CSF -1R .   LY 3 0 2 2 8 5 5p r e v e n t s  t h e  l i g a n d s  CSF -1  
a n d  IL - 34  f rom  b ind ing  to  CSF - 1R   
,  and  in  th i s  w ay  i nh ib i t s  CSF - 1R  a c ti v a t i o n .   CSF -1R  
a c t i v a t i o n  i s  r e q u i r e d  f o r  p r o p e r  f u n c t i o n i n g  a n d  s u r v i v a l  of  tum o r- a s s o c i a t e d  m a c r o p h a g e s .   
T h u s ,  b y  b l ock ing  CSF - 1R  a c ti v a t i o n ,   
 
 
 
 
 
 
 
 
In t e r a c t i o n s  b e tw e e n  t h e  i n n a t e  a n d  a d a p ti v e  imm u n e  s y s t em s  a r e  c r i t i c a l  f o r  no rm a l  immun e  
f u n c t i o n  a n d  a l s o  i n  t h e  t um o r  m i c r o e n v i r o nm e n t .   F o re x am p l e ,  h i g h  n um b e r s  o f  
tum o r- a s s o c i a t e d  m a c r o p h a g e s  i n v e r s e l y  c o r r e l a t e  w i t h  i n f i l t r a t i o n  b y  CD 8+  T  c e l ls .  CC I
I5F - MC- JSCB (d)  Phase1  Onco logy  P ro toco l Page  16
LY3022855( IMC - CS4 )A n ti - CSF- 1R  t r e a tm e n t  t h a t  l im i t s  tum o r- a s s o c i a t e d  m a c r o p h a g e s  e n h a n c e s  CD 8+  T -c e l l
i n f i l t r a t i o n ,  l e a d i n g  t o  d e c r e a s e s  i n  t um o r  b u r d e n  (D eN a r d o  e t  a l .  2 0 1 1 ) .   M o r e o v e r ,  i n  a  
s y n g e n e i c  b r e a s t  c a n c e r  m o d e l ,  d e p l e t i o n  o f  CD 8+  T  c e l ls  r end e r ed  t r e a tm en t  w i th  CS7  le s s  
e f f i c a c i o u s ,  i n d i c a t i n g  i n t e rp l ayb e tw e e n  m a c r o p h a g e  a c t i v i ty  a n d  T -c e l li n f i l t r a t i o n .   T h u s ,  
know l e d g e  n o t  o n l y  o f  t h e  m a c r o p h a g e  s u b p o p u l a t i o n  bu t  a l so  o f  th e  T -c e l lsub s e t  m ay  a f f e c t  th e  
e f f i c a c y  o f  LY 3 0 2 2 8 5 5t r e a tm e n t  i n  p a t i e n t s .
 
 
I n  a d d i t i o n ,p h a rm a c o d y n am i c  r e s u l ts  f rom  t h e  o n g o i n g  P h a s e  1  
do s e - e s c a l a t i o n  s tudy  o f  LY 3 0 2 2 8 5 5,  S tudy  I5F - IE - JSCA  ( a l s o  k n ow n  a s  IMCL  CP 2 4 - 1 0 0 1 ;  
h e r e a f t e r  r e f e r r e d  t o  a s  JSCA ) ,  h a v e  s u g g e s t e d  t a r g e t  e n g ag em e n t  a n d  b i o l o g i c  a c ti v i t y  a t  a  
do s a g eo f  1 .25m g / k g  o n c e  w e e k l y .    
T h e  s p o n s o r ,  m o n i t o r ,  a n d  i n v e s ti g a t o r s  w i l l  p e r f o rm  t h i s  s t u d y  i n  c om p l i a n c e  w i t h  t h e  p r o t o c o l ,  
g o o d  c l i n i c a l  p r a c ti c e  (GCP )  a n d  I n t e r n a t i o n a lC o n f e r e n c e  o n  H a rm o n i s a ti o n  ( ICH )  g u i d e l i n e s ,  
and  app l i c ab l e  r egu l a to ry  r equ i r em en t s .
5 .2 .Ob jec t ives
5 .2 .1 .P r ima ry  Ob jec t ive
Th e  p r im a ry ob j e c t i v e  o f  t h i s  s t u d y  i s  to  d o c um e n t  t h e  imm u n om odu l a to ry  a c t i v i t yo f  
LY 3 0 2 2 8 5 5t r e a tm e n t  i n  p a ti e n ts  w i th  a d v a n c e d ,  r e f r a c to ryb r e a s t  o rp r o s t a t e  c a n c e rs ,  a c c o r d i n g  
toth e  f o l l ow i n g  m e a s u r e s :
 C h a n g e s  f r om  b a s e l i n e  o v e r  t im e  i np e r i ph e r a l  b l ood  imm u n e  c e l l  s u b s e t s ,a s  d e t e rm i n e d
b y  f l ow  cy tom e t r i c  a n a l y s i s  u s i n g  a n  a n t ibody  p an e l ,and  th a t  m ay  i n c l u d e  b u tno t  b e  
l im i t e d  t o  t h e  f o l l o w i n g  m a r k e r s :L i v e- D e ad ,  CD3 ,  CD4 ,  CD8 ,  CD 1 4 ,  CD 1 6 ,  F o xP 3 ,  
PD-1 ,  K i- 67 ,  CTLA - 4 ,  T IM - 3 ,  LAG - 3 ,  a n d  ICOS .
CC I
C h a n g e s  f r om  b a s e l i n e  o v e r  t im ei n  s e r um  cy tok in e s ,  a s  d e t e rm i n e d  b y  M e so  S c a le  
D is cov e ry  (MSD )  m u l tip l ex  cy tok in e  immuno a s s ay  t e chno l ogyo r  e n z ym e - l i n k e d  
imm u n o s o r b e n t  a s s a y  ( EL ISA) ,a n d  t h a tm ay  i n c l u d eb u tn o t  b e  l im i t e d  t oth e  f o l l o w ing :   
CSF- 1 ,  IFN - γ ,  IL -1β ,  IL - 2 ,  IL - 4 ,  IL - 6 ,  IL - 8 ,  IL - 10 ,  IL - 12p70 ,  IL - 13 ,  IL -3 4 ,  a n d  tum o r  
n e c ro s i s  f a c to ra l p h a  (TNF-α ) .CC I
I5F - MC- JSCB (d)  Phase1  Onco logy  P ro toco l Page  17
LY3022855( IMC - CS4 )5 .2 .2 .Seconda ry  Ob jec t ives
T h e  s e c o n d a r y ob j e c t iv e s  o f  th i s  s tudy  a r e :
 To  e v a l u a t eth e  s a f e t y  and  tox i c i ty  p ro f i l e  o f  LY3022855,a s  a s s e s s e d  b yth e  Comm on  
T e rm i n ol o gy  C r i t e r i a  f o r  Adv e r s e  Ev en t s ,  v e r s i on  4 .0(CTCAE  v 4 . 0 )
 To  a s s e s sth e  p h a rm a c o k i n e t i c  (PK )  s e rum  con c en t r a t i o n so f  LY 3 0 2 2 8 5 5
 To  d o c um e n t  a n ti t um o r  a c t i v i ty ,  p e r  R e s p o n s eEv a lu a ti o n  C r i t e r i a  in  So l i d  Tum o r s ,  
v e r s i on  1 .1  (REC IST  1 .1 ) (E i s enh au e r  e t  a l .  2009 ) a n d  imm u n e - r e l a t ed  REC IST  
( i rRE C IST )( N i s h i n o  e t  a l .  2 0 1 3)(N o t e :   I f  a  p a t i e n t  h a s  c o n f i rm e d  p r o g r e s s i v e  d i s e a s e  
p e r  REC IST  [ADDRESS_753879] ,  t h e  p a t i e n t  w i l l  b e  c o n s i d e r e d  t o  h a v e  n o t  
p r o g r e s s e d . )
 Toa s s e s s  t h e  d e v e l o pm e n t  o f  a n t i b o d i e s  a g a i n s t  LY 3 0 2 2 8 5 5( imm u n o g e n i c i t y ),  a s  
a s s e s s ed  bya  v a l i d a t e d  imm u n o g e n i c i t y  a s s ay
5 .2 .3 .Exp lo ra to ryOb jec t ives
T h e  exp lo r a to ryob j e c t iv e s  o f  th i s  s tudy  a r e :
 To  e x p l o r e  s e rum  b i om a r k e r sth a t  m ay  b e  r e l ev an t  to  th e  m e c h a n i sm  of  a c t i on  o f  
LY 3 0 2 2 8 5 5,  
 To  e x p l o r e  th e  p h a rm a c o d y n am i c  e f f e c t s  o f  LY3022855on  t i s s u e  b i o m a r k e r s ,  u s i n g
f l a s h - f r o z e n  b a s e l i n e  a n d  po s t t r e a tm en t  tum o r  b i op s i e s
 T o  a s s e s s  a n ti t um o r  a c t i v i t y  i n  b o n e ,p e r  th e  P r o s t a t eC a n c e r  C l i n i c a l  T r i a l s  W or k i n g  
G r o u p  (PCWG 2 )  (S c h e r  e t  a l .  2 0 0 8 )c r i t e r i a
5 .3 .Gene ra l  In t roduc t ion  to  LY3022855
LY 3 0 2 2 8 5 5i s  a  r e comb i n an t  hum an  m ono c l on a l  an t ibody  o f  IgG 1  th a t  t a r g e t sCSF-1R ,  a  
ty r o s i n e  k i n a s e  r e c e p t o r  e x p r e s s e d  s e l e c t i v e l y  o n  m a c r o p h a g e  a n d  g r a n u l o c y t e  c e l l  l i n e a g e s  i n  
no rm a l  i n d i v i d u a l s  a n d  o n  t um o r  c e l l s  i n  c a n c e r  (K a c i n s k i  1 9 9 5 ;  S a sm ono  e t  a l .  2003 ) .  
The  p r e s e n tt r i a l  w i l l  l ook  sp e c i f i c a l ly  a t  th e  immunomodu l a to ry  a c t i v i t y  o f  LY 3 0 2 2 8 5 5i n  
p a t i en t s  w i th  a d v a n c e d  b r e a s t  o rp r o s t a t e  c a n c e rr e f r a c to ry  o r  in to l e r an t  to  a t  l e a s t  on e  p r i o r  
th e r apy  f o r  th e i r  c a n c e r .
R e f e r  t o  S e c t i o n 5 .1f o r  a  r e v i ew  o f  t h e  l i t e r a t u r e  r e l e v a n t  t o  t h i s  s t u d y .   R e f e r  t o  S e c t i o n5 .4 .5CC I
f o r  a  summ a ry  o f  p r i o r  c l i n i c a l  f i n d i n g s  r e l e v a n t  t o  t h e  p r e s e n t  t r i a l .CC I
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 18
LY3022855 (IMC -CS4)5.3.1. Definition of Immunomodulatory Change
Immunomodulatory  change is the capacit y to modify , regulate ,or potentiate one or more 
immune funct ions by [CONTACT_574420] y or rati os or changes in immune or 
inflammatory  cytokine l evels. Data from the sponsor’s preclinical animal studies and the 
literature (DeNardo et al. 2011) highlight the importance of T cell s in anti-CSF-1Rresponse s, 
illustrating the necessit y of studying this interaction further.
The present study will evaluate changes in immune function in patients with advanced, refractory  
breast orprostate cancer by [CONTACT_574421]4, CD8, regulatory  T cell s,and myelo id cel ls in the peripheral bl ood.  In 
addition, immune funct ion will be evaluated through assessments of specific immune cy tokines 
in peri pheral bl ood,such as IL -[ADDRESS_753880] ion.
5.4. LY3022855 –Nonclinical and Clinical Experience
5.4.1. Nonclinical Pharmacokinetics
The pharmacokinet ics of LY3022855 were eval uated in mice administered 20 mg/kg and in
cyno molgus monkeys at dose levels that ranged from 10 to 180 mg/kg . The PK of LY3022855
incyno molgus monkeys was characterized by a relatively long serum half -life (t 1/2) after single
(183-275 hours) or mult iple doses (158- 470 hours); these half -lives were substant ially longer
than that observed in CD -1 mice (110 hours ). Accumulat ion (approximately  2-fold) of 
LY3022855 was evident after repeated once- weekly dosing in mo nkeys, suggest ing that 
accumulat ion may similarly occur in humans, depending on the frequency of dosing. The 
estimated vo lume of distribut ion of LY3022 855in monkeys (approximately 29 -64 m L/kg) 
indicated that LY3022855 was not substant ially distributed bey ond the vasculature. In the 
cyno molgus monkey studi es,LY3022855 serum  exposures were generally  proporti onal to the 
increases in dose from 10 to 180 m g/kg and no sex differences were observed.
The concentration of serum CSF -[ADDRESS_753881] dose l evels (10 or 20 m g/kg). CSF-1 levels
were generally  sustained throughout the sampling period. However, in the repe at-dose
cyno molgus monkey study , the concentrati on of  CSF -1 began to decrease in so me animals fro m
the low-(20 m g/kg) and middle -(60 m g/kg) dose groups during the recovery  period.
Formal studies to characterize the metabo lism and disposit ion of LY3022855 have not been
conducted. As a monoclonal ant ibody , LY3022855 will be largely confined to the extracellular
space, which is supported by  [CONTACT_574422]3022855 . No formal metabo lism studi esof LY3022855 have been performed 
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 19
LY3022855 (IMC -CS4)because the catabo lism o f antibodies by [CONTACT_574423] m etabo lic degradat ion of these mo lecules are not warranted.
For details on the nonclinical PK of LY3022855 , refer to Secti on 5 of the current Investigator’s 
Brochure ( IB).
5.4.2. Nonclinical Pharmacokinetic/Pharmacodynamic Model
One of t he main pharmaco logical effect sof LY3022855 proposed to underlie the inhibit ion of 
cancer progression is the deplet ion of tum or-associated macrophages.  To model this effect and 
estimate the minimum effect ive blood level required to achieve significant ant itumor effects, 
cancer m odels established in mice were utilized.  However, since LY3022855 does not bind to 
murine CSF -1R, a sur rogate antibody , CS7, was developed and utilized in order to examine 
PK/pharmacodynamic relat ionships.  The binding affinit y of CS7 to murine CSF- 1R 
(dissociati on constant [ Kd] = 0.13nM) is 6-fold greater than that of LY3022855 to hum an CSF -
1R (K d=0.8nM) .  However, com parable potencies of the ant ibodies were observed in cell -based 
assays o f inhibit ion of CSF -1-induced phosphorylation (IC 50= 0.3nM for both antibodies), 
monocy te different iation (IC 50=0.3nM vs 0.25nM for CS7 and LY3022855 , respectively ), and 
inhibit ion of monocy te proliferat ion (IC 50 = 0.13nM or 0.1nM for CS7 and LY3022855 , 
respectively ).  Therefore, CS7 and LY3022855 were anticipated to have similar pharmaco logical 
effects in vivo at similar concentrations.  Hence, CS7 was utilized in ani mal m odels to di rectly 
predi ct the trough serum LY3022855 levels necessary  to achi eve relevant efficacy in human 
subjects .
Based on these assumpt ions, to estimate target serum concentrations for efficacy in init ial 
clinical invest igations, trough concentra tions associated wi th efficacy  were determined in human 
breast cancer HCC -1954 and human leukemia NKM -1 models established in mice.  LY3022855
was evaluated in the leukemia model established following intravenous ( I.V.)injection o f 
CSF-1R-expressing NKM -1cells.  The rat surrogate, CS7, was used in the breast cancer model 
established fo llowing subcutaneous injection of CSF -1R-negative HCC -[ADDRESS_753882] 
of LY3022855 , as efficacy  was achieved at m ean trough concentrations down to 0.2 µg/mL. For 
CS7, notably higher doses and concentrations were required to inhi bit human HCC -[ADDRESS_753883] 
cancer tum or growth, as a mean trough concentration of 425 µg/m L was associ ated wi th 
efficacy .
5.4.3. C linical Pharmacokinetics
A
sof 28 January  2016, the clinical experience of LY3022855 PK co mprised 27 pati ents enrolled 
in Study  JSCA (0.3 m g/kg once weekly  [QW] [n=4], 0.6 mg/kg QW [n=3], 1.25 m g/kg QW 
[n=5], 1.25 m g/kg once every  2 weeks [ Q2W ] [n=9], and 2.5 mg/kg QW [n=6]), and 14 pati ents 
enrolled in Study JSCB (1.25 m g/kg Q2W [n=9]and 1mg/kg on Weeks 1, 2, 4, and 5 of every 
6-week cy cle [n=5]).
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 20
LY3022855 (IMC -CS4)LY3022855 in cancer patients exhibited moderate total body  clearance (CL) (mean values on 
Day 1 ranged from  0.0378 to 0.0651 L/h), low volume of distribut ion at steady  state (V ss) (mean 
values on Day 1 ranged fro m 2.85 to 4.93 L) ,and moderate t 1/2(mean values on Day  1 ranged 
from 30.8 to 92.2 hours).
LY3022855 CL appeared to be nonlinear with respect to LY3022855 concentration, where
higher doses of LY3022855 tended to exhibit lower CL values. However, this apparent 
nonlinearit y was confounded by  [CONTACT_574424] (BLQ ),which could artificially inflate the calculated CL at 
lower doses.
An apparent lack o f relationship between pat ient body  weight and LY3022855 CL 
(Figure JSCB .1, upper panel ) resul ted in an amended dose -escalat ion plan for Study  JSCA ,to 
evaluate the safet y, PK, and immunogenicit y of LY3022855 using a f ixed-dosing approach ( that 
is, mg as opposed to mg/kg).
The clinical PKof LY3022855 are described in greater detail in Section 6.1 of the IB.

I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 21
LY3022855 (IMC -CS4)Abbreviations:  N = number of patients treated; QW = once weekly; Q2W = once every 
2 weeks.
Figure JSCB .1. Individual observed clearance versus patient body weight (upper 
panel) and LY3022855 dose (lower panel) for Studies JSC A and 
JSCB .
5.4.4. Nonclinical Toxicology
A standard nonclinical toxico logy program  for advancement of a monoclonal antibody  into
clinical trials in onco logy indicat ions was conducted to assess the safet y and toxi city of
LY3022855 . The nonclinical safet y assessm ent of LY3022855 was conducted in cyno molgus
monkeys. This species was considered a relevant model for the nonclinical safet y evaluat ion of
LY3022855 , based on a preliminary cross -species evaluat ion of t issue/receptor binding and/or
funct ional in vitro ph armacological  activity in human and cyno molgus monkey test systems and
in a subsequent comprehensive t issue cross -reactivit y study  using full panels o f monkey and
human tissues. The toxicology studies conducted with LY3022855 included an exploratory
singl e-dose toxi city and toxi cokinet ic (TK) dose range -finding study  and a pi[INVESTIGATOR_22735]  4-week
repeat -dose good laboratory  practice toxi city, TK, an d immunogenici ty study  with a 6-week
recovery  period. Anima ls were administered LY3022855 by I.V. infusio n, the intended clinical
method of administration, using the dosing schedule (once weekly) in the planned init ial clinical
investigat ions of LY3022855 . The pi[INVESTIGATOR_574416] y

I5F - MC- JSCB (d)  Phase1  Onco logy  P ro toco l Page  22
LY3022855( IMC - CS4 )p h a rm a c ol o gy  p a r am e t e r s .  B e ca u s e  o f  a n  a n t i c i p a t e d  e f f e c t  o f  LY 3 0 2 2 8 5 5on  c i r c u l a t i n g  l e v e l s  
o fth e  t a r g e t  l i g a n d ,  CSF - 1 ,  th e  l e v e l s  o f  CSF- 1  w e r e  a l so  m e a su r ed  in  th e  s tudy  an im a l s  a s  a
po t en t i a l  m a r k e r  o f  t h e  p h a rm a c o d y n am i c  a c t i v i t y  o f  t h e  a n t ibody .  A  t h o r o u g h  a s s e s sm e n t  o f
p e r i ph e r a l  b l o o d  a n d  s p l e e n  m o n o n u c l e a r  c e l l  s u b s e t s  a n d  a n  imm u n o h i s t o c h em i c a l  a n a l y s i s  o f
CD 6 8+  c e l l s  ( c e l l u l a r  m a r k e r  o f  m o n o c yt e s /m a c r o p h a g e s )  i n  l i v e r  a n d  s p l e e n  w e r e  a l s o  i n c l u d e d
t o  d e t e rm i n e  t h e  e f f e c t s  t h a t  b l o c k a d e  o f  t h e  CSF - 1  r e c e p t o r  m i g h t  h a v e  o n  th e s e  e n d p o i n t s .
A s s e s sm e n t  o f  t h e  g e n o t o x i c i ty  po t en t i a l  o f  m ono c l on a l  an t ibod i e s  i s  no t  r e l ev an t  and  w a s ,
th e r e fo r e , n o t  s t u d i e d .  B a s e d  o n  t h e  e a r l y  s t a g e  o f  c l i n i c a l  d e v e l o pm e n t  a n d  t h e  o n c o l o g y
i n d i c a t i o n ,  r e p r o d u c t i v e  t o x i c i ty  s t u d i e s  o f  LY3022855h av e  n o t  b e e n  c o n d u c t e d .
5 .4 .4 .1 . S ing le- Dose  Tox ic i ty
CC IS in g l e - d o s e  a dm i n i s t r a t i o n  o f  LY 3 0 2 2 8 5 5a t  d o s e  l e v e l s  o f  1 0 ,  4 0 ,  a n d  1 4 0  m g / k g  a dm i n i s t e r e d  
b yI .V .  in fu s i on  ov e r  a  15 - m i n u t e  p e r i o d  w a s  w e l l  t o l e r a t e d  i n  c y n om ol g u s  m o n k e y s  
(2m on k e y s / s e x / g r o u p )  d u r i n g  t h e  [ADDRESS_753884] a r g e t i n g  CSF - 1R  (W ang  e t  a l .  2011 )  o r  CSF - 1  (R a d i  e t  a l .  2 0 1 1 ) .
N o  o t h e r  a d v e r s e  c l i n i c a l  s i g n s  or  e f f e c t s  o n  f o o d  c o n s um p t i o n ,  body  w e igh t ,  h em a to l ogy ,  a n d
o rg an  w e i g h t s  w e r e  a s s o c i a t e d  w i t h  a dm i n i s t r a t i o n  o f  LY 3 0 2 2 8 5 5.
CSF- 1  s e rum  l e v e l s  i n c r e a s e d  r e l a t i v e l y  q u i c k l y  a f t e r  LY 3 0 2 2 8 5 5a dm i n i s t r a t i o n  a n d  r em a i n e d
s u s t a i n e d  t h r o u g h o u t  t h e  1 4 - d ay  o b s e r v a t i o n  p e r i od .  CSF- 1  w a s  n o t  d e t e c t e d  i n  a n y  con t ro l
a n im a l s  a t  a n y  t i m e .  Th e  max imum  l e v e l s  o f  CSF- 1  r e a c h e d  w e r e  c om p a r a b l e  a c r o s s  d o s e
g r o u p s ,  s u g g e s t i n g  t h a t  a  m a x im a l  p h a rm a c o d y n am i c  e f f e c t  o f  LY 3 0 2 2 8 5 5o n  t h i s  p a r am e t e r  
w a sa c h i e v e d  a t  e v e n  t h e  l ow e s tdo s e  l ev e l  in  th e  s tudy .
T h e  n o- o b s e r v e d - adv e r s e - e f f e c t  l ev e l  (NOAEL )  in  th i s  s tudy  w a s  c o n s i d e r e d  t o  b e  
 Th is  do s e  co r r e spond ed  to  a  do s ing  D ay  1  
 CC I
CC I
CC I
I5F - MC- JSCB (d)  Phase1  Onco logy  P ro toco l Page  23
LY3022855( IMC - CS4 )5 .4 .4 .2 . Repea t- Dose  Tox ic i ty
CC II n  t h e  p i v o t a l  r e p e a t - d o s e  t o x i c i ty , TK ,  and  immunog en i c i ty  s tudy  o f  LY 3 0 2 2 8 5 5,  do s e s  o f  0 ,  20 ,
6 0 ,  a n d  1 8 0  m g / k g / d o s e  LY 3 0 2 2 8 5 5w e r e  adm in i s t e r ed  by I .V .  i n f u s i o n  o n c e  w e e k l y  to
c y n o m ol g u s  m on k e y s  ( 5 / s e x / g r o u p )  f o r  4  w e e k s ,  f o l l ow e d  b y  a  6 - w e ek  r e cov e ry p e r i od .  
S t a n d a r d  t o x i c ol o g i c a l  and  r e l e v a n t  s a f e t y  ph a rm a co l ogy( c a rd i ov a s cu l a r ,  c en t r a l  n e rvou s [CNS ] ,  
and  r e sp i r a to ry  s y s t em s )e n d p o i n t s  w e r e  a s s e s s e d .  A s  i n  t h es i n g l e - do s e  s tudy ,  c i r c u l a t i n g  l e v e l s  
o f  CSF - 1  w e r e  m e a su r ed .  A  t h o r o u g h  a s s e s sm e n t  o fp e r i ph e r a l  b l ood  and  sp l e en  m ononu c l e a r  
c e l l  s u b s e t s  a n d  a n  imm u n o h i s t o c h em i c a l  a n a l y s i s  o fCD68+  mo n o n u c l e a r  c e l l s  i n  l i v e r  a n d  
s p l e e n  w e r e  a l s o  c o n d u c t e d .
I n t r a v e n o u s  i n f u s i o n  of  LY 3 0 2 2 8 5 5w a s  g e n e r a l l y  w e l l  t o l e r a t e d  a t  a l l  d o s e  l e v e l s .  S u s t a i n e d  
do s e - p ropo r t i on a lto  s l igh t ly - g r e a t e r- th a n - do s e - p ropo r t i on a l  i n c r e a s e s  in  expo su r e  to  LY 3 0 2 2 8 5 5
w e r eg e n e r a l l y  o b s e r v e d ,  a n d  n o  s e x  d i f fe r en c e s  in  expo su r e  w e r e  app a r en t .  M od e r a t e  
a c c um u l a t i o n( a p p r o x im a t e l y  2 -f o l d )  o f  LY3022855o c c u r r e d  a f t e r  r e p e a t e d  a dm i n i s t r a t i o n .  
A n ti - d r u g  a n ti b o d i e s  ( ADA)  
 
A s  n o t e d  i n  t h e  s i n g l e- do s e  exp lo r a to ry  s tudy ,  c i r cu l a t i n g  c o n c e n t r a t i o n s  o f  CSF - 1  i n c r e a s e d
s h o r t l y  a f t e r  LY 3 0 2 2 8 5 5a dm i n i s t r a t i o n .  CSF- 1  w a s  n o t  d e t e c t e d  i n  a n y  c o n t r o l  a n im a l s .  In
con t r a s t  to  LY 3 0 2 2 8 5 5,  t h e  c o n c e n t r a t i o n  of  CSF- 1  d i d  no t  v a ry  w i th  do s e ,  a s  com p a r a b l e
m a x im um  l e v e l s  w e r e  r e a c h e d  i n  a l l  3  d o s e  g r o u p s .  T ow a r d s  t h e  e n d  o f  t h e  r e c o v e r y p e r i od ,
CSF- 1  l e v e l s  g e n e r a l l y  d e c r e a s e d  i n  t h e  2 0 -a n d  6 0 - m g / k g  d o s e  g r o u p s ,  b u t  r em a i n e d  e l e v a t e d  i n
th e  180 -m g /kg  do s e  g roup .
Th e  k ey tox i c o l o g i c a l  f ind ing s  a t t r ibu t ed  to  LY 3 0 2 2 8 5 5a dm i n i s t r a t i o n  i n  t h i s  s t u d yw e r e  
p e r i o rb i t a l  sw e l l ing ,  in c r e a s e s  in  s e rum  t r an s am in a s e s  a s  no t ed  in  th e  exp lo r a to ry  s tudy ,c h a n g e s  
i n  l euko cy t e  popu l a t i o n s  (m ono cy t e s ,  n e u t r o p h i l s ,  CD 68+  m ononu c l e a r  c e l l s ,  n a tu r a lk i l l e r  [NK ]  
c e l l s ) ,  a n d  t a r g e t  o r g a n  e f f e c t s  i n  l i v e r  (K u p f f e r  c e l l  h y p e r t r o p h y / h y p e r p l a s i a ) ,  s p l e e n( f o l l i c u l a r  
hyp e r t rophy /d end r i t i c  c e l l  hyp e rp l a s i a ) ,  and  bon e  m a r row  (hy p e r c e l lu l a r i ty ) .  T h e
imm u n o m odu l a to ry  e f f e c t s  on  l e uko cy t e s ,  K u p f f e r  c e l l s ,  s p l e e n ,  a n d  b o n e  m a r r ow  l i k e l y  r e f l e c t
a n  e x a g g e r a t e d  p h a rm a c o l o g i c a l  r e spon s e  to  LY 3 0 2 2 8 5 5,  po s s ib ly  a s so c i a t ed  w i th  e l e v a t i o n s  i n
c i r c u l a t i n g  CSF - 1  l ev e l s  no t ed  du r ing  th e  s tudy .
E l e v a ti o n s  i n  ALT  a f t e r  t h e  l a s t  d o s i n g  of  LY302285 5w e r e  g e n e r a l l y  m i n im a l  i n  t h e  l ow e s t  d o s e
g r o u p  ( 2 0  m g / k g )  a n d  m i n im a l  t o  m o d e r a t e  a t  t h e  6 0 -a n d  1 8 0 - m g / k g  d o s e  l e v e l s .  AST  le v e l s
w e r e  m i n im a l l y  t o  m o d e r a t e l y  i n c r e a s e d  a t  a l l  d o s e  l e v e l s .  ALT  a n d  AST  r e t u r n e d  t o  b a s e l i n e  i n
th e  20 - m g / k g  g r o u p  a n d  tr e n d e d  t ow a r d s  b a s e l i n e  i n  t h e  6 0 -a n d  1 8 0 - m g / k g  g r o u p s  d u r i n g  t h e
r e cov e ry  p e r i od ,  bu t  r em a i n e d  i n c r e a s e d  i n  s om e  i n d i v i d u a l  a n im a l s  c om p a r e d  w i t h  b a s e l i n e .  N o
h i s to l og i c a l  c h a n g e s  i n  t h e  l i v e r  w e r e  n o t e d  t o  c o r r e l a t e  w i t h  t h e  t r a n s am i n a s e  i n c r e a s e s ,  n o r
w e r e  a n y c h a n g e s  n o t e d  i n  l i v e r  f u n c t i o n a l  p a r am e t e r s  ( t h a t  i s ,  AP,  b i l i rub in ,a n d  co agu l a t i o n ) .  
T h e r e f o r e ,  b a s e d  o n  t h e  sm a l l  m a g n i t u d e  o f  t h e  e l e v a ti o n s  a n d  t h e  a b s e n c e  ofh i s to l og i c a l  o r  
f u n c t i o n a l  c h a n g e s ,  t h e  i n c r e a s e s  i n  ALT  a n d  AST  w e r e  n o t  c o n s i d e r e d  a d v e r s e .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 24
LY3022855 (IMC -CS4)Increases in circulat ing white blood cells due to increases in neutrophils and monocytes were
observed in both sexes at 60 and 180 mg/kg. Flow cy tometry analysis o f spleen and peripheral
blood revealed increases in mo nocy tes in spleen and bl ood at 60 and 180 m g/kg and reducti ons
in splenic NK cells in all LY3022855 -treated groups. Variabilit y in NK cell numbers in the
peripheral  blood of  animals in all dose groups (including control) precluded assigning a
definit ive relat ionship with LY30228 55treatm ent. These changes in white blood cell counts, in
conjunction with minimal  reversible increases in serum globulin concentrations with a
corresponding decrease in albumin to globulin rat io, are consistent with the presence of an
inflammatory  response. However, no histopathologic evidence of inflammat ion was observed.
The m onocy te, neutrophil, and globulin changes were reversible by [CONTACT_574425], while the splenic NK cell reduct ions were still apparent in some a nimals. These changes
were not considered adverse because o f their small magnitude.
Anatomic patho logy changes attributed to the administration of LY3022855 at the end of the
dosing period included increased spleen weights in females (all dose groups), wh ich generally
correl ated wi th splenic fo llicular hypertrophy  (males at 60 and 180 mg/kg; females at 20 and
180mg/kg), bone marrow hy percellulari ty (all femal e dose groups, one m ale at 60 m g/kg), bone
marrow lympho id aggregates (one male, one female at 180 mg/kg), and Kupffer cell
hypertrophy /hyperplasia (primarily  minimal , all male dose groups, one female at 60 mg/kg).
Immunohistochemical analyses confirmed the presence of increased size or number of CD68+
Kupffer cells in the liver and increased numbers of CD68+ m ononuclear cells in the spleen at all
dose l evels. The CD68+ cells in the spleen were likely fo llicular dendrit ic cells. The
immunohistochemical findings in liver and spleen generally  correl ated wi th the histopathologic
diagnoses of Kupffer cel l hypertrophy /hyperpl asia and splenic fo llicular hypertrophy . Similar
anatomic patho logy findings in spleen, liver, and bone marrow were observed after the recovery
period. These changes were not considered adverse because of their small magnitude.
Slight to m oderate peri orbital swelling was observed primarily  during the recovery  phase in all
LY3022855 -treated groups (20, 60, and 180 mg/kg/dose). This clinical sign has been reported to
occur i n humans wit h another ant ibody  to CSF -1 (Sadis et al. 2009) an d may thus represent a
delayed response to LY3022855 in the treated monkeys. Watery feces was observed only in the
60-mg/kg/dose animals, but is considered possibly related to the administration of LY3022855.
These clinical signs were not considered adve rse based on thei r limit ed impact to the overall
healt h of the animal. No adverse effects were noted in assessments of the central nervous
(neurological behavioral examinat ion), respi[INVESTIGATOR_696]  (rate), or cardiovascular (heart rate, blood
pressure, electrocardi ogram [ECG] ) system s. In addit ion, no evidence of an adverse reaction or
intolerance attributable to LY3022855 was apparent at the injection sites after I.V. infusio n in the
cyno molgus monkey repeat -dose toxicit y studi es.
Based on the absence of any defini tive LY3022855- related adverse findings, the NOAEL for
LY3022855 administered via 15 -minute I.V. infusion weekly on 4 occasions was considered to 
be180 m g/kg/dose. The dose corresponded to a dosing Day 22 mean C maxof 7985 µg/mL, C 168hr
of2945 µ g/mL, and mean AUC (0-168h r)of 711340 µg·hr/mL.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 25
LY3022855 (IMC -CS4)5.4.5. Clinical Experience
Clinical experience wit h LY3022855 comprises 43 patients (as of 28 Jan uary 2016) who 
received the fo llowing doses I.V. in 2 ongoing Lilly -sponsored Phase 1 studies (I5F-IE-JSCA 
[JSCA] and I5F-MC-JSCB [JSCB ]): 2.5 mg/kg QW (n=6), 0.3 mg/kg QW (n=4), 0.6 mg/kg 
QW (n=3), 1.25 mg/kg Q2W (n=20 ), 1.25 m g/kg QW (n=5), and 1 mg/kg on W eeks 1, 2, 4, and 
5 of every  6-week cycle (n=5). At the first human dose studied, 2.5 mg/kg QW (Study  JSCA) , 
which was also the highest dose administered, laboratory  abnorm alities, including Grade 2 -3 
creatine kinase (CK) and Grade [ADDRESS_753885] el evations,were noted in 5patients but were not 
classified as dose -limiting toxicit ies (DLT s) due to the lack of clinical signs or symptoms of 
organ toxicit y.  Because of these laboratory  abnormali ties, the protocol  for Study  JSCA was 
amended and dose escalat ion was restarted at a lower dose, 0.3 mg/kg QW.
Elevated levels of CKandAST , in the absence of clinical signs or symptoms or other laboratory 
abnorm alities suggestive of end- organ damage are, in retrospect, believed to be
pharmacodynamic ind icators of target engagement ,rather than markers of drug -related toxicit y.  
This belief is strengthened by [CONTACT_574426] . (2011), in which preclinical models support 
the hypothesis that increases in the levels o f serum enzymes can be the result o f decreases in 
Kupffer cells ,in the apparent absence of hepat ic or skeletal muscle injury.   In all cases where 
elevated enzymes were observed following LY3022855 administration in Study  JSCA , the levels 
decreased to Grade <[ADDRESS_753886] been observed in Study JSCA:  an event of left 
ventri cular dy sfunct ion (Cohort 4 , 1.25 mg/kg Q2W) , an event of pancreat itis (apatient in 
Cohort 5 , 1.25 mg/kg QW), an event of rhabdo myolysis (another patient in Cohort 5), and an 
event of Grade 3 CK elevation (Cohort 7a, 
150mg QW).  The patient with the DLT of left 
ventri cular dy sfunct ion had a baseline left ventri cular ej ection fraction (LVEF )of 35% ,which 
obfuscated the relationship between LY3022855 and the DLT event; therefore, the patient was 
considered to be a suboptimal candidate for study  parti cipat ion.  The patient in Cohort 5 who 
experienced pancreat itishada medical  history  significant for i rritable bowel  syndrome and 
gastroesophageal reflux disease (GERD) ,rendering the patient prone to nausea and abdominal 
pain.  During the course of treatment in Study JSCA , this pat ient’s serum  levels o f lipase 
gradually increased, from 21 U/L (baseline) to 13 8U/L (Cy cle 1, Week 6 [C1W6] )(C1W2 = 79 
U/L, C1W3 = 90 U/L, C1W4 = 121 U/L, C1W5 = 149 U/L).  Following the C1W3 
administration of LY3022855, the pati ent’s treatment with study  drug was held due to rising 
lipase l evels.  Steroi ds were not i nitiated unt il the patient presented for medical attention with 
complaints of nausea, vomit ing, and abdo minal pain on C1W6, at which t ime the patient was 
diagnosed wi th Grade 3 pancreat itis.  The symptoms improved with hospi[INVESTIGATOR_12191], supportive 
therapy , and systemic steroids.  Although this particular case resulted in a DLT, the relat ionship 
between elevated lipase and gastrointestinal symptoms is not clear, given the patient’s history  of 
irritable bowel  syndrome and GERD.
Following the occurrence of the 2DLTs in Cohort 5 of Study  JSCA , dose escalat ion was 
temporarily halted.  Subsequent PK and pharm acodynamic analyses revealed the fo llowing:
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 26
LY3022855 (IMC -CS4)A lack of correlat ion between body  weight and LY3022855 clearance ( Figure JSCB .1)
Intermittent inhibit ion of CSF -1R si gnaling with Q2W dosing of LY3022855, as 
evidenced by [CONTACT_574427] -1 and peripheral  CD14dimCD16brightcells by 
[CONTACT_74064] -activated ce ll sorting ( FACS )(Figure JSCB. 2)
Sustained inhibit ion of CSF -1R signaling with 2.5 mg/kg QW and 1.25 mg/kg QW 
dosing (Study  JSCA Cohorts 1 and 5, res pectively )of LY3022855, as evi dence dby 
[INVESTIGATOR_67132] o f both circulating CSF -1 and peripheral CD14dimCD16brightcells by [CONTACT_7811] (Figure 
JSCB. 2)
Based on these observat ions, the protocol for Study JSCA was amended to:  (1)examine fixed 
(non-weight-based) dosing of LY3022855 on weekly adminis trationschedule sto optimize the 
biological  effects of LY3022855 on CSF-1R inhibiti on, (2) redefine a DLT as any LY3022855 -
related AE that occurs during Cycle 1 and does not improve to Grade ≤2, unless stated otherwise, 
despi[INVESTIGATOR_45862], including steroids (if applicable) within 7 days o f docum ented 
occurrence , and (3) incorporate management guidelines for immune -related AEs.  Do sing in 
Study  JSCA resume dat a fixed dose of 100 mg QW ,which is co mparable to 1.33 mg/kg in a 75 -
kg person and within the coefficient of variat ion in exposure (34% to 49%).  As of [ADDRESS_753887] received 100 mg QW for 6 weeks ( Cycle 1, DLT 
assessment period) without experiencing a DLT. Of the 3 pati ents treated at the next higher d ose 
level of 150 mg QW, 1 patient experienced a DLT of Grade 3 CK elevation associated with 
elevated serum  and urine my oglobin.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 27
LY3022855 (IMC -CS4)Abbreviation:  C = cohort .
Figure JSCB. 2. CD14dimCD16bright(relative percentage of CD45+HLA-DR+CD14+) in 
the blood of patients from Study JSCA .
More informat ion about the known and expected benefits, risks ,and reasonably anticipated AEs 
may be found in the IB.  I nform ation on AEs expected to be related to the invest igational product 
may be found in Sect ion 7 (Development Core Safety Information) of the IB.  Information on 
SAEs expected in the study  popul ation independent of drug exposure and that will be assessed 
by [CONTACT_240209], periodically during the course of the study , may be found in Secti on 
6 (Effects in Humans) of the IB.

I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 28
LY3022855 (IMC -CS4)5.5. Rationale for Selection of Dose
The optimal dose and schedule of LY3022855 in humans are not known.  The protocol will 
utiliz e 4dosages of LY3022855 ,where Dosage sA and B are weight based , while Dosage sC and 
D are non -weight based (that i s, fixed) ,as prior data suggest that weight -based dosing does not 
affect exposure (Section 5.4.3 ).  Refer to Table JSCB. 1for a summary of the LY3022855 
dosages to be used in this stu dy.
Table JSCB. 1. Summary of LY3022855 Dosages in Study JSCB
Dosage Dose Schedule (based on a 6 -week cycle)
Dosage A (weight based dose) 1.25 mg/kg Q2W
Dosage B (weight based dose) 1 mg/kg Weeks 1, 2, 4, and 5 of a 6 -week cycle
Dosage C (non -weight based /fixed dose ) 100 mg QW
Dosage D (non -weight based /fixed dose ) 100 mg Q2W
Abbreviations:  QW = weekly; Q2W = ever y 2 weeks (Weeks 1, 3, and 5) .
The rati onale for each dosage is presented as fo llows.
DosageA is based on the following observations from  Study  JSCA :
A dosage of 1.25 m g/kg every  [ADDRESS_753888] dosagetested i n Study  JSCA that 
demonstrat ed a significant increase in the 2 li gands of CSF -1R (CSF -1,IL-34).
Results demonstrated an acceptable clinical safet y profile of LY3022855 at a dose of 
1.25 mg/kg every 2 weeks .
Dosage B rationale:
PK parameters from Study  JSCA revealed a 34% to 49% coefficient of variat ion in 
exposure (AUC 0-∞) for pati ents administered LY3022855 at 1.25 mg/kg every  2 weeks or 
1.25 m g/kg weekly.  Dosage B at 1 m g/kg on Weeks 1, 2, 4, and 5 of a 6 -week cy cle will 
resul t in a cumulat ive dose of 4 mg/kg every 6 weeks, which is 0.25 mg/kg (6.7%) 
greater than the cumulat ive dose per (6- week) cy cle of  Dosage A (1.25 mg/kg every 
2weeks).  However, a 6.7% increase in exposure is within the variation o f exposure 
docum ented in Cohorts 4 and 5.  Thus, Dosage B is a reasonable dose and schedule in 
terms of safet y.  Addi tionally, dosing 2 consecutive weeks is expected to enhance 
inhibit ion of CSF-1R, based upon preliminary pharmacodynamic data (CSF -1 and IL -34) 
from Cohorts 4 and 5.  Furthermore, interruption of dosing every  3 weeks provi des an 
opportunit y for LY3022855 -associ ated l aboratory  abnorm alities to no rmalize pri or to 
resum ption of dosing, as has been observed in the Phase 1 dose -escalat ion Study  JSCA.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 29
LY3022855 (IMC -CS4)Dosage C rationale:
Pharmacodynamic data (Secti on 5.4.5 )suggest that weekly administration of LY3022855 
resul ts in enhanced target engagement.  Thus, Dosage C will be implemented to examine 
weekly administration of LY3022855.
Dosage D rationale:
It has been observed that all pat ients who were treate d with LY3022855 and experienc ed
antitumor activit y (as evidence dby [CONTACT_574428] y) as of [ADDRESS_753889] 2016
were treated on a Q2W schedule .  Thus, Dosage D will be implemented to continue 
explor ingQ2W dosing ,but ata fixed (non -weight -based) dose.  Furthermore, the Q2W 
schedule may be preferable forqualit y of life, because the pati ent will requi refewer 
clinic visits.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 30
LY3022855 (IMC -CS4)6.Investigational Plan
6.1. Study Population
Individuals with advanced, r efractory  breast or prostate cancer are eligible. Specifically, to be 
enrolled in the trial, patientsmust have a biopsy -proven breast or prostate cancer diagnosis wi th 
clinical evidence of advanced -stage disease and must be willing to undergo 2separate core 
needle or surgi cal biops y procedures (1at baseline [predose] and 1prior to Cycle 2) , optimally 
from the same lesio n. Patients are considered evaluable if they complete 1cycle of treatment 
(at least Cy cle 1,Day 43, based on a 6- week cy cle), undergo 1baseline and 1posttreatment 
tumor biopsy procedure (ie, attem pted, whether the biopsy is successful or not) , and complete 
immune blood studies for 1cycle.
Individuals who do not m eet the cri teria for parti cipati on in this study  (screen failure) m ay be re -
screened if agreed upon by  [CONTACT_456] . Ifa pati ent discont inues prior to the second biopsy, the 
patient will be replaced.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1.1. Inclusion Criteria
Patients may be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to fi rst dose of study  drug.
[1] Have a confirmed diagnosi s of advanced, refractory  breast or prostate cancer
that is evaluable by [CONTACT_574429] .  Pati ents m ust have experienced tumor 
progression on or treatm ent intolerance to at least one prior therapy  for thei r 
cancer and have declined or are ineligible for a standard treatment .
[2a
]For p atients with metastati c castrate -resistant prostate cance r(CRPC) only:
a)must continue ongoing androgen deprivat ion therapy  (gonadotropin -
releasing hormone [GnRH] agonist or antagonist) with castrate levels of 
serum  testosterone <50 ng/dL determined wit hin 4 weeks prior to starting 
treatm ent;
b)if receiving an ant iandrogen as part of first -line hormonal therapy, must 
have shown progression of disease off the ant iandrogen prior to 
enrollment ;
c)must be willing to continue androgen deprivat ion therapy while on study , 
if no pri or orchi ectomy ;
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 31
LY3022855 (IMC -CS4)d)must m eet at least 1 of the following 3 criteria for progressive metastatic 
disease ,according to PC WG2 cri teria:
i. a rise in prostate -specific antigen (minimal value 2 ng/m L; 
≥3consecut ive rising values) , or
ii.≥2 new metastases on transaxial imaging or radionuclide bone scan ,or
iii. so ft tissue progressi on;
e)replacement horm one therapy  (including predniso ne or equivalent up to 
10mg/day) initiated before study  entry  is permi tted per Secti on7.5.
[2b] For pati ents wi th breast cancer only:
a)may cont inue ongoing ant iestrogen therapy ( for example , an arom atase 
inhibitor) , 
b)replacement horm one therapy  initiated before study  entry is permitted per 
Secti on7.5,and
c)may cont inue ongoing trastuzumab therapy .
[3] Are 18 years of age .
[4] H ave given written informed consent prior to any  study -specific procedures .
[
5] Have adequate organ and hematologic function, incl uding:
Hepati c:  Bilirubin 1.5 ×the upper limit of normal (ULN), and ALT and 
AST 3.0×ULN.  For patients with tumor invo lvement of the liver, AST 
and ALT ≤5.0 ×ULN are acceptable.  For pati ents wi th tumor 
involvement of the bone , alkaline phosphatase ≤5.0 ×ULN is acceptable .
Renal:  Serum creat inine 2.0×ULN.
Absolute neutrophil count (ANC) ≥1.0× 109/L.
Hem oglobin ≥9 g/dL (5.58 mmo l/L).
Platelets ≥90
× 109/L.
[6] Have a performance status of ≤2 on the Eastern Cooperative Onco logy Group 
(ECOG) scal e.  
See Attachment 8.
[
7] Except as addressed in Inclusion Criterion [2], have discont inued all 
disease -modifying therapy  for the primary  cancer >[ADDRESS_753890] reso lved or stabilized to Grade ≤1 toxicit y >[ADDRESS_753891] resolved 
to Grade ≤2.  Continuat ion of a stable dose (minimum of 28 days prior to 
study  entry ) of denosumab or bisphosphonate is permitted on study .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 32
LY3022855 (IMC -CS4)[8] Are reliable and willing to make themselves available for the duration of the 
study  and are willing and able to comply  with study  procedures (includes 
1baseline and 1 posttreatment tumor biopsy procedure) and instructions .  
Patients enrolled in this trial must receive the study  treatm ent at the study  
center.
[9a] M ale pati ents:
agree to use a reliable method of birth control and to not donate sperm during 
the study  and f or at least [ADDRESS_753892] dose of study  drug or 
country  requi rements, whi chev er is longer.
[9b] Female pat ients:
arewom en of childbearing potential who test negative for pregnancy within 
7days prior to enrollment based on a urine or serum pregnancy test and agree 
to use a reliable method of birth control during the study  and f or [ADDRESS_753893] feeding ,
OR
are postm enopausal  wom en.  Postm enopausal  women include wom en wi th:
1) at l east 6 weeks postsurgical bilateral oophorectomy  with or wi thout 
hysterectomy, confirmed by [CONTACT_574430]
2) spon taneous am enorrhea for at l east 12 m onths, not induced by a 
medical condit ion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea that induced the amenorrhea (for example, oral 
contraceptives, hormones, gonadotropin releasing hormone, 
antiestrogens, selective estrogen receptor modulators, or chemotherapy )
or
3) spon taneous am enorrhea 6 to 12 m onths and a follicle -stimulat ing 
horm one level greater than 40 mIU/mL.
[10]Have an est imate d life expectancy that, in the j udgment of the investigator, 
will permit the patient to complete 1 cycle o f treatment.
[11]May have received treatm ent wi th an investi gational product or non -approved 
use of a drug (other than the study drug used in this st udy) or devi ce for 
non-cancer indications ;however ,not within 28 days prior to the init ial dose of 
study  drug (see al so Exclusio n Cri terion [1 2]).
Refer to Section 7.5for addit ional details regarding concomitant therapy .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 33
LY3022855 (IMC -CS4)6.1.2. Exclusion Criteria
Potenti al study  patients m ay not be included in the study  if any of the fo llowing apply during 
screening.
[12]Have received treatment within [ADDRESS_753894] or non -approved use of a drug or device (other 
than the study  drug/device used in this study ) for non -cancer indications or are 
concurrent ly enro lled in any other ty pe of m edical  research j udged not to be 
scientifically or medically co mpatible wit h this study (see also Inclusio n 
Criterion [1 1]).
[13]Have serious preexist ing medical condit ions (left to the di screti on of  the 
investigator).
[14]Have symptom atic CNS malignancy or metastasis (screening not required).
Patients wi th treated CNS metastases are eligible for this study  if they  are not 
currently receiving corticosteroids (to controlCNS edem a), and thei r disease 
is asymptomat ic for at least 28days prior to enrollment .  Magnet ic resonance 
imaging (MRI )docum enting disease stabilit y within 60 days prior to 
enrollment is also required.
[15]Have an act ive fungal, bacterial, and/or known viral inf ection,including 
human immunodeficiency virus ( HIV)or viral (B or C) hepatit is (screening 
requi redfor HIV and viral hepat itis B and C within 60 days prior to 
enrollment ).
[16]Have any of the following cardi ovascular condi tions:
a)symptom atic coronary artery  disease current ly or within the past 6 months ,
b)confirmed left ventricular ejection fract ion ≤50% or any  cardiac 
insufficiency > [LOCATION_001] Heart Associat ion (NYHA) class II* currently 
or wi thin the past 6 months ,
c)uncontrolled hypertension (>170/ 100 mm  Hg) current ly or within the past 
7 day s, or
d)serious cardi ac arrhy thmia (well -controlled atri al fibrillat ion is permitted)
currently or within the past 6 months .
[17] H ave a second active primary malignancy that, in the judgment of the 
investigato r or sponsor, may affect the interpretation of the results .
[18] A re unwilling or unable to participate in tumor biopsies .
[
19]Have corrected QT interval of >500 msec on screening ECG.
[20] Have receive dtreatm ent wi th agents specifically targeting CSF -1 or CSF -1R
,
including imat inib, nilot inib, and sunit inib.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 34
LY3022855 (IMC -CS4)*NYHA Congestive Heart Failure Classification (NYHA 1994) :
Class I –Patients with no limitation of activities; they suffer no symptoms from ordinary  activities.
Class II –Patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion.
Class III –Patients with marked limitation of activity; they are comfortable only at rest.
Class IV –Patients who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest.
Refer to Section 7.5for addit ional details regarding concomitant therapy .
6.2. Summary of Study Design
Study I5F-MC-JSCB (JSCB) i s a single -center, open -label,nonrando mized, noncontrolled
Phase [ADDRESS_753895] infusio n, decreasing by 30 minutes for subsequent 
infusio ns, unt il administered over 30 minutes (refer to Section 7.2for further details o f study  
drug administration).  Study  JSCB is intended to explore clinical response and immunological
activit y of single -agent LY3022855 in approximat ely 40patients ( enrolled, of who m 36will be
evaluable) , by [CONTACT_574431], cy tokines, and immune cells .  The study  schema is 
shown in Figure JSCB. 3.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 35
LY3022855 (IMC -CS4)Abbreviations:  LY = LY3022855 (IMC -CS4); PD = progressive disease.
Figure JSCB. 3. Study JSCB study design .
Enroll ment will be sequent ial, starting with the assignment of patients to Dosage A ( LY3022855 , 
1.25 m g/kg every  2 weeks [Q2W] of a 6-week cycle ), then the assignment of patients to Dosage 
B (LY3022855 , 1.0 m g/kg on Weeks 1, 2, 4, and 5 of a 6 -week cy cle) once the Dosage A cohort 
is fully enrolled.   Once the Dosage B breast cancer cohort is fully enrolled , pati ents with breast 
cancer will be assigned by [CONTACT_574432] C (LY3022855, 100 mg QW of a 6 -week 
cycle)or D (LY3022855, 100 mg Q2W of a 6 -week cy cle) on an alternat ing basis until [ADDRESS_753896] igators will review clinical data to determine if enro llment of an
additional 5 pat ients to each of Dosage s C and D is warranted (refer to Secti on 10for details 
regarding sample size).

I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 36
LY3022855 (IMC -CS4)Patients will receive Dosage A , B, C,or Dfor one 6 -week cycle or until  the patient m eets one or 
more cri teria for study discont inuat ion.  After 1cycle, p atients who are benefitt ing from study  
treatm ent (that is, no disease progression or unacceptable toxicit y) may cont inue to receive study  
treatm ent at the sa me dose and schedule unt il there is clear (confirmed) evidence of disease 
progression or other withdrawal criteria are met .  At the time of study  com pletion, if a patient 
continues to benefit fro m study  treatm ent, that pati ent may  enter the continued acces s period.
Immune studies will include evaluat ions of changes in baseline over time in:  (1) peripheral 
blood immune cell subsets , as determined by [CONTACT_574433], 
andthat may include but not be limited to the follo wing ma rkers : Live-Dead, CD3, CD4, CD8, 
CD14, CD16, FoxP3, PD-1, Ki-67, CTLA -4, TIM -3, LAG- 3, and ICOS, as well as (2) serum  
cytokines, as determined by [CONTACT_574434] ,and 
that may  include but not be limited to CSF -1, IFN-γ, IL -1β, IL -2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, IL -34, and TNF -α.  Blo od sam ples f or the immuno modulatory  studies will be 
taken as described in Attachment 4 ,Attachment 5, and Attachm ent 6 .
In addit ion, for all  patients, 2separate tumor biopsy procedures will be performed(attem pted) :  
the first will be performedat baseline (predose) , within [ADDRESS_753897] a pat ient who ei ther:  (1)
discontinues from  the study  prior to the second biopsy procedure ,or (2) does not have sufficient 
tumor tissue for the second biopsy procedure and in the opi[INVESTIGATOR_3078] n of the investigator is benefitt ing 
from study  treatm ent (in which case, the patient will  be allowed to rem ain on study  treatm ent).  
In addit ion to the required blood and tumor samples previously noted, optional tumor biopsies 
and/or blood sam ples f or biomarker research may  be obtained at the invest igator’s discretion in 
discussio n with the pati ent, such as at the time of radiographic response or treatment progression .
For pati ents wi th measurable disease per RECIST , clinical endpo ints for response will be 
standard tumor response as determined by  [CONTACT_393] 1.[ADDRESS_753898] 2 new lesio ns are observed on bone scan
(com pared wi th baseline), and are then confi rmed on a foll ow-up bone scan performed at least 
6weeks later. However ,if thepoint when the new lesio ns are observed is the first interval bone 
scan ( that is, Week 6 ), then the confirmatory  bone scan m ust dem onstrate at least 2 addit ional 
new lesio ns (that is, a total  of at least 4 new l esions f rom baseline).   Further details o f the 
PCWG2 criteria are provi dedin Section8.3.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 37
LY3022855 (IMC -CS4)To document the immuno modulatory  activityof LY3022855 treatm ent in pati ents wi th
advanced, refractory  breast orprostate cancers , an adequate sam ple size is required (refer to 
Secti on 10) .
The pl anned durat ion of treatment is not fixed; pat ients will remain on study unt il they fulfill one 
of the cri teria for study  discont inuation (Section 6.3).
Refer to Attachment 1 for the Study  Schedule.
6.2.1. Study Completion and End of Trial
This study willbe considered complete (that is, the sci entific evaluation will be co mplete[study
completion]) when 36evaluable pat ients*are attained .  “End of trial”refers to the date of the last 
visit or l ast scheduled proced ure for the last patient .
*Patients are considered evaluable if they co mplete 1cycle of t reatment (at least Cycle 1, 
Day 43, based on a 6 -week cycle), undergo 1baseline and 1posttreatment tumor biops y 
procedure (ie, attem pted, whether the biopsy  is successful  or not) , and com plete immune blood 
studi es for 1cycle.
6.2.2. Continued Access Period
All patients remaining on study  treatm ent without disease progression fo llowing the final 
analysis of the primary  and secondary  endpoints will be a ble to enter the continued access period
of thestudy .  The continued access period begins after study  com pletion and ends at the end of 
trial.  During the continued access period, pati ents on study  treatm ent who continue to 
experience clinical benefit may continue to receive study  treatm ent until dise ase progressi on, 
death, unacceptable toxicit y, or start of new ant icancer treatment.   The continued access period 
includes a fo llow-up visi t.  The foll ow-up visit begins after the last dose of study  drug and lasts 
approximately  
30days.   If it is deemed to be in the best interest of the patient to start a new 
anticancer treatment prior to the scheduled end of the fo llow-up visi t, the f ollow-up visit duration 
may be shortened. In this case, the fo llow-up assessments should be completed prior to the 
initiation of  the new therapy .
Lilly will notify invest igators when the continued access period begins .
During the continued access period, a ll AEs, SAEs, study drug dosing, and dose reduction of 
treatm ent will be collected on the electronic case report form ( eCRF ).
Serious adverse events will also be reported to Lilly Global Pat ient Safet yand collected in the 
pharmacovigilance system .  In the event that an SAE occurs, additional informat ion (such as 
local laboratory  resul ts, concomi tant m edicat ions, and hospi[INVESTIGATOR_165433]) may  be requested by  
[CONTACT_574435].
Invest igators may perform other standard procedures and tests needed to treat and evaluate 
patients; however, Lilly will not routinely collect the results of these assessments.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 38
LY3022855 (IMC -CS4)6.3. Discontinuations
6.3.1. Discontinuation of Patients
The cri teria for enrollment m ust be fo llowed explici tly.  If the invest igator site ident ifies a patient 
who did not meet enrollment criteria and who was inadvertent ly enro lled, the sponsor must be 
notified.  If the sponsor i dentifies a pat ient who did not meet enrollment criteria and who was 
inadvertent ly enro lled, the invest igator site will be notified. A discussio n must occur between 
the sponsor clinical research physician (CRP) and the invest igator to determi ne whether the 
patient may  cont inue in the study , with or wi thout investi gational product.  Inadvertent ly 
enrolled patients may be maintained in the study and on investigat ional product when the Lilly  
CRP agrees with the investigator that it is medically a ppropri ate for that pati ent. The patient 
may not continue in the study  with or wi thout investi gational product if the Lilly  CRP does not 
agree wi th the invest igator’s determinat ion that i t is m edically appropriate for the patient to 
continue. The invest igator m ust obtain docum ented approval fro m the Lilly CRP to allow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thout invest igational product.
In addit ion, pati ents will  be discont inued fro m the study  drug in the following circumsta nces:
Enrollment in any other clinical trial involving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
Invest igator/Physician Decisio n
othe invest igator/ physician decides that the patient should be discontinued from the 
study or study drug(s)
oifthe pat ient, for any  reason, requi res treatm ent with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  drug(s) occurs prior to introduction of the other 
agent
PatientDecision
othe patientor the pati ent’s designee (for example, parents or legal guardian) 
requests to be discont inued from the study or study drug
Sponsor Decisio n
oLillystops the study  or stops the patient’s participation in the study  for medical, 
safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and GCP
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 39
LY3022855 (IMC -CS4)The patient has confi rmed evidence o f progressive disease.
oExcept ions for con tinuing wi th study  treatm ent bey ond confirmed radiographic 
progression may be m ade on a case -by-case basis for pati ents who are believed to 
be clinically  benefi ting from protocol  therapy  and both the invest igator and 
sponsor (the CRP/ clinical research scient ist [CRS ])agree that con tinuing protocol 
therapy  is in the patient’s best interest.
The patient experiences unacceptable toxicit y.
The patient experiences a Grade 3 or 4 infusion -related reacti on (IRR) to LY3022855 .
The patient experiences Grade ≥[ADDRESS_753899] or ALT elevat ion andGrade ≥2 bilirubin 
elevation(cases confirmed by [CONTACT_25742]’s Law).
The patient is nonco mpliant with study  procedures and/or treatment (Section 7.6).
The reason for and date ofdiscont inuat ion will be collected for all pat ients.  The Date of 
Discontinuati on(for any  of the above reasons) from study  treatm ent is to be reported on the 
eCRF.  Patients who discont inue will have fo llow-up procedures performed as shown in the 
Study Schedule ( Attachment 1 ).
6.3.2. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ethical review board 
(ERB) of the study  site judges it necessary for any  scientific, m edical , safet y, regul atory , ethi cal, 
or other reason s consistent with applicable laws, regulat ions, and GCP .
6.3.3. Discontinuation of the Study
The study  will be di scontinued if Lilly , while considering the rights, safet y, and well -being o f the 
patient(s), judges it necessary  for any  scientific, medi cal, safet y, regulatory , ethi cal, or other 
reasons consistent with applicable laws, regulations, and GCP .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 40
LY3022855 (IMC -CS4)7.Treatment
7.1. Materials and Supplies
LY3022855 for Inject ion is supplied at 5 mg/mL strength as a solut ion dosage, packaged in glass 
vials wit h an elastomeric closure.  Each vial of LY3022855 for Injection contains [ADDRESS_753900] ( 100 mg/20 -mL vial).  Vials of LY3022855 for Injectionshoul d be stored 
refrigerated at 2°C to 8°C.  The drug product is formulated to contain the active LY3022855 in 
10mM histidine, 100m M glycine, 100mM arginine, and 0.01% polysorbate 80 at pH 6.0.   
LY3022855 is a clear or slightly opalescent and colorless or slight ly yellow liquid without 
visible particles.
LY3022855 will be administered as an I.V.infusio n.  The dose is prepared and infused at room 
temperature (23 °C-27°C).  LY3022855 will be diluted in normal saline to a final vo lume of 
250mL.  Lilly instructi ons regarding dilution requirements should be followed.
Clinical study  materials will be l abeled according to the country ’s regul atory  requi rements.
7.2. Study Drug Administration
Four dosages of LY3022855 will be administered in this study .  Refer to Table JSCB. 1for a 
summary of the LY3022855 dosages to be used.  Eligible patients will receive LY3022855 asan 
I.V. infusio n administered over a minimum durat ion of 30 minutes and a maximum duration of 4 
hours, based on the known safety  and stabili ty of the prepared drug.  The infusio n rate should not 
exceed 25 m g/minute.
Suggested infusio n times are as fo llows:
[ADDRESS_753901] infusio n; if no IRR is observed ,decrease the infusio n time to 
60minutes
60 minutes for the second infusio n; if no IRR is observed ,decrease the infusion t ime to 
30 minutes
[ADDRESS_753902] dose of LY3022855 is dependent upon the patient’s baseline body 
weight in kil ograms.  Subsequent doses of LY3022855 must be recal culate d if there is a ≥10% 
change (increase or decrease) in body  weight from baseline; subsequent doses may be 
recal culat ed if there is a <10% change (increase or decrease) in body  weight from baseline.
For pati ents wi th fluid retention, the estimated dry  weight, instead of the actual body  weight, 
shoul d be used for dose calculat ion or recal culat ion (in the setting o f substant ial fluid retention, 
the Lilly  CRP or desi gnee shoul d be consul ted regarding optimal assessment of dry  weight).
Dosage sC and D are to be n on-weight based (f ixed dosing).
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 41
LY3022855 (IMC -CS4)The invest igator or designee is responsible for:
explaining the correct use of the investigational agent(s) to the site personnel,
verifying that instructions are fo llowed properly,
maintaining accurate records of study  drug dispensati on, destructi on,andcollection, and
returning or destroying all unused m edicat ion to Lilly or its designee at the end of the 
study .
Patients will  be instructed to contact [CONTACT_240220] a com plaint 
or probl em with the study  drug(s) so that the situatio n can be assessed.
7.2.1. Dose Adjustments and Delays
Dose reductions are not permitted within a cycle, only between cycles.
If benefitting fro m treatm ent(that i s, no di sease progressi on or other withdrawal criteria) , a 
patient who experiences a toxicitymay continue to receive LY3022855 upon agreem ent of  the 
sponsor and according to the dose reduction guidelines for this study  (Table JSCB. 2).  For any 
given pat ient in the study , their dose m ay be reduced up to a maximum o f [ADDRESS_753903] Reduction
A 1.0 mg/kg (Weeks 1, 2, 4, and 5) 0.6 mg/kg ( QW) 0.3 mg/kg ( QW) 0.3 mg/kg ( Q2W )
B 1.25 mg/kg ( Q2W ) 0.6 mg/kg ( QW) 0.3 mg/kg ( QW) 0.3 mg/kg ( Q2W )
C 100 mg (QW) 75 mg (QW) 50 mg (QW) 40 mg (QW)
D 100 mg (Q2W) 75 mg (Q2W) 50 mg (Q2W) 40 mg (Q2W)
Abbreviations:  QW = weekly; Q2W = ever y 2 weeks (Weeks 1, 3, and 5) .
In the case of the toxicit ieslisted in Table JSCB. 3, study  treatm ent may  be held (if appropriate, 
in the opi[INVESTIGATOR_3078] n of the invest igator and upon agreement with the sponsor) for a m aximum  of 
4weeks, until reso lution to baseline or improvement to Grade <2.  Upon resolut ion to baseline or 
improvement to Grade <2, study  treatm ent m ay be administered at a reduced dose (according to 
Table JSCB. 2), beginning wit h the next cy cle, if appropri ate, in the opi[INVESTIGATOR_3078] n of the invest igator 
and upon agreement with the sponsor .  If toxicit y does not resolve to baseline or improve to 
Grade <[ADDRESS_753904] administered dose, study  treatm ent shou ld be 
perm anent ly discont inued and the pati ent shoul d be di scont inued fro m the trial.
Once a pat ient has had a dose reduction (has started a new cy cle at the reduced dose), all 
subsequent infusio nswill be at the reduced dose level; there will be no resump tion to pri or dose 
level(s).  Any patientexperiencing toxicit y that woul d necessi tate m ore tha n 3dose reductions 
must discont inue treatment.   Dose reductions must be confirmed by [CONTACT_456].
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 42
LY3022855 (IMC -CS4)Table JSCB. 3. Toxicities for Which Dose A djustments and Delay sApply
Grade 4 hematologic toxicity
Grade 3 hematologic toxicity lasting >7 days
Grade 3 or 4 no nhematologic toxicity.  Exceptions may be be made for the following, if agreed upon by  [CONTACT_574436]:
oGrade ≥[ADDRESS_753905] (LFT) abnormality , such as alkaline phosphatase, gamma glutamyl 
transferase (GGT), AST, and ALT, n ot suspected to be drug related
oTransient Grade ≥2 bilirubin elevation in the presence of known li ver metastases lasting ≤7 days
oLaborato ry abnormalities that improve to Grade <2 or baseline levels within 7 days after initial 
documentation
oLaborato ry abnormalities ≥Grade 3 that are deemed not clinically significant 
oGrade ≥3 asymptomatic elevation of CK WITHOUT elevation in serum and urine myoglobin
Abbreviations:  ALT = alanine aminotransferase ; AST = aspartate aminotransferase ; CK = creatine kinase; 
CRP =clinical research physician.
Refer to Section [IP_ADDRESS] (Infusio n-Related Reactions) regarding dose adj ustment, delay, and 
discontinuat ion of study  treatm ent due to LY3022855 IRRs .
[IP_ADDRESS]. Infusion -Related Reactions
If a patient experiences Grade 1 IRR/allergic reactio n, the infusio n rate shoul d be decreased by 
50% for the duration of the infusio n.  In case of a Grade 2 IRR/allergic react ion, the infusio n 
must be st opped until reso lution to Grade ≤1; the infusio n may then be resumed at 50% of the 
prior infusio n rate (the duration of the infusio n shoul d not exceed 3hours).  Once the infusio n 
rate has been reduced for a Grade 1 or 2 IRR , it is recommended to m aintain the l ower infusio n 
rate for all s ubsequent infusio ns (prem edicat ion must be provided prior to any subsequent doses 
of LY3022855 if the patient has experienced a Grade 1 or 2 IRR).  Occurrence of a Grade [ADDRESS_753906] 1 hour after the end of the infusio n of LY3022855 .  This 
observat ion is to be done in an area with resuscitat ion equipment and medicat ions necessary for 
advanced life support and cardiopulmo nary resuscitation, such as bronchodilators, vasopressor 
agents ( for example , epi[INVESTIGATOR_238]), oxy gen, gl ucocorti coids, ant ihistamines, and I.V. fluids, etc.
CAUTION:  Infusion -related reacti onsmay occur during or fo llowing LY3022855
administration.
Prem edicat ion is not recommended to be administered prior to the first infusio n of LY3022855 .  
However, if the pat ient experiences a Grade [ADDRESS_753907] igator and the Lilly CRP.  In such cases (Grade 1 or 
2 IRRs ), administration of steroids should be avo ided, if possible.   Any premedicat ion 
administered should be documented in the eCRF, including dose and route of administration.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 43
LY3022855 (IMC -CS4)If at any  time a patientexperiences an IRR to LY3022855 , all attempts will be made to obtain a 
blood sample for immunogenicit y analysis as close t o the onset of the event as possible, at the 
resol ution of the event, and 30 day sfollowing the event. A portion of the sample taken for 
immunogenicit y testing may be used for PK analysis, in the setting of IRRs .
Forfurther details regarding IRRs , including characterizat ion according to CTCAE v4.0 and 
treatment gui delines ,refer to the LY3022855 IB.
[IP_ADDRESS]. Other Adverse Events
Based on observations in nonclinical toxico logical studi es wi th LY3022855 and/or observations 
in one clinical trial wit h another mo noclonal antibody  targeting CSF -1 (Sadis et al. 2009), 
patients receiving LY3022855 shoul d be cl osely  moni tored for si gns indicat iveof hepatic 
funct ion impairment ( for example , increases in transaminases, LDH , bilirubin, coagulat ion 
disorders), inflammat ion (for example , leukocy te alterati ons, C -reactive protein ), CK increases, 
and periorbital swelling.  For details, refer to the LY3022855 IB.
[IP_ADDRESS].1. Immune -Related Adverse Events (irAE s)
Symptom s occurring during or following infusio n of investigational therapy  will be defined 
according to the NCI- CTCAE, Version 4.0.
In the setting of symptoms consistent with irAE soccurring following infusio n of invest igational 
therapy , invest igators are encouraged to refer to Attachment [ADDRESS_753908] ic 
medical evaluat ions for possible non -immune -related causes of AEs.  Attachment 10 is a 
guideline for the m anagement of i rAEs; local standards m ay supersede recommendat ions when 
deem ed appropri ate by [CONTACT_093].
7.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be assigned to receive LY3022855 in this study .  
Before each pat ient’s enro llment into the study, an eligibilit y check must be conducted between 
the invest igational site and the Lilly clinical  research per sonnel to confirm that each patient 
meets all enrollment criteria.  Upon confirmation of eligibilit y, the sponsor will confirm the dose 
and ident ificat ion number assignment for each patient.
7.4. Blinding
This is an open -label study .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 44
LY3022855 (IMC -CS4)7.5. Concomitant Therapy
No othe r chemotherapy , immunotherapy , or experimental drugs will be permitted while the 
patients are on thi s study (refer to Secti ons6.1.1 and 6.1.2 for entry  criteria) . Exception swill be 
made for :
Prostate cancer patients continuing GnRH agonist /antagonist therapy (refer to Incl usion 
Criterion [2] in Section 6.1.1 )
Prostate cancer patients receiving prednisone up to 10 mg/day ( or an equivalent dose of 
another glucocortico id agent)
Breast can cer pati ents continuing antiestrogen therapy  (for example , an arom atase 
inhibitor) or trastuzum ab
Palliat ive radiotherapy  will be allowed provi ded pati ents do not have overt signs of progression .  
Any disease progression requiring other forms of specific a ntitumor therapy  will also necessi tate 
early  discontinuat ion from the study .  Appropri ate docum entati on forall forms of prem edicat ion, 
supportive care, and conco mitant m edicat ion must be captured on the eCRF . Replacement 
horm onal therapy  initiated before study  entry  will be allowed.
Patients shoul d receive full supportive care with the except ion that the routine use of granulocyte 
colony-stimulat ing factors is not permitted during this study. Should the use of hematopoiet ic 
colony-stimulat ing factors (CS Fs) be necessary, the American Societ y of Clinical Oncol ogy 
(ASCO) recommendat ions for the use of CSFs (Smit h et al . 2006) should be fo llowed.  If 
clinically indicated at any  time during the study , erythropoi etin and packed red blood cell 
transfusio ns m ay be used according to ASCO guidelines (Rizzo et al. 2010).
All conco mitant m edicat ions should be recorded throughout the patient’s participat ion in the 
study .
7.6. Treatment Compliance
LY3022855 will be administered I.V.at the investigational site, under the direct ion of the 
investigator.  As a result, a patient’s co mpliance wit h study  drug administration is ensured.  
Patients shoul d attend scheduled clinic visit s and must comply  with study  criteria under thei r 
control . Deviat ion(s) fro m the prescribed dosage regimen should be recorded on the eCRF.
7.6.1. Evaluable Patients
Patients who wi thdraw from  the study  before receiving study  drug(s) will be replaced and will 
not be included in the safet y or efficacy  assessments.  Safet yanalyses will be conducted on all 
patients who have received at least onedose of study  drug, regardl ess of whether they  are 
deem ed evaluable for the assessment of a dose level.
Any pat ient who does not complete 1cycle of LY3022855 treatm ent, undergo 1 baseline and 
1posttreatment tumor biops y procedure (ie, attempted, whether the biopsy is successful or not) , 
and co mplete immune blood studies for 1 cycle will be deemed nonevaluable for assessment of a 
dose l evel.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 45
LY3022855 (IMC -CS4)Patients who complete 1cycle of LY302285 5treatment, undergo 1baseline and 1posttreatment 
tumor biopsy procedure (ie, attem pted, whether the biopsy is successful or not) , and com plete 
immune blood studies for 1cyclewill be considered evaluable for the assessment of a dose level.   
Nonevaluabl e pati ents m ay be repl aced to ensure that [ADDRESS_753909] igator(s) and the Lilly CRP or CRS to ensure 
adequate PK data.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 46
LY3022855 (IMC -CS4)8.Safety , Pharmacokinetic, Pharmacody namic, and 
Efficacy Data Collection
8.1. Safety Evaluations
The safet y and tol erabilit y of LY3022855 have been assessed in nonclinical toxico logy studi es 
and the results from these studi es are detailed in the IB.  This Phase 1 study  contains detailed 
safet y monitoring that will permit further characterizat ion of the safet y profile o f LY3022855 in 
patients , bey ond that ini tially characteri zed in Phase 1 study  JSCA .  Study  procedures and th eir 
timing, including co llection ofblood and urine samples, are described in the Study  Schedule 
(Attachm ent 1 ).
Standard laboratory  tests, includin g chemistry , hematol ogy, coagul ation,and urinalysis panels , 
will be performed.  A urine or serum pregnancy test (based on institutional standards) will be 
administered if applicable.  Other clinical laboratory tests will also be co llected.  Attachment [ADDRESS_753910] to 
follow-up.  Frequency  of AE and SAE follow-up evaluat ion is left to the discret ion of the 
investigator.
The timing of all safet y evaluat ions is shown in the Study  Schedule ( Attachm ent 1 ).  
Table JSCB .4presents a summary  of AE and SAE reporting guidelines.  Table JSCB .4also 
shows which database or system is used to store AE and SAE data .
8.1.2. Adverse Eve nts
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical occurrence 
in a pati ent or clinical invest igation subject administer ed a pharmaceut ical product and which 
does not necessarily  have a causal  relati onship wi th this treatm ent.  An adverse event (AE) can 
therefore be any  unfavorable and unintended sign (including an abnormal laboratory  finding), 
symptom
, or disease tem porall y associated wi th the use of m edicinal (invest igational) product, 
whether or not related to the medicinal (invest igational) product .  Any clinically significant 
findings fro m labs, vital sign measurements, and so on that occur should also be reported to Lilly
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 47
LY3022855 (IMC -CS4)or its desi gnee as an AE .  Lack of drug effect is not an AE in clinical studies because the purpose 
of the clinical study  is to establish drug effect.
The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs. All pat ients will be assessed routinely for AEs as outlined in the study  schedule.  All AEs 
observed will be graded using CTCAE v4.0.
The National Cancer Inst itute (NCI)-CTCAE v4.0 will serve as the reference document for 
choosing appropriate termino logy for, and grading the severit y of,all AEs and other symptoms . 
All AEs observed will be graded using CTCAE v4.0.  Any minor versio n of CTCAE v4.0 (for 
example, v ersion 4.0X) m ay be used for thi s study .  Minor CTCAE v4.[ADDRESS_753911] igator will be responsible for selecting the appropri ate sy stem  
organ class and assessing severit ygrade based on t he intensity of the event.   Note that both 
CTCAE term (actual or coded) and severit y grade must be selected by  [CONTACT_574437].  Thi s collection is in addition to verbat im text used to describe the AE.
In addit ion to collect ing the AE verbat im, the CTCAE term, and the CTCAE severit y grade, AE 
verbat im text will also be mapped by [CONTACT_574438].
Cases of pregnancy that occur during maternal or paternal exposures to study  drug shoul d be 
reported.  Data on fetal outcome and breastfeeding should be collected, if feasible, for regulatory 
reporting and drug safet y evaluat ion.
Upon docum entati on of  pregnancy , the pati ent m ust be re moved fro m the study  and treatment 
with study  drug(s) m ust be stopped immediately.
For all enrolled pat ients, study  site personnel will record the occurrence and nature of each 
patient’s preexist ing condit ions, including clinically  significant si gns and sy mptoms of the 
disease under treatment in the study .  While the pati ent is on study , site personnel will record any  
change in these preexist ing condit ion(s) and the occurrence and nature of any  AEs.  In addit ion,
all AEs related to protocol  procedures are r eported to Lilly or desi gnee.
If a patient's dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly or its desi gnee via eCRF the ci rcumstances and data 
leading to any  such dosage reduction or discont inuation of treatment.
Invest igators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure orstudy drug via eCRF.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 48
LY3022855 (IMC -CS4)The invest igator decides whether he or she interprets the observed AEs as ei ther rel ated to 
disease, to the study  medicat ion, study  procedure, or other concomitant treatment or pathologies.  
To assess the relat ionship of the AE to the study  drug, the fo llowing termino logies are defined:
Related :  Adirect cause and effect relat ionship between the study  treatm ent and 
the AE i s likely.
Possibly related :  Acause and effect relat ionship between the study  treatm ent 
and the AE has not been demo nstrated at th is time and is not probable, but is also 
not impossible.
Unrelated :  Without question, the AE is definitely not associated with the study  
treatm ent.
As per Lilly’s standard operating procedures ,all “related” and “possibly  related” AEs and SAEs 
will be d efined as rel ated to study  drug.
[IP_ADDRESS]. Serious Adverse Events
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
Planned hospi [INVESTIGATOR_574417]’s medical history  at the time of study enrollment shoul d not be 
considered SAEs.  Hospi[INVESTIGATOR_338253] a precipi[INVESTIGATOR_454828](for example , for the a dministrati on of  study  therapy or other protocol -requi red 
procedure )should not be considered SAEs.
An SAE is any  adverse event during this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094] (excep t for study  drug 
administration)
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
considered significant by  [CONTACT_574439], be life -threatening, or require 
hospi [INVESTIGATOR_338255], based on appropriate medical judgment, they  
may jeopardize the patient and may require medical or surgical intervent ion to prevent one of the 
outcomes listed in this definit ion.
Serious adverse events due to disease progression, including death, should not be reported unless 
the invest igator deems them to be possibly related to the study  drug.
Study  site personnel  must al ert Lilly orits designee of any SAE within [ADDRESS_753912] igator 
awareness o f the event via a sponsor -approved method.  If alerts areissued via telephone , they
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 49
LY3022855 (IMC -CS4)are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow-up SAE 
inform ation.
If an invest igator becomes aware of SAEs occurring after the patient’s participation in the trial 
has ended, and the invest igator believes that the SAE is relat ed to a protocol procedure or study  
drug, the invest igator should report the SAEs to the sponsor, and the SAEs will be entered in the
Lilly Safety  System .
Inform ation on SAEs expected in the study  popul ation independent of drug exposure and that 
will be assessed by  [CONTACT_92356].
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting
Data on SAEs that occur before the end of trial will be stored in the col lection database and the 
Lilly S afety  System (see Attachment 7 for reporting recommendations ).
[IP_ADDRESS].1. Prior to Administration of Study Drug(s)
During screening, all AEs and SAEs (regardless of relatedness to protocol procedures) are 
collected after the patient has signed the informed consent form (ICF) .  For patients who do not 
enroll in the tri al (that is, have not receive dat least onedose of LY3022855 ), only  AEs and 
SAEs related to protocol procedures are required to be collected.
[IP_ADDRESS].2. On Therapy
All AEs and SAEs, regardless of relatedness to study  drug(s) or protocol procedures, occurring 
while the patient is receiving study  drug m ust be reported to Lilly or its designee.  A patient is 
considered to be receiving study  drug from  the time he/she rec eives the first dose of study  drug
until the t imehe/she receives the last dose of study drug.
[IP_ADDRESS].3. 30-Day Follow -Up Visit
All AEs and SAEs , regardl ess of relatedness to study  drug(s) or protocol procedures, occurri ng 
during the 30-D ay 
Follow-up visit must be r eported to Lilly or its desi gnee .  The 30-D ay
Follow-up visit starts fo llowing the l ast dose of study  drug and lastsapproximately [ADDRESS_753913] specific safet y
assessments 
(Attachm ent 1 ).  The timing o f these safet y assessments is to occur 30 day s ±[ADDRESS_753914] 
possibly  related to study  drug.  In thi s instance, the pati ent shoul d be f ollowed in subsequent 
follow-up visits (every  30 days) until the event is reso lved, the event is no longer considered to 
be drug -related, the event becomes stable or returns to baseline, a new treatment is init iated for 
the pati ent, or the patient dies or is lost to fo llow-up.
If it is deemed to be in the best interest of the patient to start a new ant icancer treatment prior to 
the scheduled end of the 30-D ay Follow -up visi t, the durati on for this visit may be shortened. In 
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 50
LY3022855 (IMC -CS4)this case, the fo llow-up assessments should be completed prior to the init iation of the new 
therapy .
After the 30-D ayFollow-up visit ,AEs are not required to be reported unless the invest igator 
feels the AEs were related to either study  drug, drug delivery  system , or a protocol  procedure. If 
an invest igator becomes aware of an SAE believed to be related to protocol p rocedures or study  
drug, the invest igator should report the SAE to the sponsor, and the SAE will be entered in the
Lilly Safety  System .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are serious adver se events that are 
not listed in the Devel opment Core Safet y Informati on  in the IB and that the invest igator 
ident ifies as related to study drug or procedure.  The [LOCATION_002] [ADDRESS_753915] ive 2001/20/EC ,and th e associ ated detailed guidances or nati onal 
regul atory  requi rements in partici pating countri es requi re the reporting of S[LOCATION_003]Rs.  Lilly has 
procedures that will be fo llowed for the recording and expedited reporting of S[LOCATION_003]Rs that are 
consistent with glo bal regulatory  regul ationsand the associated detailed guidances.
[IP_ADDRESS]. Summary of AE/SAE Reporting Guidelines
The AE and SAE reporting guidelines are summarized in Table JSCB .4.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 51
LY3022855 (IMC -CS4)Table JSCB .4. Adverse Event and Serious A dverse Reporting Guidelines for 
Study JSCB
Timing Types of AEs/SAEs ReportedCollection 
DatabaseLilly Safety 
System
Prestudy (baseline assessments)
(starts at the signing of informed consent and 
ends immediately before the first dose of study 
drug)Preexisting conditions
All AEs
All SAEs ,regardless of 
relatednessx
x
x x
On therapy
(starts at first dose of study drug and ends at 
last dose of study drug)All AEs
All SAEs ,regardless of 
relatednessx
x x
30-Day  Follow -up v isit
(starts justafter the last dose of study drug and 
ends when end-of-study  safety  assessments are 
completed [ 30 days ± [ADDRESS_753916] dose of 
study drug] )All AEs
All SAEs ,regardless of 
relatednessx
x x
Subsequent follow -up visits, if necessary for 
patient monitoringOngoing AEs possibly related to 
study drug(s) or protocol 
procedures
All SAEs related to protocol 
procedures or study drugx
x x
Continued access period (starts after study 
completion and ends at the end of the trial)All AEs
AllSAEs ,regardless of 
relatednessx
x x
Continued access period follow -up
(starts justafter the last dose of study drug and 
ends when end -of-study  safety  assessments are 
completed [ 30 days ± [ADDRESS_753917] dose of 
study drug])All AEs
All SAEs ,regardless of 
relatednessx
x x
Patient no longer on study All SAEs related to protocol 
procedures or study drug that the 
investigator becomes aware ofx
Abbreviations:  AEs = adverse events; SAEs = serious adverse events.
8.1.3. Other Safety Measures
[IP_ADDRESS]. Electrocardiograms
For each patient, a local 12-lead digital ECG will be collected (norm al vs clinically significant ly 
abnorm al)according to the Study  Schedule (Attachment 1 ).  Patients must be supi[INVESTIGATOR_51938]  [ADDRESS_753918] ion of more ECGs (more replicates) than expected at a particular time point i s allowed to 
ensure high -qualit y records.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 52
LY3022855 (IMC -CS4)Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patientis still pres ent,to determine whether the patient meets entry  criteria at the rel evant visit(s) 
and for immediate patientmanagement, should any clinically r elevant findings be identified.
If a clinically significant quantitative or qualitat ive change fro m baseline isident ified after 
enrollment, the investigator will assess the patientfor symptom s (for example , palpi[INVESTIGATOR_814], near 
syncope, syncope) to determine whether the patientcan continue in the study .  The invest igator 
or qualified designee is responsible for de termining if any change in patientmanagement i s 
needed and must document his/her review of the ECG printed at the time of evaluat ion from at 
least oneof the replicate ECGs from each t ime point.
8.1.4. Safety Monitoring
The Lilly CRP or CRS will mo nitor safety  data throughout the course of the study .
Representatives from Lilly Glo bal Patient Safet y will specifically  monitor SAEs.  Lilly will 
review SAEs wit hin time frames mandated by [CONTACT_365203].   The 
LillyCRP/CRS will, as is appropriate, consult with the funct ionally  independent Gl obal Pati ent 
Safety therapeuti c area physician or clinical research scient ist, and periodically review:
Trends in safet y data.
Laboratory  analy tes,including AP, ALT, AST, CK, LDH, and C-react ive protein .
Adverse events ,including monitoring of hepatotoxicit y and m uscle dam age.
If a study  patient experiences elevated ALT ≥5 × ULN and elevated total bilirubin ≥2 ×
ULN, clinical and laboratory  monitoring shoul d be ini tiated by  [CONTACT_154715].
For pati ents entering the study  with ALT ≥3 × ULN, monitoring should be triggered at 
ALT ≥2 × baseline.
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.  To ensure patient saf ety and to comply with regulatory  guidance, the 
investigator is to consult with the Lilly CRP/CRS regarding collect ion of specific reco mmended 
clinical informat ion and fo llow-up laboratory  tests (see Attachm ent 3 ).
8.1.5. Complaint Handling
Lilly collects complaints on study  drugs used in clinical studies in order to ensure the safet y of 
study  participants, m onitor quali ty, and f acilitate process and product improvements.
Com plaint s related to concomitant drugs are reported directly to the manufacturers of those 
drugs in accordance with the package insert.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 53
LY3022855 (IMC -CS4)The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
complaint process in accordance with the instructions provided for this study :
recording a complete descript ion of the complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed complaint for m within [ADDRESS_753919] igation, he/she will return a copy  of the 
product complaint form with the product.
8.2. Sample Collection and Testing
Attachm ent [ADDRESS_753920] ions 
specifically for PK, pharmacodynamic s, and immunogenicit y in this study .
8.2.1. Samples for Study Qualification and Health Monitoring
Blood, urine , and t issue samples will be collected to determine whether patients meet 
inclusio n/excl usion criteria and to m onitor pati ent heal th.
C-reactive protein will be assessed as a serum marker of inflammat ion.  Total CK will be 
monitored vi a the chemistry  panel ,and serum and urine myoglo bin will be measured in the event 
that serum  CK ≥2.5 × ULN.   Coagulation parameters will be assessed prior to bi opsy  procedures.   
Refer to Attachment [ADDRESS_753921] 6 core needle samples ;however, if it is not medically feasible 
to collect [ADDRESS_753922] discussed with and agreed upon by  [CONTACT_92338] .  Due diligence should 
be used to ensure that tumor specimen (not normal adjacent or tumor margins) is provided.
Invest igators must document their review of each laboratory  safety  report.   Invest igators must 
also document their determination o f clinical significance of all abnormal laboratory  values.
Samples co llected for specified laboratory te sts will be destroy ed wi thin [ADDRESS_753923] results.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run ,or to retain the samples until the end of the study  to confirm  that the resul ts 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on standards.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 54
LY3022855 (IMC -CS4)8.2.2. Samples for Drug Concentration Measurements 
Pharmacokinetics/ Pharmacodynamics
Pharmacokinet ic and pharmacodynamic samples will be co llected as specified in Attachment 1 .
[IP_ADDRESS]. Pharmacokinetic Samples
At the visit s and t imes specified in the sampling schedule ( Attachment 4 ,Attachment 5, and 
Attachm ent 6 ), venous blood samples of approximately [ADDRESS_753924] ion and handling of blood samples will be provi ded by  [CONTACT_103] .  The actual date and time o f each sampling mustbe clearly  and accurately recorded.
These s amples will be analyzed at a laboratory  designated by  [CONTACT_456].  Serum concentrati ons 
of LY3022855 will be assayed using a validated ELIS Amethod.
The PK s amples will be stored at a facilit y (in the [LOCATION_002]) designated by  [CONTACT_456].
The rem aining serum from the samples co llected for PKmay be pool ed and used for exploratory  
metabo lism work as deemed appropriate.
Bioanaly tical samples collected to measure invest igational product concentration will be retained 
for a maximum of [ADDRESS_753925] patient visit for the study .
[IP_ADDRESS]. Pharmacodynamic Samples
The fo llowing pharmacodynamic assessments are based on the primary  study  object ive and are, 
therefore, required assessments.  Samples will be tested for changes fro m baseline over time in 
peripheral  blood immune cell  subsets and in serum cy tokines to document the 
immuno modulatory  activity of LY3022855 treatment in patients with advanc ed, refractory  breast 
orprostate cancers .  Flow cy tometric analysis using an ant ibody  panel thatmay include ,but not 
be limited to markers Live -Dead, CD3, CD4, CD8, CD14, CD16, FoxP3, PD-[ADDRESS_753926] ion of samples for other bio marker research is also part of this study .
I5F - MC- JSCB (d)  Phase1  Onco logy  P ro toco l Page  55
LY3022855( IMC - CS4 )R equ ir ed  s amp l e s  fo r  b i om a r k e r  r e s e a r c h  t o  b e  c o l l e c t e d  f r om  a l l  p a t i e n ts  in  th i s  s tudy  a r e  t h e  
f o l l o w i n g :
 b l o od  ( f o r  exp l o r a to ry  a n a l y s i s  o f  s e rum  b i om a rk e r s  th a t  m ay  b e  r e l ev an t  to  th e
m e c h a n i sm  of  a c t i on  o f  LY 3 0 2 2 8 5 5,
 t um o r  t i s s u e  ( f o r  e x p l o r a t o r y  a n a l y s i s  of  th e  imm u n o m odu l a to ry  e f f e c t s  o f  LY 3 0 2 2 8 5 5
a dm i n i s t r a t i o n ,  i n c l u d i n g  t h e  u n d e r s t a n d i n g  o f  th e  p h a rm a c o d y n am i c  e f f e c t so f
LY 3 0 2 2 8 5 5)
T i s s u eb i o p s y  w i l l  b e  t a k e n  b y  co r e  n e ed l e  b i op sy  o r  su rg i c a l  b i op sy .   F in e - n e e d l e  a s p i r a t i o n
shou l d  no t  b e  u s ed  a s  a  m e t h o d  o f  t i s s u e  a c q u i s i t i o n ,  u n l es s  f i r s t  d i s c u s s e d  w i t h  t h e  L i l l y  CRP .   
D u e  d i l i g e n c e  s h o u l d  b e  u s e d  t o  e n s u r e  t h a t  t um o r  s p e c im e n  ( n o t  n o rm a l  a d j a c e n t  o r  t um o r  
m a rg in s )  i s  p rov id ed .   P a tho logy no t e s  a c com p any ing  th e  t i s su e  m a y  a l s o  b e  r e q u e s t e d .   T i s s u e  
a n d  b l o o d  s am p l e s  w i l l  b e  k e p t  w i th  t h e  i n t e n t i o n  t o  p e r f o rm  t e s t s  a s  n ew  t e c h n i q u e s ,  r e s e a r c h  
too l s ,  a n d  b i o m a r k e r s  b e c om e  a v a i l a b l e .
Op t ion a l  t i s s u e( co r e  n e ed l e  o r  su rg i c a l  b i op sy )a n d /o rb l o o d  s am p l e s( i n  a d d i ti o n  t o  t h e  r e q u i r e d  
s am p l e s  p r ev iou s ly  d e s c r ib ed )f o r  b i om a r k e r  r e s e a r c h  m ayb e  ob t a in ed  a t  th e  i n v e s t i g a t o r ’ s
d i s c r e t i o n  i n  d i s c u s s i on  w i th  th e  p a t i e n t ,  s u c h  a s  a t  t h e  t im e  o f  r a d i o g r a p h i c  r e s p o n s e  o r  t r e a tm e n t  
p r o g r e s s i o n .
T h e  s am p l e s  w i l l  b e  c o d e d  w i t h  t h e  p a t i e n t  n um b e r  a n d  s t o r e d  a t  a  f a c i l i t y  s e l e c t ed  by  [CONTACT_3433] e  
spon so r  f o r  u p  t o  a  m a x im um  o f  1 5y ea r s  a f t e r  th e  l a s t  p a t i en t  v i s i t  fo r  th e  s tudy .   Th e  s am p l e s  
a n d  a n y  d a t a  g en e r a t ed  f rom  th em  c an  on ly  b el ink ed  b a ck  to  th e  p a t i en t  by  i n v e s ti g a t o r  s i t e  
p e r s o n n e l .   T h e  d u r a t i o n  a l l ow s  t h e  s p o n s o r  t o  r e s p o n d  t o  r e g u l a t o r y  r e q u e s t s  r e l a t ed  to  th e  s tudy  
d rug .
S amp l e s  w i l l  b e  d e s t roy e d  a c c o r d i n g  t o  a  p r o c e s s  c o n s i s t e n t  w i t h  l o c a l  r e g u l a t i o n .  P a t i e n t s  m a y  
r equ e s t  to  h av e  th e i r  s amp l e s  d e s t roy ed  a t  any  t i m e .
8 .2 .3 .Samp les  fo r  Ta i lo r ing  B ioma rke rsCC I
Th e r e  is  g r ow i n g  e v i d e n c e  t h a t  g e n e t i c  v a r i a t i o n  m ay i mp a c t  a  p a t ien t ’ s  r e spon s e  to  th e r apy .   
V a r iab l e  r e spon s e  to  th e r apy  m ay  b e  d u e  t o  g e n e t i c  d e t e rm i n a n t s  t h a t  im p a c t  d r u g  a b s o r p t i o n ,  
d i s t r i b u t i o n ,  m e t a b ol i sm ,  a n d  e x c r e t i o n ,  t h e  m e c h a n i sm  o f  a c t i o n  o f  t h e  d r u g ,  t h e  d i s e a s e  
e t i o l ogy  and /o r  th e  m o l e c u l a r  s u b t y p e  o f  t h e  d i s e a s e  b e i n g  t r e a t e d .   T h e r e f o r e ,  w h e r e  l o c a l  
r egu l a t i o n s  a n d  ERB s  a l l ow ,  a  b lood  s am p l e  w i l l  b e  c o l l e c t e d  f o r  p h a rm a c o g e n e ti c  a n a l y s i s .
I n  t h e  e v e n t  o f  a n  u n e x p e c t e d  AE  o r  t h e  o b s e r v a t i o n  o f  u n u s u a l  r e s p o n s e ,  t h e  p h a rm a c o g e n e t i c  
b i om a rk e r  s am p l e s  m ay  b e  g eno ty p ed  and  an a ly s i s  m ay  b e  p e r fo rm ed  to  ev a l u a t e  a  g e n e ti c  
a s so c i a t i o n  w i th  r e spon s e  to  LY 3 0 2 2 8 5 5.   T h e s e  i n v e s t i g a t i o n s  m a y  b e  l im i t e d  t o  a  f o c u s e d  
c and id a t e  g en e  s tudy  o r ,  i f  app rop r i a t e ,  g enom e - w i d e  a n a l y s i s  m a y  b e  p e r f o rm e d  t o  i d en ti f y  
r eg i on s  o f  th e  g enom e  a s so c i a t ed  w i th  th e  v a r i ab i l i ty  o b s e r v e d  i n  d r u g  r e s p o n s e .   T h e  
p h a rm a c o g e n e ti c  b i om a r k e r  s am p l e s  w i l l  o n l y b e  u s e d  f o r  i n v e s t i g a t i o n s  r e l a t ed  to  d i s e a s e  a n d  
d r u g  o r  c l a s s  of  d rug s  und e r  s tudy  i n  t h e  c o n t e x t  o f  t h i s  c l i n i c a l  p r og r am .   T h e y  w i l l  n o t  b e  u s e d  
f o r  b ro ad  exp l o r a to ry  u n s p e c i f i e d  d i s e a s e  o r  p o p u l a t i o n  g e n e t i c  a n a l y s i s .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 56
LY3022855 (IMC -CS4)The samples will be coded with the patient number and stored for up to a maximum o f 15years 
after the l ast pati ent vi sit for the study , at a f acilit y selected by  [CONTACT_456].  The samples and any 
data generated from them can only be linked back to the patient by  [CONTACT_240241].  
The durati on allows the sponsor to respond to regulatory  requests related to the study  drug.
Samples will  be destro yed according to a process consistent with local regulat ion.
Refer to Section [IP_ADDRESS] , Pharmacodynamic Samples, for details of samples collected for other 
biomarker research that is part of this study .  These other samples may be used for research to 
develop methods, assays, prognosti cs and/or com panion diagnosti cs rel ated to CSF -1, CSF-1R,
and/or the mechanism o f action of  study  drugs (LY3022855 ).
8.2.4. Samples for Immunogenicity Research
Blood s amples for immunogen icity testing will  be collected to determine ant ibody  producti on 
agains t LY3022855 .  Immunogenicit y will be assessed by  a validated assay  designed to detect 
ADA in the presence of LY3022855 .  Ant ibodies may be further characterized and/or evaluated 
for thei r abili ty to neutralize the activit y ofLY3022855.
In addit ion to pl anned sampling for immunogenicit y testing, if at any  time a patientexperiences 
an IRR to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicit y 
analysis as close to the onset of the event a s possible, at the resolution of the event, and [ADDRESS_753927] pati ent visit for the trial at a 
facilit y selected by  [CONTACT_574440]3022855 .  
The durati on allows the sponsor to respond to regulatory requests related to LY3022855 .
8.3. Efficacy Evaluation
One of the s econdary  obje ctivesof the study  is to measure any ant itumor activit y.  Ref er to 
Attachm ent 1 for details regarding the timing of specific efficacy measures.
Each patient will be assessed by  [CONTACT_45332] m ore of the fo llowing radi ologic tests for tum or 
measurement:
Com puted tom ography  (CT) scan
Magnet ic resonance imaging (MRI)
Chest x-ray, as clinically  indicated
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 57
LY3022855 (IMC -CS4)Each patient’s full extent of disease will also be assessed as fo llows:
For pati ents wi th measurable disease defined by  [CONTACT_393], t umor measurements 
are to be assessed by [CONTACT_393] 1.1 ( Eisenhauer et al. 2009 ; Attachment 9 ) and 
irRECIST ( Nishino et al. 2013 ).
For pati ents wi thprostate cancer, bone metastatic disease is to be evaluated by [CONTACT_43877]2 
criteria (Scher et al. 2008).  ACRPC patient will be considered to have progressed by 
[CONTACT_574441] 2 new l esions are observed on bone scan (com pared wi th 
baseline) , and arethen confirmed on a fo llow-up bone scan perform ed at least [ADDRESS_753928] interval scan 
(Week 6), then the confirmatory  bone scan must dem onstrate at l east 2addit ional new 
lesions ( that is, a total o f at least 4 new l esions,compared withbaseline) . This 
confirmatory  bone scan is required, given the prevalence of pseudoprogression ,often 
referred to as “bone scan flare .” For this trial, bone scans will be performed at baseline, 
Week 6 (first interval), and every  6 weeks thereafter , or as clinically indicated .
The f ollowing are further details o f the PCWG2 criteria for progression in bone :
oFor the first interval assessment bone scan performed following Cycle 1, Day 1, at 
least [ADDRESS_753929] 2new lesio ns (that is, a total of at least4new lesio ns from 
baseline) .
oFor all otherinterval assessment bone scans (that is, after the first posttreatment 
scan) , at least [ADDRESS_753930] be visualized, and a 
confirmatory  bone scan shoul d be perform ed and dem onstrate confirmat ion of 
these 2 (or more) new l esions(that i s, a total  of at least 2 new lesio ns from 
baseline) to be considered progression .
oThe date of progression is considered the date of the first scan that demonstrates
at least2 new l esions.
oChanges in intensit y of bone lesio ns or the extent of exist ing bone lesio ns on bone 
scint igraphy are not considered in the assessment of bone disease progression per 
PCWG2 criteria.
oAmbiguous results on bone scint igraphy may be clarified wit h other imaging 
modalities (CT/MRI) ,per invest igator discretion.
Within [ADDRESS_753931] dose of study  drug ( that is, baseline), each patient will be assessed 
by a radi ologic imaging study  for tum or measurement.  Ul trasound will not be permitted as a 
method of tumor measurement.
Tumor assessment shoul d be repeated every  6weeks, using the same radio logic method that was 
used at baseline.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 58
LY3022855 (IMC -CS4)8.4. Procedure/Sampling Compliance
Every  attem pt will be m ade to enroll patients who have the ability to understand and co mply 
with instructi ons.  Noncom pliant pati ents m ay be discontinued from the study .
The collection t imes of safet y assessments, PK samples, pharm acodynamic samples, and efficacy  
measurements are given as targets, to be achieved within reasonable limits.  The scheduled time 
points m ay be subject to minor alterations; however, the actual collect ion time must be correctly 
recorded on the eCRF or l ab requi sitionform.
The scheduled co llection times may be modified by [CONTACT_365208] y 
and PK informat ion obtained during the study .  Any  major m odificat ions that might affect the 
conduct of the study , pati ent safet y, and/or data integrit y will be detailed in a protocol 
amendment.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 59
LY3022855 (IMC -CS4)9.Data Management Methods
9.1. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
Provide instructi onal material to the study  sites, as appropriate .
Sponsor start-up training to instruct the investigators and study  coordinators.  This 
session will give instruction on the protocol, the complet ion of the eCRFs, and study  
procedures .
Make peri odic visi ts to the study  site.
Be available for consultation and stay in contact [CONTACT_57999] h the study  site personnel  by e-mail, 
telephone, and/or fax .
Review and evaluate eCRF data and/or use standard system editchecks and manual 
listing reviews to detect errors in data collect ion.
Conduct a qualit yreview of the eCRF database.
In addit ion, Lilly or its representatives may periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_82412]/or regulatory  agencies at any  time. Invest igators will be given notice before 
an audit occurs.
To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, the invest igator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study .  If requested, the 
investigator will provide the sponsor, applicable regulatory  agencies, and applicable IRB s/ERBs 
with direct access to the original source documents.
9.2. Data Ca pture S ystems
9.2.1. Case Report Form
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_92363] -provided electronic data capture system.
For data handled by a data managem entthird-party organization ( TPO ), eCRF data and some or 
all data that are related will be managed and stored electronically in the TPO system.  
Subsequent to the final database lock, validated data will be transferred to the Lilly data 
warehouse, using s tandard Lilly  file transfer processes.
For data handled by [CONTACT_365210], eCRF data and some or all data that are related will 
be managed by  [CONTACT_574442]’s system.
9.2.2. Ancillary Data
Data m anaged by  a central  vendor will be stored electronically in the central laboratory’s 
database system.  Data will subsequent ly be transferred from the central vendor to the Lilly 
generic labs system.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 60
LY3022855 (IMC -CS4)Bioanaly tical data will  be stored electronically in the bioanaly tical laborator y’s database.  Data 
will subsequently be transferred fro m the bioanaly tical laboratory  to the Lilly  generi c labs 
system .
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 61
LY3022855 (IMC -CS4)10.Data A nalyses
For thi s study , approximately  40patients will be enro lled. Patients withprostate cancer willbe 
treated at [ADDRESS_753932] cancer will be treated at 1 of 4
dosages of LY3022855 .  Of those enrolled patients, approximately  36 patients will be evaluable :  
[ADDRESS_753933] cancer and 6 patients with advanced, refractory  
prostate cancer .  Refer t o Secti on6.1for the definition of an evaluable patient.
CSF-1 is the primary  pharmacodynamic biomarker documented in Study  JSCA. Serum  CSF-1 
was quant ified for 17 patients over time ;that is, at baseline and [ADDRESS_753934] size (or Cohen’s d) is 5.81. Consequently, the power of observing any change 
between the eighth hour and baseline is clo se to 1 as long as the number of samples is ≥3.
However , when the effect size is as small as 1 for the pharmacodynamic markers other than
CSF-1, the power i s approximately 0.159 if only  3 pati ents are sam pled.
For Dosage sC and D (patients wi th breast cancer) , the sample size of [ADDRESS_753935] overall response rate (ORR) less than 20% indicates inadequate antitumor activit y, then at a 
one-sided t ype 1 error rate of 5%, the total sample size of 10 w ill provide 80% power if the true 
best ORR is 60% or higher ,using a 2-stage desi gn method as fo llows.During the first stage, 5 
patients will  be enrolled and treated on each o f Dosages C and D .If 2or more of the 5 patients 
on ei ther dosage (C or D) are observed to be responders by [CONTACT_574443] , an 
additional [ADDRESS_753936] of an internal review for both the final study  report and any  study -related 
materi al to be authori zed by  [CONTACT_338289].
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 62
LY3022855 (IMC -CS4)10.2. Patien t Disposition
All patient discont inuat ions will be documented, and the extent of each pat ient’s participat ion in 
the study  will be reported.  If known, a reason for their discont inuation will be given.
Asummary  of the number and percentage of patients entered into the study , enrolled in the 
study , and treated ,as well as number and percentage of patients discont inuing (overall and by 
[CONTACT_41419]),will be provided .
A summary  of all importa nt protocol deviat ions will be provided.
10.3. Patient Characteristics
Patient characterist ics will include the fo llowing:
Patient dem ographics
Baseline disease characterist ics
ECOG perform ance status
Preexist ing condit ions
Historical illnesses
Prior disease -related therapi [INVESTIGATOR_014] (including informat ion on best response and 
time toprogressive disease)
Concomitant medicat ions
Other patient characterist ics will be summarized as deemed appropriate.
10.4. Safety Analyses
All patients who receive at least one dose of LY3022855 will be evaluated for safet y and 
toxicity.  Adverse event term s and severit y grades will be assigned by  [CONTACT_454881] v4.0.
All safet y summaries and analyses will be based upon the Safet y Popul ation,defined as all 
enrolled patients who hav e received at l east one dose of study  drug.
Overall exposure to study  drug, the numbers of patients complet ing each cycle, and the dose 
intensity will be summari zed using descriptive statist ics.
An overall summary will be provided for AEs deemed by [CONTACT_574444], and repeated for events regardless of study  drug causalit y.
The number of evaluable pat ients who experienced a TEAE, an SAE, or an AE rel ated to study  
drug, or who died or discontinued from the study  due to an AE will be summariz ed.
Reasons for death will be summari zed separately for on -therapy  and wi thin [ADDRESS_753937] 
dose of study  drug.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 63
LY3022855 (IMC -CS4)Laboratory  resul ts will be classified according to CTCAE v4.0.  Laboratory  resul ts not 
corresponding to a CTCAE v4.[ADDRESS_753938] had samples collected ,and PKserum  concentrations of LY3022855 will 
be determined.
The parameters for analysis will include but not be limited to maximum concentration (C max) 
and trough concentration (Ctrough)of LY3022855 .  Addit ional analyses will be performed if 
warranted by  [CONTACT_33653] ,and other validated PK software programs ( for example, NONMEM) may  be 
used if appropriate and approved by  [CONTACT_574445].  The version of any 
software used for the analysis will be documented and the program will meet the Lilly 
requi rements of so ftware validat ion.
10.6. Pharmacodynami c Analyses
Pharmacodynamic data from all patients undergoing pharmacodynamic assessments will be 
analyzed.
To study  the impact of the study  drug and the dose levels onthe pati ents, the changes from 
baseline over time in peri pheral  bloodimmune cell subset swill be documented .The
immuno modulatory  activity of LY3022855 will be docum ented by  [CONTACT_574446], but are not limited to: Live-Dead, CD3, CD4, CD8, CD14, CD16, FoxP3, PD -1, Ki-67, 
CTLA -4, TIM -3, LAG -3, and ICOS .The expression of those m arkers will be quant ified by [CONTACT_574447] h an ant ibody  panel .
In addit ion, changes fro m baseline over time in serum cytokines will be determined by [CONTACT_574448] . The markers tobe measured using th ese
techno logiesinclude, but are not limited to : CSF-1, IFN-γ, IL -1β, IL -2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, IL -34, and TNF -α.
Biomarker m easures of protein expressio n, based on flow cyto metry, MSD, and ELISA ,will be 
summarized by  [CONTACT_44835]/or dosage , based on enrolled pat ients.  Summary  stati stics may
include means, medians, corresponding standard errors, quartiles, and ranges.  Graphics, 
including profile plots of markers over time, will be generated to explore potential patterns 
between pati ents.  Correl ation analyses between biomarkers and relat ive laboratory  tests maybe 
perform ed to further explore the activit y of LY3022855.
10.7. Pharmacokinetic/Pharmacodynamic Analyses
An exploratory  correl ative analysis o f LY3022855 PK and pharm acodynamics may be 
conducted.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 64
LY3022855 (IMC -CS4)10.8. Efficacy Anal yses
Tumor response data will be reported using list ings and descript ive statist ics.TheORR is 
estimated by [CONTACT_574449] a best overall response of complete 
response ( CR) or partial response ( PR). The disease control  rate ( DCR )is est imated by [CONTACT_574450] a best overall response of CR, PR, or stable disease. A 
95% exact confidence interval will be constructed to determine the level o f preci sion of the ORR 
and D CR if appropriate. Time -to-event variables such as progression -free survival (PFS), 
durati on of  response, and overall survival (OS) will be tabul ated if appropriate. The Kaplan -
Meier method (Kaplan and Meier 1958) will be used to estimate the survival curves, m edians, 
and survival rates at specified time po ints, ifapplicable.
10.9. Interim Analyses
Since this is a Phase 1 study , safety data will be reviewed on an ongoing basis.
For Dosages C and D (patients wi th breast cancer) , interim analyses will be condu cted in each 
dosage to review available safety , efficacy, PK, and pharm acodynamic data after [ADDRESS_753939] patient visit.  In this case, all 
data until the data cutoff date will be used for the analysis o f safet y, efficacy , PK, and 
pharmacodynamic bio markers.   All data defined in the protocol will continue to be collecte d 
from patients on treatment after the data cutoff date.  These data may be reported separately ,and 
the analyses on all patients including these data may not be performed.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 65
LY3022855 (IMC -CS4)11.Informed Consent, Ethical Review, and 
Regulatory Considerations
11.1. Informed Consent
The invest igator is responsible for ensuring that the patient understands the potential risks and 
benefits of part icipating in the study, including answering any questions the patient may have in 
regard to the study  procedures and patient requirements throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the patient’s willingness to continue 
his or her participat ion in the study  in a timely manner.
The ICFwill be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study  and to document that the 
patient is sat isfied with his or her understanding o f the potential risks and benefits o f 
participat ing in the study and desires to participate in the study.
The invest igator is ult imately responsible for ensuring that informed consent is given by [CONTACT_365215] l egal representati ve before the study  is started.  Thi s includes o btaining the appropriate 
signatures and dates on the ICFprior to the performance o f any protocol screening procedures 
and prior to the administration of study  drug.
In thi s protocol , the term  “informed consent ”includes all consent and assent given by [CONTACT_574451].
11.2. Ethical Review
Lilly or its representatives must approve all ICFs before they  are used at invest igative sites(s).  
All ICFs must be co mpliant with the ICH guideline on GCP.
Docum entati on of  ERB approval  of the protocol and the ICF m ust be provi ded to Lilly before the 
study  may begin at the investi gative si te(s).  The ERB(s) will review the protocol as required.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing prior to any  study  activit ies and 
during the cou rse of the trial for any amendments/addendums or administrative notifications :
the current IB
ICF
relevant curri cula vi tae
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 66
LY3022855 (IMC -CS4)11.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m internati onal ethics guidelines, including the 
Declaration of Helsinki and Council forInternational Organizat ionsofMedical Sciences
International Ethical Guidelines 
2) ICH GCP Guideline [E6]
3) applicable laws and regulat ions
The investigator or designee will prompt ly submi t the protocol  to applicable ERB(s).
Some of the obligat ions of the sponsor will be assigned to a TPO.
An identificat ion code assigned by [CONTACT_574452]’s 
name [CONTACT_65146]’s identit y when reporting AEs and/or other study -related data.
11.3.1. Investigator Information
Site-specific contact [CONTACT_246689] a separate document.
11.3.2. Protocol Si gnatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative along with the IB acknowl edgement 
form.
11.3.3. Final Report Signature
[CONTACT_574469] s study , indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will approve the final clinical study  
report for this study , confi rming th at, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 67
LY3022855 (IMC -CS4)12.References
Bourette RP, Rohrschneider LR. Early events in M -CSF receptor signaling. Grow th Factors.
2000;17 (3):155-166.
Cancer Therapy  Evaluat ionProgram , Comm on Terminol ogy Criteria for Adverse Events, 
Versi on 4.0, DCTD, NCI, NIH, DHHS. 2009. Publish date: [ADDRESS_753940] ionally regulates response to 
chemotherapy. Cancer Discov . 2011;1(1):[ADDRESS_753941] R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (ve rsion 1.1). 
Eur J Cancer . 2009;45(2) :228-247.
Ide H, Hatake K, Terado Y, Tsukino H, Okegawa T, Nutahara K, Higashihara E, Horie S. Serum 
level of macrophage co lony-stimulating factor i s increased in prostate cancer patients with 
bone metastasis. Hum Cell. 2008;21(1):[ADDRESS_753942] cancer. Ann Med.
1995;27(1):79 -85.
Kaplan EL, Meier P. Nonparametric estimat ion from incomplete observat ions. J Amer Stat
Assoc . 1958;53(282):457-481.
Lawicki S, Szmitko wski M, Wo jtukiewicz M. The pretreatment plasma level and diagnostic 
utilit y of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta.
2006;371(1 -2):[ADDRESS_753943] role of macrophages in different tumor microenvir onments. 
Cancer Res . 2006;66(2):605 -612.
Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, 
Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT. 
Discovery  of a cy tokine and i ts receptor by  [CONTACT_574453]. 
Science. 2008;320 (5877) :807-
811.
Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. 
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res.
2006;66(23):[ADDRESS_753944] JW. Colony -stimulat ing factor 1 promotes progression 
of mammary  tumors to m alignancy. J Exp Med. 2001;193(6):[ADDRESS_753945] imulat ing factor 
levels in co lorectal  cancer pati ents correlate with lymph node metastasis and poor prognosis. 
Clin Chim Acta. 2007;380(1 -2):208 -212.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 68
LY3022855 (IMC -CS4)Nishino M, Gi obbie -Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS . Developi[INVESTIGATOR_007] a 
commo n language for tumor response to immunotherapy: immune -related response cri teria 
using unidimensio nal measurements . Clin Cancer Res . 2013;19(14):3936-3943.
Nowi cki A, Szenajch J, Ostrowska G, Wojtowicz A, Wo jtowicz K, Kruszewski AA, 
Maruszynski M, Aukerman SL, Wiktor -Jedrzejczak W. Impaired tumor growth in colony -
stimulat ing factor 1 (CSF -1)-deficient, macrophage -deficient op/op mouse: evidence for a role 
of CSF -1-dependent macrophages in format ion of tum or stroma. Int J Cancer.
1996;65(1):112 -119.
Oken MM, Creech RH , Torm ey DC, Horton J , Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria of the Eastern Cooperative Oncology Group .Am J Clin Oncol . 
1982;5 (6):649-655.
Pi[INVESTIGATOR_432484], Stanley ER. CSF -1 regul ation of the wandering macrophage: co mplexity in act ion. 
Trends Cell Biol. 2004;14 (11):628-638.
Radi ZA, Koza -Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, Lawton MP, Sadis S. 
Increased serum enzyme levels associated with kupffer cell reduct ion with no signs of hepat ic 
or skel etal muscle injury . 
Am J Pathol. 2011;179(1):240 -247.
Rizzo JD, Brouw ers M, Hurley P, Seidenfeld J, Arcaso y MO, Spi[INVESTIGATOR_92316], Bennett CL, Bohlius J, 
Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Societ y of 
Clinical Onco logy; American Societ y of Hematol ogy. American Societ y of Clinical  
Onco logy/American Society of Hematol ogy clinical  practice gui deline update on the use of 
epoetin and darbepoetin in adult pat ients with cancer. J Clin Oncol. 2010;28(33):4996 -5010.
Sadis S, Mukherjee A, Olson S, Dokmanovich M, Maher R, Cai C -H, Le V . Safet y, 
p
harmacokinet ics, and pharmacodynamics of PD -0360324, a human monocl onal antibody  to 
monocyte/macrophage colony stimulating factor, in healthy volunteers. ACR/ARHP Annual 
Meet ing Abstract (Poster 408), Philadelphia PA, 2009.
Sasm ono RT, Oceandy  D, Pollard JW, Tong W, Pavli P, Wai nwright BJ, Ostrowski  MC, 
Himes SR, Hum e DA. A macrophage colony -stimul ating factor receptor -green fluorescent 
protein transgene is expressed throughout the mononuclear phagocy te system  of the m ouse. 
Blood. 2003;101(3):1155 -1163.
Scher HI, Hala bi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, 
Higano C, Bubl ey GJ, Drei cer R, Petrylak D, Kantoff P, Ba sch E, Kelly  WK, Figg WD, 
SmallEJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials 
Working Group. Desig n and end points of clinical trials for patients with progressive prostate 
cancer and castrate levels of testosterone: recommendat ions of the Prostate Cancer Clinical 
Trials Working Group. J Clin Oncol . 2008;26(7):[ADDRESS_753946] J, Cross SJ, Demetri G, Desch CE, Pi[INVESTIGATOR_150301] o PA, Schiffer CA, 
Schwartzberg L, Som erfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, 
WolffAC. 2006 update of recommendat ions for the use of white blood cell growth factors: an 
evidence -based clinical pract ice guideline. J Clin Oncol. 2006;24 (19):3187 -3205.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 69
LY3022855 (IMC -CS4)Wang T, Papoutsi  M, Wiesmann M, DeCristofaro M, Keselica MC, Skuba E, Spaet R, 
Markovi tsJ, Wo lf A, Moulin P, Pognan F, Vancutsem P , Petry k L, Sutton J, Chibout SD, 
Kluwe W. Invest igation of correlat ion amo ng safety  biomarkers in serum , histopathol ogical 
examinat ion,and toxi cogeno mics. Int J Toxicol . 2011 ;30(3):300-312.
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, W ang L, Tang ZY, 
Sun HC. Hi gh expressio n of macrophage co lony-stimulat ing factor in peritumoral liver tissue 
is associated with poor survival after curative resection of hepatocellular carcino ma. J Clin 
Oncol. 2008;26 (16):2707 -2716.
I5F-MC-JSCB(d ) Phase 1 Oncology Protocol Page 70
LY3022855 (IMC -CS4)Attachment 1. Protocol JSCB Study  Schedule s
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 71
LY3022855 (IMC -CS4)Baseline and Cycle 1 A ssessments (for All Dosing Schedules )
ProcedureBaseline
Treatment Cycle 1 only CommentsRelative Day Prior 
to Day 1 of Cycle 1
≤28 ≤14 ≤7Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_753947] be signed prior to performance of any protocol -specific tests/procedure s.
Medical history X
β-hCG Pregnancy test X At baseline, a urine or serum pregnancy test is required for WOCBP.  Thereafter ,
every [ADDRESS_753948] dose or according to local regulations, whichever is 
more frequent.
ECG X X X Note that in cases where ECG and blood sample collection are scheduled at the 
same time, all blood sampling should be performed prior to ECG assessment.
ECOG PS assessment X X X X X X X
Safety Assessments
Physical examination X X X X I ncludes height (at baseline only) , and thoracic, abdominal, and symptom -directed 
examination .
Vital signs and weight 
measurementX X X X X X X Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.  
Vital signs will be checked and recorded prior to each infusion of LY3022855 , 
midway through each infusion, at the end of each infusion, and every [ADDRESS_753949] hour following each infusion, including Cycle 1, Day 1 (also to be checked 
and recorded at nontreatment visits during Cycle 1).
Toxicity/AE assessment X X X X X X X Any preexisting toxicity should be documented, recorded, and graded (CTCAE v4.0 
grade) as a part of the baseline medical history.
AEs that are serious, considered related to study treatment or the study, or that 
caused the patient to discontinue before completing the study should be followed 
until the event is resolved, the event is no longer considered to be drug -related, the 
event becomes stable or returns to baseline, a new treatment is initiated for the 
patient, or the patient dies or is lost to follow -up.  Frequency of AEand SAE
follow -up evaluation is left to the discretion of the investigator .  Data on SAEs that 
occur before the end of the trial will be stored in the collection database and the 
Lilly  Safety  System.
Concomitant medication 
assessmentX X X X X X X Including those medications taken within [ADDRESS_753950] dose of study 
therapy .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 72
LY3022855 (IMC -CS4)ProcedureBaseline
Treatment Cycle 1 only CommentsRelative Day Prior 
to Day 1 of Cycle 1
≤28 ≤14 ≤7Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
Laboratory Tests
HIV and viral hepatitis B 
and C screeningX* Includes HIV and hepatitis B and C, per institutional standards.
If done within [ADDRESS_753951] of care, does not 
need to be repeated.
* Should be done within [ADDRESS_753952] 12 weeks on therapy.
Coagulation X X* Evaluations performed as part of the baseline assessment do not need to be repeated 
on Cycle 1, Day 1 ,unless required in the opi[INVESTIGATOR_871] .
*Required within [ADDRESS_753953] 12 weeks on therapy , and every 2 weeks thereafter .
Urinalysis X Evaluations performed as part of the baseline assessment do not need to be repeated 
on Cycle 1, Day 1 ,unless required in the opi[INVESTIGATOR_871] .  Urinalysis 
evaluations will be performed at the beginning of each cycle (that is, approximately 
every [ADDRESS_753954] dose of study therapy).  If urine dipstick >1+ for 
protein, obtain 24 -hour urine collection for protein analysis.
Serum and urine 
myogl obinX* X* X* X* X* X* X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Tailoring biomarkers X 10 mL of blood to be drawn for future pharmacogenetic biomarker testing.
Blood sampling for PK, 
PD, IGRefer to Attachment 4 ,Attachment 5 ,and Attachment 6 .All sampling indicated in Attachment 4 ,Attachment 5 ,and Attachment 6 is to be 
done only after study eligibility is met .
Efficacy Assessments
Imaging studies 
(CT/MRI)X* X Radiographic assessment of tumor response should be performed prior to the start of 
a cycle so that results are available before the patient receives a new cycle of 
treatment.  If done within [ADDRESS_753955] of 
care, does not need to be repeated prior to the start of Cycle 1.
* For patients with treated CNS metastases that are eligible for this study , abaseline 
MRI documenting disease stability within 60 days prior to enrollment is required.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 73
LY3022855 (IMC -CS4)ProcedureBaseline
Treatment Cycle 1 only CommentsRelative Day Prior 
to Day 1 of Cycle 1
≤28 ≤14 ≤7Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
Bone scan X X* Breast cancer cohort :  Abaseline bone scan is required, except in the event that a 
PET scan is performed within [ADDRESS_753956] dose of study therapy that is 
negative for bone disease.  Routine bone scans during treatment are not required, 
except in the setting of bon e-only disease (no lymph node, visceral, skin, or 
subcutaneous metastases), or as deemed appropriate by [CONTACT_093].
*Prostate cancer cohort :  Bone scans are required at baseline and (follow -up 
[posttreatment]) every [ADDRESS_753957] of care, does not 
need to be repeated prior to the start of Cycle 1.
Tumor core needle or 
surgical biopsyX X Required :  The first tumor biopsy will be taken (attempted) at baseline (predose), 
within 14days prior to dosing on Cycle 1, Day 1, and the second tumor biopsy will 
be taken (attempted) within 14days prior to dosing on Cycle 2, Day 1.
Optional :  In cases of disease progression, if the patient’s condition allows it, an 
optional tumor biopsy will be performed, as clinically indicated (refer to 
Section [IP_ADDRESS] ).
Ad hoc tumor tissue and 
blood samplingX Optional :  Additional tumor tissue and/or blood samples for biomarker research 
may be obtained at the investigator’s discretion in discussion with the patient, such 
as at the time of radiographic response or treatment progression .  If, at any time 
during the study, tumor tissue is obtained through a core biopsy, surgical biopsy, or 
resection as routine clinical care, the sponsor requests a tissue block or unstained 
slides for analysis of potentially relevant surrogate biomarkers.
Study Therapy Administration
Administer LY3022855
Weekly (on Days 1, 8, 
15, 22, 29, and 36)X X X X X X
Administer LY3022855
Every  2 Weeks (on Days 
1, 15, and 29 )X X X
Administer LY3022855
on Weeks 1, 2, 4, and 5 
(on Days 1, 8, 22, and 
29)X X X X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 74
LY3022855 (IMC -CS4)Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; CNS 
= central nervous system; CT = computed tomography; CTCAE v4.0 = Common Terminology Criteria for Adverse Events, version 4.0; ECG = electrocardiogram; ECOG PS= 
Eastern Cooperative Oncology Group performance status; HIV = human immunodeficiency virus; ICF = informed consent form; IG =immunogenicity; MRI = magnetic 
resonance imaging; PET = positron emission tomography; PD = pharmacodynamic(s); PK=pharmacokinetic(s); SAE = serious adverse event; ULN = upper limit of normal; 
WOCBP = women of childbearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 75
LY3022855 (IMC -CS4)Cycle 2Assessments (for All Dosing Schedule s)
ProcedureTreatment Cycle 2 only Comments
Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36 Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_753958] dose or 
according to local regulations, whichever is more frequent.
ECG Note that in cases where ECG and blood sample collection are scheduled at the same time, all blood 
sampling should be performed prior to ECG assessment.
ECOG PS assessment X To be performed only on dosing days.  Dosing schedules, per protocol: Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
Physical examination X Includes thoracic, abdominal, and symptom -directed examination.
Vital signs and weight 
measurementX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.  Vital signs will be 
checked and recorded prior to each infusion of LY3022855 , midway through each infusion, at the end 
of each infusion, and every [ADDRESS_753959] hour following each infusion.
Toxicity/AE assessment X To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
AEs that are serious, considered related to study treatment or the study, or that caused the patient to 
discontinue before completing the study should be followed until the event is resolved, the event is no 
longer considered to be drug -related, the event becomes stable or returns to baseline, a new treatment 
is initiated for the patient, or the patient dies or is lost to follow -up.  Frequency of AE and SAE 
follow -up evaluation is left to the discretion of the invest igator.  Data on SAEs that occur before the 
end of the trial will be stored in the collection database and the Lilly Safety System.
Concomitant medication 
assessmentX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
Laboratory Tests
Hematology X X X X X X Every  week for the first [ADDRESS_753960] 12 weeks on therapy , and every 2 weeks thereafter .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 76
LY3022855 (IMC -CS4)ProcedureTreatment Cycle 2 only Comments
Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36 Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated otherwise .
Urinalysis X Urinalysis evaluations will be performed at the beginning of each cycle (that is, approximately every 
[ADDRESS_753961] dose of study therapy) . If urine dipstick >1+ for protein, obtain 24 -hour 
urine collection for protein analysis.
Serum and urine myoglobin X* X* X* X* X* X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Blood sampling for PK, PD, 
IGRefer to Attachment 4 ,Attachment 5 ,and 
Attachment 6 .
Efficacy Assessments
Imaging studies (CT/MRI) X Radiographic assessment of tumor response should be performed prior to the start of a cycle so that 
results are available before the patient rece ives a new cycle of treatment.
Bone scan X* Breast cancer cohort :  Routine bone scans during treatment are not required, except in the setting of 
bone -only disease (no lymph node, visceral, skin, or subcutaneous metastases), or as deemed 
appropriate by [CONTACT_093].
*Prostate cancer cohort :  Follow -up (posttreatment) bone scans are required every 6 weeks, or as 
clinically indicated.
Tumor assessments X Radiographic assessment of tumor response should be performed prior to the start of a cycle so that 
results are available before the patient rece ives a new cycle of treatment.
Ad hoc tumor tissue and 
blood samplingX Optional :  Additional tumor tissue and/or blood samples for biomarker research may be obtained at 
the investigator’s discretion in discussion with the patient, such as at the time of radiographic 
response or treatment progression .  If, at any time during the study, tumor tissue is obtained through a 
core biopsy, surgical biopsy, or resection as routine clinical care, the sponsor requests a tissue block 
or unstained slides for analysis of potentially relevant surrogate biomarkers.
Study Therapy Administration
Administer LY3022855
Weekly (on Days 1, 8, 15, 
22, 29, and 36), X X X X X X
Administer LY3022855
Every  2 Weeks (on Days 1, 
15, and 29X X X
Administer LY3022855
Weeks 1, 2, 4, and 5 (on 
Days 1, 8, 22, and 29X X X X
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; CT = 
computed tomography; ECG = electrocardiogram; ECOG PS= Eastern Cooperative Oncology Group performance status; IG = immunogenicity; MRI = magnetic resonance 
imaging; PET = positron emission tomography; PD=pharmacodynamic(s); PK=pharmacokinetic(s); SAE = serious adverse event; ULN = upper limit of normal; WOCBP = 
women of childbearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 77
LY3022855 (IMC -CS4)Cycle 3+Assessments (for All Dosing Schedule s)
ProcedureTreatment Cycle 3 and beyond Comments
Day 1 Day 8 Day 15 Day 22 Day 2 9 Day 3 6Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_753962] dose and 
every 12 weeks thereafter, or according to local regulations, whichever is more frequent.
ECG X* X* Note that in cases where ECG and blood sample collection are scheduled at the same 
time, all blood sampling should be performed prior to ECG assessment.
* As clinically indicated ,prior to last infusion of treatment cycle.
ECOG PS assessment X To be performed only on dosing days.  Dosing schedules, per protocol: Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
Physical examination X Includes thoracic, abdominal, and symptom -directed examination.
Vital signs and weight 
measurementX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.  Vital 
signs will be checked and recorded prior to each infusion of LY3022855 , midway  
through each infusion, at the end of each infusion, a nd every [ADDRESS_753963] hour 
following each infusion.
Toxicity/AE assessment X To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2 , 4, 
and 5 (on Days 1, 8, 22, and 29).
AEs that are serious, considered related to study treatment or the study, or that caused the 
patient to discontinue before completing the study should be followed until the event is 
resolved, the event is no longer co nsidered to be drug -related, the event becomes stable 
or returns to baseline, a new treatment is initiated for the patient, or the patient dies or is 
lost to follow -up.  Frequency of AE and SAE follow -up evaluation is left to the 
discretion of the investig ator.  Data on SAEs that occur before the end of the trial will be 
stored in the collection database and the Lilly Safety System.
Concomitant medication 
assessmentX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 78
LY3022855 (IMC -CS4)ProcedureTreatment Cycle 3 and beyond Comments
Day 1 Day 8 Day 15 Day 22 Day 2 9 Day 3 6Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
Laboratory Tests
Hematology :
For Weekly and 
Every -2-Week 
schedulesX X X Cycle 3 and beyond:  Every 2 weeks for patients receiving treatment on the Weekly or 
Every -2-Week dosing schedule (on Days 1, 15, and 29).
For Weeks 1, 2, 4, 
and 5 scheduleX X Cycle 3 and beyond:  Every 3 weeks for patients receiving treatment Weeks 1, 2, 4, and 5 
(on Weeks 1 and 4 [that is, Days 1 and 22]).
Serum chemistry:
For Weekly and 
Every -2-Week 
schedulesX X X Cycle 3 and beyond:  Every 2 weeks for patients receiving treatment on the Weekly or 
Every -2-Week dosing schedule (on Days 1, 15, and 29).
For Weeks 1, 2, 4, 
and 5 scheduleX X Cycle 3 and beyond:  Every 3 weeks for patients receiving treatment Weeks 1, 2, 4, and 5 
(that is, on Weeks 1 and 4 [that is, Days 1 and 22]).
CEA and CA [ADDRESS_753964] cancer cohort sand if clinically applicable.
C-reactive protein
assessmentX X X Cycle 3 and beyond:  Every 2 weeks.
Urinalysis X Urinalysis evaluations will be performed at the beginning of each cycle (that is, 
approximately every [ADDRESS_753965] dose of study therapy) . If urine dipstick 
>1+ for protein, obtain 24 -hour urine collection for protein analysis.
Serum and urine 
myogl obinX* X* X* X* X* X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Blood sampling for PK, 
PD, IGRefer to Attachment 4 ,Attachment 5 ,and Attachment 6 .
Efficacy Assessments
Imaging studies (CT/MRI) X Radiographic assessment of tumor response should be performed prior to the start of a 
cycle so that results are available before the patient receives a new cycle of treatment.
Bone scan X* Breast cancer cohort :  Routine bone scans during treatment are not required, except in 
the setting of bone -only disease (no lymph node, visceral, skin, or subcutaneous 
metastases), or as deemed appropriate by [CONTACT_093].
*Prostate cancer cohort :  Follow -up (posttreatment) bone scans are required every 6 
weeks, or as clinically indicated.
Tumor assessments X Radiographic assessment of tumor response should be performed prior to the start of a 
cycle so that results are available before the patient rece ives a new cycle of treatment.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 79
LY3022855 (IMC -CS4)ProcedureTreatment Cycle 3 and beyond Comments
Day 1 Day 8 Day 15 Day 22 Day 2 9 Day 3 6Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
Ad hoc tumor tissue and 
blood samplingX Optional :  Additional tumor tissue and/or blood samples for biomarker research may be 
obtained at the investigator’s discretion in discussion with the patient, such as at the time 
of radiographic response or treatment progression .  If, at any time during the study, 
tumor tissue is obtained through a core biopsy, surgical biopsy, or resection as routine 
clinical care, the sponsor requests a tissue block or unstained slides for analysis of 
potentially relevant surrogate biomarkers.
Study Therapy Administration
Administer LY3022855
Weekly (on Days 1, 8, 15, 
22, 29, and 36)X X X X X X For patients being treated on Dosage C and who are clinically benefitting, after the 
completion of Cycle 3, the dosing interval may be change dto once -every -2-week dosing 
after discussion with the sponsor.   If a patient ’s dosage is changed from that of DosageC 
(that is, weekly) to every -2-week dosing and then the patient develops progressive 
disease, the patient ’s dosage may then be changed back to weekly dosing if agreed upon 
by [CONTACT_86206].
Administer LY3022855
Every  2 Weeks (on Days 
1, 15, and 29 )X X X
Administer LY3022855 on 
Weeks 1, 2, 4, and 5 (on 
Days 1, 8, 22, and 29 )X X X X
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; CT = 
computed tomography; EC G = electrocardiogram; ECOG PS= Eastern Cooperative Oncology Group performance status; IG = immunogenicity; MRI = magnetic resonance 
imaging; PET = positron emission tomography; PD=pharmacodynamic(s); PK=pharmacokinetic(s); SAE = serious adverse event; ULN = upper limit of normal; WOCBP = 
women of childbearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 80
LY3022855 (IMC -CS4)Follow -upAssessments (for All Dosing Schedule s)
Procedure 30-Day Follow -upComments
Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_753966] is required for WOCBP.
ECG X In cases where ECG and blood sample collection are scheduled at the same time, all blood sampling should be 
performed prior to ECG assessment.
ECOG PS assessment X
Physical examination X Includes thoracic, abdominal, and symptom -directed examination.
Vital signs and weight measurement X Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.
Toxicity/AE assessment X All SAEs and LY3022855 -related AEs will be followed until the event is resolved, stabilized, returned to 
baseline, deemed irreversible, or otherwise explained (frequency of follow -up evaluations is left to the 
discretion of the investigator).  Data on SAEs that occur before the end of the trial will be stored in the 
collection database and the Lilly Safety Sy stem.
Concomitant medication assessment X
Laboratory Tests
Hematology X
Serum chemistry X
C-reactive protein assessment X
Urinalysis X If urine dipstick > 1+ for protein, obtain 24- hour urine collection for protein analysis.
Serum and urine myoglobin X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Blood sampling for PK, PD, IG Refer to Attachment 4 ,
Attachment 5 ,and 
Attachment 6 .
Efficacy Assessments
Tumor core needle or surgical 
biopsyX Optional :  In cases of disease progression, if the patient’s condition allows it, an optional tumor biopsy will be 
performed, as clinically indicated (refer to Section [IP_ADDRESS] ).
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CK = creatine kinase; CRP = clinical research physician; ECG =electrocardiogram; 
ECOG PS= Eastern Cooperative Oncology Group performance status; IG = im munogenicity; PD=pharmacodynamic(s); PK=pharmacokinetic(s); SAE = serious adverse 
event; ULN = upper limit of normal; WOCBP = women of childbearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 81
LY3022855 (IMC -CS4)Attachment 2. Protocol JSCB Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematologya
Hemoglobin
Hematocrit
Platelet s
Leukocytes (WBC) ,including differential
Neutrophils –absolute and percentage
Lymphocy tes –absolute and percentage
Monocytes –absolute and perc entage
Eosinophils –absolute and percentage
Basophils –absolute and percentageClinical Chemistrya(Serum Concentrations )
Sodium
Potassium
Chloride
Bicarbonate
Magnesium
Calcium
Phospho rus
Total bilirubin
Direct bilirubin
Alkaline phosphatase
Alanine aminotran sferase (ALT)
Aspartate aminotransferase (AST)
Gamma glutamyl transpeptidase
Albumin
Total protein
Creatinine
Blood urea nitrogen (BUN)
Uric acid
Glucose (random)
Lipase
Amylase
Creatin ekinase (CK)Coagulationa
Partial thromb oplastin time (PTT)
Prothrombin time (PT)/INR
Urinalysisa
Specific gravity
pH
Protein
Glucose
Ketones
Blood
Leukocyte esterase
Serum or Urine Pregnancy TestaCardiaca
Troponin I or T
Serologiesa
HIV screening
Viral hepatitis B and C screeningIsoenzymesb
Lactate dehydrogenase (LDH)
Creatine kinase (CK)
Alkaline phosphatase
Serum Markers of Bone Metabolismb
CTX -ISerum Markers of Inflammationa
C-reactive protein
Additional tests to be performed ,as clinically 
indicated , at a routine follow -up visita
Serum myoglobin –if CK ≥2.5 × ULN
Urine myoglobin –if CK ≥2.5 × ULNSerum Tumor Markers -as clinically indicateda
CEA
CA 15 -3
Abbreviation s:  CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; HIV = 
human immunodeficiency virus; PT/INR = International Normalized Ratio of prothrombin time; ULN = upper 
limit of normal ; WBC = white blood cells .
aLocal or investigator -designated laboratory .
bAssay ed by [CONTACT_11007] -designated laboratory .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 82
LY3022855 (IMC -CS4)Attachment 3. Protocol JSCB Hepatic Monitoring Tests 
for Tr eatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly clinical research physician
(CRP) .
Hepatic Monitoring Tests (local laboratory)
Hepatic Hematology Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation
RBC Prothrom bin time, INR
WBC
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody
AST
GGT Anti -smooth muscle antibody
CK
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatine kinase; GGT = gamma 
glutamyl transferase; Ig = immunoglobulin; INR = International Normalized Ratio; RBC = red blood cells; WBC = white 
blood cells.
aAs clinically indicated.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 83
LY3022855 (IMC -CS4)Attachment 4. Protocol JSCB Pharmacokinetic ,Pharmacody namic , and 
Immunogenicity Sampling Schedule for Dosage sA and B Only
Note:  All sampling indicated in Attachment [ADDRESS_753967] 
infusionDosing Day
Cycle 1, Day 1 
(C1D1) C1D2Dosing 
Day
C1D8Dosing 
Day
C1D15Dosing 
Day
C1D22Dosing 
Day
C1D2 9Dosing 
Day
C1D3 6
Comments(≤14 days 
of C1D1)1 hr
(±6 
min)
EOI4 hr
(±24 
min)
EOI24 hr
(±2 h r
24 min)
EOIPredose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)
Pharmacokinetics X X X X X X X The date and the time of all 
sampling must be clearly and 
accurately recorded.
Immunogenicity X X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X X PD #1= CSF-1, IL -34
PD #2 - MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X X PD #4= MSD assay for IFN -γ, IL-
1β,IL-2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X X X X FC #2= Live-Dead, CD3, CD4, 
CD8, FoxP3, PD -1, Ki -67, CTLA -
4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X X X X AP isoenzymes, total CK, CK 
isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X X X CTX -I
Troponin I or T -MSKCC lab X X X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 84
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing 
Day
C2D1Dosing Day
C3D1 C3D2Dosing 
Day
C3D8Dosing 
Day
C3D22
CommentsPredose
(±25 h r)Predose
(±25 h r)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 h r
24 min)
EOIPredose
(±25 h r)Predose
(±25 h r)
Pharmacokinetics X X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4= MSD assay f orIFN-γ, IL-1β, IL- 2, IL -4, IL -6, 
IL-8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -
67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X AP isoenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
Bone marker -Central lab X CTX -I
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 85
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±25 h r)
Pharmacokinetics X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *T o be done at this time point and every [ADDRESS_753968] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X PD #4= MSD assay f orIFN-γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC#1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cytometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a patient experiences an infusion -related reaction to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicity analysis as close to
the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be used for PK 
analysis, in the setting of infusion- related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 86
LY3022855 (IMC -CS4)Pharmacokinetic, Phar macodynamic, and Immunogenicity Blood Sampling Schedule for Every -2-Week Dosing
AnalysesPrior to 
the first 
infusionDosing Day
Cycle 1, Day1 (C1D1) C1D2 C1D8
Comments(≤14 days 
of C1D1)1 hr
(±6 min)
EOI4 hr
(±24min)
EOI24 hr
(±2 hr
24min)
EOI168 hr
(±25 h r)
EOI
Pharmacokinetics X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -
4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 87
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C1D15Dosing Day
C1D29 C1D30 C1D36
CommentsPredose
(±50 hr)Predose
(±50 hr)24 hr
(±2 hr
24 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X PD #2=CBC with differential
PD #3 -MSKCC lab X* X PD #3=ALT, AST
* For this time point, a separate sample should not be collected 
for PD #3 assessment .  Use the serum chemistry sample 
(Attachment 1 ) taken at this time point for the PD #3 assessment.
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -
10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 88
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C2D1Dosing Day
C3D1 C3D2 C3D8
Comments Predose Predose1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2hr
24 min)
EOI168hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, 
IL-10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 89
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C3D15Dosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±50 hr)Predose
(±50 hr)
Pharmacokinetics X X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *T o be done at this time point and every [ADDRESS_753969] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL-2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, 
TNFα
Flow cytometry
FC #1 -Central lab X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, 
and ICOS
Isoenzymes -Central lab X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cy tometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a pat ient experiences an infusion -related reaction to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicity analysis as close to 
the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A p ortion of the sample taken for immunogenicity testing may be used for PK 
analysis, in the setting of infusion- related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 90
LY3022855 (IMC -CS4)Pharmacokinetic, Pharmacodynamic, and Immunogenicity Blood Sampling Schedule for Week s1, 2, 4, and [ADDRESS_753970] 
infusionDosing Day
Cycle 1, Day1 (C1D1) C1D2Dosing Day
C1D8 C1D15
Comments(≤14 days 
of C1D1)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 hr
24 min)
EOIPredose
(±25 hr)1 hr
(±6 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X X The date and the time of all sampling must be 
clearly and accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1=CSF- 1, IL -34
PD #2 -MSKCC lab X PD #2=CBC with differential
PD #3 -MSKCC lab X* PD #3=ALT, AST
* For this time point, a separate sample should not 
be collected for PD #3 assessment.  Use the serum 
chemistry sample ( Attachment 1 ) taken at this 
time point for the PD #3 assessment.
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, 
IL-6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -
1, Ki -67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total 
LDH, LDH isoenzymes
Bone marker -Central lab X X CTX -I
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 91
LY3022855 (IMC -CS4)Week s1, 2, 4, and 5 Schedule (continued)
AnalysesDosing Day
C1D22Dosing Day
C1D29Dosing Day
C2D1Dosing Day
C3D1
CommentsPredose
(±50 hr)Predose
(±25 hr)Predose
(±50 hr)Predose
(±50 hr)1 hr
(±6min)
EOI4 hr
(±24 min)
EOI
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X PD #2=CBC with differential
PD #4 -MSKCC lab X X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -
10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 92
LY3022855 (IMC -CS4)Week s1, 2, 4, and 5 Schedule (continued)
AnalysesDosing Day
C3D8 C3D15Dosing Day
C3D22Dosing Day
C5D1Dosing Day
C5D29
CommentsPredose
(±25 hr)1 hr
(±6 min)
EOI168hr
(±25 hr)
EOIPredose
(±50 hr)Predose
(±50 hr)Predose
(±25 hr)
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X* *To be done at this time point and every [ADDRESS_753971] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, 
IL-6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, 
Ki-67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X AP isoenzymes, total CK, CK isoenzymes, total 
LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 93
LY3022855 (IMC -CS4)Week s1, 2, 4, and 5 Schedule (continued)
AnalysesDosing Day
C6D29
30-Day Follow -up
(±7 days) CommentsPredose
(±25 hr)
Pharmacokinetics X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, and 
ICOS
Isoenzymes -Central lab X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cytometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a patient experiences an infusion -related reaction to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicity analysis as close to
the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be used for PK 
analysis, in the setting of infusion- related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 94
LY3022855 (IMC -CS4)Attachment 5. Protocol JSCB Pharmac okinetic ,Pharmacody namic , and 
Immunogenicity Sampling Schedule for Dosage C Only
Note: All sampling indicated in Attachment 5is to be done only after study eligibility is met.
Pharmacokinetic, Pharmacodynamic, and Immunogenicity Blood Sampling Schedule for Weekly Dosing
AnalysesPrior to 
the first 
infusionDosing Day
Cycle 1, Day 1 
(C1D1) C1D2Dosing 
Day
C1D8Dosing 
Day
C1D15Dosing 
Day
C1D22Dosing 
Day
C1D2 9Dosing 
Day
C1D3 6
Comments(≤14 days 
of C1D1)1 hr
(±6 
min)
EOI4 hr
(±24 
min)
EOI24 hr
(±2 h r
24 min)
EOIPredose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)
Pharmacokinetics X X X X X X X X The date and the time of all 
sampling must be clearly and 
accurately recorded.
Immunogenicity X X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X X PD #1= CSF-1, IL -34
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X X PD #4= MSD assay for IFN -γ, IL-
1β, IL -2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13,TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X X X X FC #2= Live-Dead, CD3, CD4, 
CD8, FoxP3, PD -1, Ki -67, CTLA -
4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X X X X AP isoenzymes, total CK, CK 
isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 95
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing 
Day
C2D1Dosing Day
C3D1 C3D2Dosing 
Day
C3D8Dosing 
Day
C3D22
CommentsPredose
(±25 h r)Predose
(±25 h r)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 h r
24 min)
EOIPredose
(±25 h r)Predose
(±25 h r)
Pharmacokinetics X X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4= MSD assay f orIFN-γ, IL-1β, IL- 2, IL -4, IL -6, 
IL-8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -
67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X AP isoenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 96
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±25 h r)
Pharmacokinetics X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *T o be done at this time point and every [ADDRESS_753972] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X PD #4= MSD assay forIFN-γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cytometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at an y time a patient experiences an infusion -related reaction to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicity analysis as close to 
the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be used for PK 
analysis, in the setting of infusion- related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 97
LY3022855 (IMC -CS4)Attachment 6. Protocol JSCB Pharmacokinetic ,Pharmacody namic , and 
Immunogenicity Sampling Schedule for Dosage D Only
Note:  All sampling indicated in Attachment 6is to be done only after study eligibility is met.
Pharmacokinetic, Pharmacodynamic, and Immunogenicity Blood Sampling Schedule for Every -2-Week Dosing
AnalysesPrior to 
the first 
infusionDosing Day
Cycle 1, Day1 (C1D1) C1D2 C1D8
Comments(≤14 days 
of C1D1)1 hr
(±6 min)
EOI4 hr
(±24min)
EOI24 hr
(±2 hr
24min)
EOI168 hr
(±25 h r)
EOI
Pharmacokinetics X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -
4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 98
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C1D15Dosing Day
C1D29 C1D30 C1D36
CommentsPredose
(±50 hr)Predose
(±50 hr)24 hr
(±2 hr
24 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X PD #2=CBC with differential
PD #3 -MSKCC lab X* X PD #3=ALT, AST
* For this time point, a separate sample should not be collected 
for PD #3 assessment .  Use the serum chemistry sample 
(Attachment 1 ) taken at this time point for the PD #3 assessment.
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -
10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 99
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C2D1Dosing Day
C3D1 C3D2 C3D8
Comments Predose Predose1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2hr
24 min)
EOI168hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, 
IL-10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 100
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C3D15Dosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±50 hr)Predose
(±50 hr)
Pharmacokinetics X X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *T o be done at this time point and every [ADDRESS_753973] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, 
TNFα
Flow cytometry
FC #1 -Central lab X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, 
and ICOS
Isoenzymes -Central lab X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cytometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a patient experiences an infusion -related reaction to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicity analysis as close to 
the onset of the event as p ossible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be used for PK 
analysis, in the setting of infusion- related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 101
LY3022855 (IMC -CS4)Attachment 7. Protocol JSCB Recommendations for 
Reporting Serious Adverse Events
Recommendations for Reporting Serious Adverse Events
When contact[CONTACT_338297] a SAE, pl ease have the fo llowing inform ation available:
Patient Demographics
patient identificat ion (number), sex, date of birth, origin, hei ght, and wei ght
Study Identification
full trial protocol number, invest igator's name, and invest igator’s number
Study Drug
drug code or drug name, unit dose, total daily dose, frequency, route, start dose, 
cycle details, start date ,and last dose date (if applicable)
Adverse Event
descript ion, date of onset, severit y, treatm ent (including hospi[INVESTIGATOR_3094]), acti on 
taken wi th respect to study  drug, clinical significance, and test and procedure 
resul ts (if applicable)
Relationship to Study Drug andProtocol Procedures
Concomitant Drug Therapy
indicat ion, total  daily dose, duration of treatment, start date, and action taken
In Case of Death
cause, autopsy  finding (if available), date, and relati onship to study  drug and 
protocol  procedures
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 102
LY3022855 (IMC -CS4)Attachment 8. Protocol JSCB ECOG Performance Status
ECOG Performance Status
Activity Status Description
[ADDRESS_753974] ion
1 Restricted in physically strenuous activit y but ambul atory  and able to carry  
out work of a light or sedentary  nature, eg, light house work, office work
2 Ambulatory  and capable o f all self- care but unable to carry  out any  work 
activit ies.  Up and about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours
4 Com pletely disabled.  Cannot carry  on any  self-care.  Totally confined to 
bed or chair
5 Dead
Abbreviation:  ECOG = Eastern Cooperative Oncology Group .
Source:  Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP . Toxicity and 
response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol . 1982;5(6):649 -655.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 103
LY3022855 (IMC -CS4)Attachment 9. Protocol JSCB RECIST Criteria 1.1
Response and progression will be evaluated in this study  using the international criteria proposed 
by [CONTACT_574454] (RECIST): Revised RECIST 
Guideline (versi on 1.1; Eisenhauer et al. 2009).
Measurability of Tumor at Baseline
Tumor lesi ons/lymph nodes will be categorized at baseline as measurable or nonmeasurable.  
Measurable disease is defined by  [CONTACT_92379] l east 1 m easurable l esion.
Measurable
Tumor lesi ons:  Measured in at least 1 dimensio n (longest di ameter in the plane o f measurement 
is to be recorded) with a min imum size of:
10 mm by  [CONTACT_92380]  (CT) or m agnet ic resonance imaging (MRI) 
scan (slice thickness 5 mm)
10 mm caliper measurement by  [CONTACT_40133] (non -measurable lesio ns if cannot 
be accurately measured with calipers)
[ADDRESS_753975] X -ray.
Malign ant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node m ust be [ADDRESS_753976] scan (CT scan thickness recommended 
to be 5 mm ).
Nonmeasurable
All other lesio ns, including small lesio ns (lo ngest di ameter <10 mm or pathological lymph nodes 
with 10 to <15 mm short axis) as well as truly nonmeasurable lesio ns.  Lesio ns considered truly  
non-measurable include:  leptomeningeal disease, ascites, pleural/pericardial effusio ns, 
lymphangitis cut is/pulmo nis, inflammatory breast disease, lymphangit is involvement of skin or 
lung, abdo minal masses/abdo minal organo megaly ident ified by [CONTACT_92381].
Special Considerations for Lesion Measurability
Bone l esions:
Bone scan, positron emissio n tom ography ( PET)scan,or plain films are not 
considered adequate imaging techniques to measure bone lesio ns.
Lytic bone lesio ns or mixed ly tic-blastic l esions, wit h ident ifiable so ft tissue 
components, that can be evaluated by  [CONTACT_240263], can be considered measurable lesio ns if the so ft tissue com ponent 
meets the definit ion of measurabilit y.
Blastic bone l esions are non -measurable.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 104
LY3022855 (IMC -CS4)Cystic lesions:
Simple cysts should not be considered as malignant lesions (neither measurable 
nor nonm easurable) .
Cystic lesions thought to represent cystic metastases can be considered as 
measurable lesio ns, if they meet the definit ion of measurabilit y.  If noncyst ic 
lesions are presented in the same patients, these are preferred for select ion as 
target lesio ns.
Lesio ns wi th Prior Local Treatm ent:
Tumor lesi ons situated at a previ ously i rradiated area, or i n an area subjected to 
other l oco-regional therapy, are non -measurable unless there has been
demonstrated progression in the lesio n.
Baseline Documentation of Target and Non -Target Lesion
Target Lesions
When more than 1 measurable lesio n is present at baseline, a ll lesions up to a m aximum  of 
5lesio ns total  (and a m aximum  of 2 lesions per organ) representati ve of all invo lved organs 
shoul d be i dentified as target l esions and will  be recorded and m easured at baseline. Non-nodal  
Target l esions shoul d be selected on the basis of their size (lesions with the longest diameter), be 
representative of al l involved organs, and can be reproduced in repeated measurements.  
Measurable lymph nodes are target lesio ns if they meet the criteria of a short axis of [ADDRESS_753977] scan.  All measurements are to be recorded in the eCRF in millimeters (or decimal fracti ons 
of centimeters [cm ]).
Nontarget Lesions
All other lesio ns (or sites of disease) are ident ified as nontarget lesio ns(chosen based on their 
representativeness o f involved organs and the ability to be reproduced in repeated measurements) 
and should be recorded at baseline.  Measurement of thes e lesions are not required but should be 
followed as ‘present ,’ ‘absent ,’or in rare cases ‘unequivocal progression .’  In addit ion, it is 
possible to record mult iple nontarget lesio ns involving the same organ as a single item on the 
eCRF (for example, mult iple liver m etastases recorded as one liver lesio n).
Lymph nodes with short axis 10 mm  but <[ADDRESS_753978] a short axis <10 mm are considered nonpathological and are not recorded or 
followed.
Specifications by [CONTACT_92383], using a ruler or calipers if clinically 
assessed.  All baseline evaluat ions should be performed as closely as possible to the beginn ing of 
treatm ent and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
ident ified and reported lesio n at baseline and during fo llow-up.  Im aging- based eva luation is 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 105
LY3022855 (IMC -CS4)shoul d always be done rather than clinical examination unless the lesio n(s) being fo llowed 
cannot be imaged but are assessed by [CONTACT_461].
An adequate vo lume of a suitable contrast agent should be given so that the metastases are 
demonstrate d to best effect and a consistent method is used on subsequent examinat ions for any  
given pat ient.  If prior to enrollment it is known a patient is not able to undergo CT scans with 
I.V.contrast due to allergy or renal insufficiency, the decisio n as to wh ether a non -contrast CT or 
MRI (wi th or wi thout I.V.contrast) should be used to evaluate the patient at b aseline and 
follow-up shoul d be guided by  [CONTACT_574455].
Clinical Lesions:  Clinical les ions will only be considered measurable when they  are superficial  
and 10 mm diameter as assessed using calipers (for example, skin nodules).  For the case of 
skin lesio ns, docum entati on by [CONTACT_92385] , incl uding a rul er to estimate the size of the 
lesion is recommended.  When lesio ns can be evaluated by [CONTACT_51752], 
imaging evaluat ion should be undertaken since it is more object ive and may be reviewed at the 
end of the study .
Chest X -ray:  Chest CT is preferred over chest X -ray whe n progression is an important endpoint.  
Lesio ns on chest X -ray may be considered m easurable if they  are cl early  defined and surrounded 
by [CONTACT_92387] l ung.
CT and MRI :  CT scan is the best currently available and reproducible method to measure lesio ns 
selecte d for response assessment.  Measurabilit y of lesio ns on CT scan is based on the 
assumpt ion that CT slice thickness is [ADDRESS_753979] slice thickness > 5 mm, the 
minimum size for a measurable lesio n shoul d be twi ce the slice thickness.  MRI is also 
acceptable in certain situations (for example, for body  scans).  If there is concern about radiat ion 
exposure at CT, MRI may be used instead of CT in selected instances.
Ultrasound:   Ultrasound should not be used to measure lesion size.  Ultrasound examinat ions 
cannot be reproduced in their ent irety for independent review at a later date and, because they are 
operator dependent, it cannot be guaranteed that the same technique and measurements will be 
taken fro m one assessment to the next.  If new lesions are identified by  [CONTACT_92388] , confi rmation by [CONTACT_462] i s advised.
Endoscopy, Laparoscopy :  The utilizat ion of these techniques for o bject ive tumor evaluat ion is 
not advised.  However, such techniques can be useful to confirm co mplete pathol ogical response 
when biopsies are obtained or to determine relapse in trials where recurrence fo llowing com plete 
response (CR) or surgical resect ionis an endpo int.
Tumor Markers :  Tum or markers al one cannot be used to assess tumor response.  If markers are 
initially above the upper normal limit, they  must norm alize for a patient to be considered in CR.  
Specific guidelines for both prostate -specific antigen response (in recurrent prostate cancer) and 
CA-125 response (in recurrent ovarian cancer) have been published .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 106
LY3022855 (IMC -CS4)Cytology, Histology :  These techniques can be used to different iate between partial response 
(PR) and CR in rare cases if required by [CONTACT_60662]  (for example, resi dual lesio ns in tumor ty pes 
such as germ cell tumors, where known residual benign tumors can remain).  When effusio ns are 
known to be a potential adverse effect of treatment (for example, with certain taxane compounds 
or angiogenes is inhibitors), the cy tological confirmati on of  the neopl astic origin o f any effusio n 
that appears or worsens during treatment can be considered if the measurable tumor has met 
criteria for response or stable disease (SD) in order to different iate between response (or SD) and 
progressive disease.
PETScan (FDG- PET, PET CT) :  PET is not recommended for lesion assessment . If a new 
lesion is found by  [CONTACT_10052], another assessment must be done by  [CONTACT_4654], unless the PET CT i s of 
diagnosti c quali ty.  If CT is done to conf irm the resul ts of the earlier PET scan, the date of 
progression must be reported as the earlier date of the PET scan.
Bone Scan :  If lesions measured by [CONTACT_92390], it is necessary to repeat 
the bone scan when trying to ident ify a CR or PR in target disease or when progression in bone is 
suspected.
Response Criteria
Evaluation of Target Lesions
Complete Response (CR):   Disappearance o f all target lesio ns.  Any pathological lymph nodes 
(whether target or non -target) m ust have reduct ion in short axi s to <[ADDRESS_753980] norm alized.
Partial Response (PR):   At least a 30% decrease in the sum o f diameter of target l esions, taking 
as reference the baseline sum diameters.
Progressive Disease :  At least a 20% in crease in the sum of the diameters of target lesio ns, 
taking as reference the smallest sum on study  (including the baseline sum if that is the smallest).  
In addit ion to the relat ive increase of 20%, the sum must also demonstrate an abso lute increase 
of atleast 5 mm.   The appearance of one or more new lesio ns is also considered progression.
For equivocal findings of p rogressi on (for example, very  small  and uncertain new l esions; cyst ic 
changes or necrosis in exist ing lesions), treatment may co ntinue unt il the next scheduled 
assessment. If at the next sc heduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progressio n was suspected.
Stable Disease (SD):   Neither sufficient shrinkage to qualify for PR nor suffi cient increase to 
qualify  for progressive disease , taking as reference the smallest sum diameters while on study .
Not Evaluable:  When an inco mplete radio logic assessment of target lesio ns is performed or 
there is a change in the method of measurement from baseline that impact sthe abilit y to make a 
reliable evaluat ion of response .
Evaluation of Nontarget Lesions
Complete Response:   Disappearance of all nontarget lesio ns and normalizat ion of tum or marker 
level.  All lymph nodes must be non -pathol ogical or norm al in size (<10 mm short axi s).
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 107
LY3022855 (IMC -CS4)Non-CR/ non -progressive disease :  Persistence of oneor more nontarget lesio ns and/or 
maintenance of tumor marker level above the normal limits.
Progressive Disease:  Unequivocal progression o f exist ing nontarget lesio ns.  The appearance o f 
oneor more new l esions is also considered progression.
Not Evaluable : When a change in method of measurement from baseline occurs and impacts the 
abilit y to make a reliable evaluat ion of response .
Evaluation of Best Overall Response
The best overall response is the best response recorded fro m the start of the study  treatment until 
the earliest of object ive progression or start of new anticancer therapy, taking into accoun t any  
requi rement for confirmat ion.  The patient’s best overall response assignment will depend on the 
findings of both target and nontarget disease and will also take into considerat ion the appearance 
of new lesio ns.  The Best Overall Response will be calculated via an algorithm using the 
assessment responses provided by [CONTACT_92391].
Time Point Response
It is assumed that at each protocol -specified t ime point, a response assessment occurs.  ( When no 
imaging/measurement is done at all at a particular time point, the patient is not evalu able (NE) at 
that time po int.)  Table [ADDRESS_753981] measurable disease at baseline.
Table 1. Time Point Response: Patients with Target ( Nontarget) Disease
Target L esions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/no n-PD No PR
CR Not evaluated No PR
PR Non-PD or not all evaluated No PR
SD Non-PD or not all evaluated No SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yesor No PD
Any Any Yes PD
Abbreviations:  CR = complete response; NE= inevaluable ; PD = progressive disease; PR = partial response; SD = 
stable disease.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 108
LY3022855 (IMC -CS4)Table [ADDRESS_753982] nonmeasurable disease only .
Table 2. Time Point Response: Patients with Nontarget Disease Only
Nontarget Lesions New Lesions Overall Response
CR No CR
Non-CR/no n-PD No Non-CR/no n-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
Abbreviations:  CR = complete response; NE = inevaluable ; PD = progressive disease; SD = stable disease .
anon-CR/non -PD is preferred over SD for nontarget disease. 
Frequency of Tumor Re -Evaluation
A baseline tumor evaluat ion must be performed within [ADDRESS_753983] therapy  is not known, fo llow-up every  6-8 weeks is 
reasonabl e.  Norm ally, all target and non -target si tes are evaluated at each assessment using the 
same m ethod.  However, bone scans may need to be repeated only when CR is ident ified in 
target disease or when progression in bone is suspected.
Confirmatory Measureme nt/Duration of Response
Confirmation :
The m ain goal  of confirmat ion of object ive response in clinical trials is to avoid overest imating 
the response rate observed. The confirmat ion of response is particularly important in 
nonrandomized trials where response (CR/PR) is the primary  end point.  In this setting, to be 
assigned a status of PR/CR, changes in tumor measurements must be confirmed by [CONTACT_62442] [ADDRESS_753984] occur; assessment of 
nontarget lesions is not requi red.
However, in randomized trial (Phase 2 or 3) or studies where SD or progression is the primary 
endpo ints, confirmat ion of response is not required.  But, eliminat ion of the requirement may
increase the importance of central review to protect against bias, in particular of studies which 
are not blinded.
In the case of SD, fo llow-up m easurements m ust have met the SD criteria at least once after start 
of treatm ent at a minimum interval not les s than [ADDRESS_753985] met for 
CR or PR (whichever is first recorded) until the first date that disease is recurrent or objective 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 109
LY3022855 (IMC -CS4)progression is observed (taking as reference for progressive disease the smallest m easurements 
recorded on study ).
The durati on of  overall CR is measured fro m the time measurement criteria are first met for CR 
until the first date that recurrent disease is object ively documented.
Duration of Stable Disease
Stabl e disease is m easured from  the start of the treatment (in rando mized trials, from date of 
rando mizat ion) unt il the criteria for objective progressio n are m et, taking as reference the 
small est sum  on study  (if the baseline sum is the smallest, that is the reference for calculat ion of 
progressive disease ).
Independent Review of Response and Progression
When object ive response (CR + PR) is the primary end point, and when key drug development 
decisio ns are based on the observat ion of a minimum number of responders, it is recommended 
that all claimed responses be reviewed by [CONTACT_13461](s) independent of the study .  If the study  is a 
rando mized trial, ideally reviewers should be blinded to treatme nt assignment.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 110
LY3022855 (IMC -CS4)Attachment 10. Protocol JSCB Guidelines for the 
Management of Immune -Related A dverse Events
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 111
LY3022855 (IMC -CS4)Guide lines for the Management of Pot ential Toxicities Encountered with Immuno -Oncology Agents
System Organ Class Adverse EventCTCAE, Version 4.0 Grade (if 
applicable) and/or Symptomsa
Treatment PlanbGrade Symptoms
Endocrine Thyr oid issues Asymptomatic, with TSH 
<0.5 × LLN or >2 × ULNContinue drug and include free T4 in subsequent cycles.
Symptomatic Continue drug.  Administer thyroid replacement.
Hypotension, altered 
mental status, headache, 
fatigueEndocrine issues aside from 
thyroid ( for example ,
hypophysitis , diabetes 
mellitus )Withhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).
Resume drug when symptoms resolve and are stable on hormone 
replacement.  In case of adrenal crisis, administer stress -dose steroids .
Permanently discontinue for Grade 3 or 4 .
Gastrointestinal Diarrhea, abdominal pain, 
blood in stool2 Withhold drug for 1 wk.  Administer antidiarrheal medication and check 
etiology.
Resume drug when symptoms resolve to Grade 1.  If > 5 day s’ duration 
despi[INVESTIGATOR_235204], begin steroids (0.5 mg/kg/d prednisone); can resume 
drug during taper when symptoms resolve to Grade 1.
Diarrhea, ileus, perforation ≥3 Withhold drug and administer 1-2 mg/kg/day prednisone (no steroids if 
possible perforation); discontinue drug if Grade 3 persists or Grade 4.
If >3 days despi[INVESTIGATOR_397713], add nonsteroid immunosuppressive.
Symptomatic pancreatitis 1 or 2 Withhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Can 
resume drug during taper.
≥3 Permanently discontinue drug .  Administer steroids (1 -2 mg/kg/d 
prednisone).  Can resume drug during taper .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 112
LY3022855 (IMC -CS4)System Organ Class Adverse EventCTCAE, Version 4.0 Grade (if 
applicable) and/or Symptomsa
Treatment PlanbGrade Symptoms
Hepatobiliary Liver abnormality AST or ALT >5 × ULN but 
≤20 × ULN
AND
total bilirubin ≤ULNDiscuss with sponsor and consider c ontinu ingprotocol treatment provided 
patient remains without other evidence of liver toxicity.
AST or ALT >20 ×ULN
AND
total bilirubin ≤ULNDiscuss with sponsor and consider holding protocol treatment until 
AST/ALT becomes ≤20 ×ULN.
AST or ALT >5 × ULN
AND
total bilirubin >ULNWithhold drug. Administer steroids (1 -2 mg/kg/d prednisone).  Consider 
resuming protocol treatment once total bilirubin ≤ULN .
Discontinue protocol therapy permanently if bilirubin does not return to 
below the ULN within 3 wk of holding drug.
3 or 4 GGT or alkaline phosphatase Continue protocol treatment provided patient remains without other 
evidence of liver toxicity.
Musculoskeletal Muscle abnormality CK >2.5 ×but ≤[ADDRESS_753986]
AND
Serum and urine myoglobin 
≤ULNDiscuss with sponsor and consider c ontinu ingprotocol treatment provided 
patient remains without other evidence of muscle or renal toxicity.
CK ≥2.5 ×ULN
AND
Serum and urine myoglobin 
>ULNWithhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Consider 
resuming protocol treatment once serum and urine myoglobin ≤ULN .
Discontinue protocol therapy permanently if serum and urine myoglobin 
does not return to below the ULN within 3 wk of holding drug .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 113
LY3022855 (IMC -CS4)System Organ Class Adverse EventCTCAE, Version 4.0 Grade (if 
applicable) and/or Symptomsa
Treatment PlanbGrade Symptoms
Nervous Weakness, paresthesia (for 
example, Guillain -Barré 
syndrome, my asthenia 
gravis)No impact on activities of 
daily  living (ADL)Withhold drug.  Resume drug when symptoms resolve.
Impact on ADL Withhold drug.  Administer appropriate medical intervention and steroids 
(1-2 mg/kg/d prednisone).  Can resume drug during taper and after 
discussion with sponsor .
Respi[INVESTIGATOR_574418], hy poxia, 
pneumonitis1 Consider to withhold drug.  Resume drug when stable.
2 M ildtomoderate symptoms Withhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Can 
resume drug during taper.
≥3 Severe Permanently discontinue drug.  Administer steroids (1 -2 mg/kg/d 
prednisone).
If >2 days despi[INVESTIGATOR_397713], add nonsteroid immunosuppressive .
Renal and urinary Elevated creatinine, 
decreased urine output, 
blood in urine, edema1 <1.5 × baseline Continue drug.
2 to 3 >1.5 × ULN but <6 × ULN
OR
>1.5 × baselineWithhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).If 
symptoms resolve to Grade ≤1, taper steroids over [ADDRESS_753987] >7 days or worsen treat with Grade 4
recommendations .
4 >6 × ULN Permanently discontinue drug.  Administer steroids (1-2 mg/kg/d 
prednisone).
Skin Rash, pruritus ≤50% skin affected Withhold drug. Start supportive medications for pruritus, for example,
hydroxyzine/loratadine.   If symptoms persist or worsen after 1 wk, 
administer topi[INVESTIGATOR_143806]. Resume dru g if rash improves to 
mild (localized) and steroid dose <7.5 mg.
Stevens -Johnson syndrome, 
toxic epi[INVESTIGATOR_194], 
necrosis, bullous or 
hemorrhagic lesionsPermanently discontinue drug.  Begin steroids (1 -2 mg/kg/d prednisone).
Abbreviations:  ADL = activities of daily living; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Cr iteria 
for Adverse Events; I.V. = intravenous(ly); LLN = lower limit of normal; TSH = thyroid -stimulating hormone; ULN = upper lim it of normal.
aIf definition of grade not specified, use CTCAE, Version 4.0 definition.
bTreatment plan should always include a thorough workup of the issue to rule out other potential etiologies.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 114
LY3022855 (IMC -CS4)Note:  Other steroid options can be given at equivalent doses.  For severe cases, recommend using IV steroids.  For adrenal c risis, mineralocorticoid also needs to 
be added to stress -dose IV steroids.  Also, steroids should be tapered over 1 month once sym ptoms improve to grade 1, and drug should not be restarted 
until taper over at least 1 month complete.  During steroid use, add prophylactic antibiotics for opportunistic infections.  Immunosuppressive refers to 
infliximab or cyclophosphamide.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 115
LY3022855 (IMC -CS4)Attachment 11. Protocol JSCB Protocol Amendment I5F-
MC-JSCB (d)Summary Phase 1 Study  to Identify  the 
Immunomodulatory  Activity  of LY3022855 (IMC -CS4) in 
Patients with A dvanced, Refractory  Breast or Prostate 
Cancer
Overview
Protocol  I5F-MC-JSCB Phase 1 Study  to Identify the Immunomodulatory  Activity of 
LY3022855 (IMC -CS4) in Patients with Advanced, Refractory  Breast or Prostate Cancer has 
been amended.  The new protocol is indicated by  [CONTACT_11827] ( d) and will be used to conduct the 
study  in place of any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
Revised globally throughout the protocol to refer to the mo lecule primarily as 
LY3022855 (Lilly  code) , rather than as IMC -CS4 (ImCl one code) .
Updated the reference for irRECIST fro m Wolchok et al. 2009 to Nishino et al. 
2013.
Updated LY3022855 content on clinical pharmacokinet ics (Section 5.4.3 )and 
clinical experience (Secti on 5.4.5 ), based on updated informat ion.
MAIN REASON FOR AMENDMENT:  Revised and/or added content on dose 
rationale (Secti on 5.5 ), study  design (Secti on 6.2), study  drug administrati on 
(Secti on 7.2), dose adjust ments and delays (Section 7.2.1), data analyses (Section 
10), study schedules (Attachment 1), and sampling schedules (Attachments 5 and 
6)to account for the addit ion of 2 new dosages, Dosage C ( 100 mg QW ) and 
Dosage D (100 mg Q2W ), based on the RP2D from Study  JSCA.   Clinical 
activit y in terms of tumor reduction or disease stabilit y was observed in pat ients 
with breast cancer enro lled to Study JSCA .  Based upon these results, additional
patients will be enro lled to this study  for the purpose of collecting addit ional 
inform ationto further delineate the immunomodulato ry activit y of LY3022855 in 
patients wi th breast cancer.
Revised language to permit re -screening of pat ients, if agreed upon by  [CONTACT_103] .
Revised Exclusio n Criterion [16] to exclude only those patients with current (but 
not historical) cardiovascular risks, to permit enrollment of patients with historical 
cardi ovascular risks who have been trea ted and are now asymptomatic.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 116
LY3022855 (IMC -CS4)Revised criteria for dose adjust ments and delays in Secti on 7.2.1 for clarity.  
Extended the time permitted for holding study  treat ment and increased the 
number of dose reductions permitted to provi de addi tional opportuni ty for
resol ution of any  toxicitiesoccurring in patients benefitting fro m study  treatm ent.
Added new Section [IP_ADDRESS].1 on immune -related AEs (i rAEs) and a guideline for 
management of irAEs (Attachment 10) , due to the immune modulat ion potential 
of LY3022855.
Added further details in Sect ion 10.8 regarding data analyses for efficacy (tumor 
response data) .
Added further details in Sect ion 10.9 regarding interim analyses .
Deleted som e assessments in Attachment 1 for physical examinat ions during 
Cycle 1, to minimize physician visits.
Added assessments in Attachment [ADDRESS_753988] cancer cohorts.
Deleted som e assessments in Attac hment [ADDRESS_753989].
Deleted som e sam pling time points in Attachment [ADDRESS_753990].
Deleted the sam pling summary  attachm ent, because i t is not requi red in the 
protocol .
Addit ional minor clarificat ions/corrections were made , including but not limited to:
Deleted l anguage in Section 10 stating a SAP will be provided.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 117
LY3022855 (IMC -CS4)Revised Protocol Sections
Note: All deletions have been ident ified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
4. Abbreviations and Definitions
AUC 0-∞ area under the plasma concentration -time curve from time zero to infinity
BLQ below the quantifiable lower limit of the assay
CnWn Cycle and Week numbers
CA 15-3 cancer antigen 15 -3
CEA carcinoembryonic antigen
CL total body clearance
DCR disease control rate
FACS fluorescence -activated cell sorting (a type of flow cytometr y)
GERD gastroesophageal reflux disease
IMC-CS4 sSponsor code name [CONTACT_574468] G, subclass 1 (IgG1) 
monoclonal antibody targeted to the colony -stimulating factor -1 receptor (CSF -1R); also 
known as LY3022855
irAE immune- related adverse event
LVEF left ventricular ejection fraction
ORR overall response rate
OS overall survival
PD pharmacodynamic or progressive disease
Note -“Pharmacodynamic” and “progressive disease” are spelled out throughout this 
protocol, except as follows:  The abbreviation “PD” appears only in Figure JSCB. 1the 
study design figure and in tables in the protocol attachments .  In these locations, the 
abbreviation is clearly defined.
PFS progression -free survival
Q2W q2w once every 2 weeks
QWqw once weekly
Vss volume of distribution at steady state
WOCBP women of child-bearing potential
I5F - MC- JSCB(d )Phase1  Onco logy  P ro toco l Page  118
LY3022855( IMC - CS4 )5 .1 .  Ra t iona le  and  Jus t i f ica t ion  fo r  the  S tudy
LY 3 0 2 2 8 5 5  ( h e r e a f t e r  r e f e r r e d  t o a l s o  k n ow na s  IMC - CS 4)i s  a  r e c om b i n a n t  h um a n  m o n o c l o n a l  
a n t ibody  o f  th e  immunog l o b u l i n  G ,  s u b c l a s s  1  ( I gG 1 )  t a r g e t i n g  CSF -1R .   LY 3 0 2 2 8 5 5IMC - CS 4  
p r e v e n t s  th e  l ig and s  CSF - 1  and  IL - 3 4  f r om  b ind ing  to  CSF - 1R   
,  a n d  i n  t h i s  w a y  i n h i b i t s  CSF - 1R  
a c t i v a t i o n .   CSF - 1R  a c t i v a ti o n  i s  r e q u i r e d  f o r  p r o p e r  f u n c t i o n i n g  a n d  s u r v i v a l  o f  t um o r -
a s so c i a t ed  m a c roph ag e s .   Thu s ,  by  b l o ck ing  CSF - 1R  a c t i v a ti o n ,   
 
 
 
 
 
 
 
 
 
A n ti - CSF- 1R  t r e a tm e n t  t h a t  l im i t s  tum o r- a s s o c i a t e d  m a c r o p h a g e s  e n h a n c e s  CD 8+  T -c e l l
i n f i l t r a t i o n ,  l e a d i n g  t o  d e c r e a s e s  i n  t um o r  b u r d e n  (D eN a r d o  e t  a l .  2 0 1 1 ) .   M o r e o v e r ,  i n  a  
s y n g e n e i c  b r e a s t  c a n c e r  m o d e l ,  d e p l e t i o n  o f  CD 8+  T  c e l ls  r end e r ed  t r e a tm en t  w i th  CS7  l e s s  
e f f i c a c i o u s ,  i n d i c a t i n g  i n t e rp l a y  b e tw e e n  m a c r o p h a g e  a c t i v i t y  a n d  T -c e l li n f i l t r a t i o n .   T h u s ,  
know l e d g e  n o t  o n l y  o f  t h e  m a c r o p h a g e  s u b p o p u l a t i o n  bu t  a l so  o f  th e  T -c e l lsub s e t  m ay  a f f e c t  th e  
e f f i c a c y  o f  LY 3 0 2 2 8 5 5IMC - CS 4t r e a tm e n t  i n  p a t i e n t s .
 
 
 In  add i t i o n ,  p h a rm a c o d y n am i c  r e s u l ts  f rom  th e  o n g o i n g  P h a s e  1  
do s e - e s c a l a t i o n  s tudy  o f LY 3 0 2 2 8 5 5IMC - CS 4,  S tudy  I5F - IE - JSCA  ( a l s o  k n ow n  a s  IMCL  CP 2 4 -
1 0 0 1 ;  h e r e a f t e r  r e f e r r e d  t o  a s  JSCA ) ,  h a v e  s u g g e s t e d  t a r g e t  e n g a g em e n t  a n d  b i ol o g i c  a c t i v i ty  a t  a  
d o s a g e  o f  1 . 2 5  m g / k g  o n c e  w e e k l y .    
5 .2 .1 .  P r ima ry  Ob jec t ive
Th e  p r im a ry ob j e c t i v e  o f  t h i s  s t u d y  i s  to  d o c um e n t  t h e  imm u n om odu l a to ry  a c t i v i t yo f  
LY 3 0 2 2 8 5 5IMC - CS4t r e a tm e n t  i n  p a t i e n ts  w i th  adv an c ed ,  r e f r a c to ry  b r e a s t  o r  p r o s t a t e  c a n c e r s ,  CC I
a c c o r d i n g  t o  t h e  f o l l o w i n g  m e a s u r e s :CC I
CC I
CC I
I5F - MC- JSCB(d )Phase1  Onco logy  P ro toco l Page  119
LY3022855( IMC - CS4 )5 .2 .2 .  Seconda ry  Ob jec t ives
T h e  s e c o n d a r y ob j e c t iv e s  o f  th i s  s tudy  a r e :
 To  e v a l u a t eth e  s a f e t y  and  tox i c i ty  p ro f i l e  o f  LY3022855IMC - CS 4,  a s  a s s e s s e d  b y  t h e  
C omm on  T e rm i n ol o gy  C r i t e r i a  f o r  A d v e r s e  E v e n t s ,  v e r s i o n  4 . 0  (CTCAE  v 4 . 0 )
 To  a s s e s s  th e  p h a rm a c o k i n e t i c  (PK )  s e rum  con c en t r a t i o n so f  LY 3 0 2 2 8 5 5IMC - CS 4
 T o  d o c um e n t  a n ti t um o r  a c t i v i ty , p e r  R e s p o n s eEv a lu a ti o n  C r i t e r i a  in  So l i d  Tum o r s ,  
v e r s i on  1 .1  (REC IST  1 .1 )(E i s enh au e r  e t  a l .  2009 ) a n d  imm u n e - r e l a t ed  REC IST  
( i rREC IST )( W ol c hok  e t  a l .  2009 N ish ino  e t  a l .  2013 )(N o t e :   I f  a  p a t i e n t  h a s  c o n f i rm e d  
p r o g r e s s i v e  d i s e a s e  p e r  REC IST  [ADDRESS_753991] ,  t h e  p a t i e n t  w i l l  b e  c o n s i d e r e d  
to  h av e  no t  p r og r e s s ed . )
 T o  a s s e s s  t h e  d e v e l o pm e n t  o f  a n ti b o d i e s  a g a i n s t  LY 3 0 2 2 8 5 5IMC - CS 4( imm u n o g e n i c i t y ) ,  
a s  a s s e s s e d  b y  a  v a l i d a t e d  imm u n o g e n i c i t y  a s s ay
5 .2 .3 .  Exp lo ra to ry  Ob jec t ives
T h e  exp lo r a to ryob j e c t iv e s  o f  th i s  s tudy  a r e :
 To  exp lo r e  s e rum  b i om a r k e r sth a t  m ay  b e  r e l ev an t  to  th e  m e c h a n i sm  of  a c t i on  o f  
LY 3 0 2 2 8 5 5IMC - CS 4,   
 To  e x p l o r e  t h e  p h a rm a c o d y n am i c  e f f e c t s  o f  LY 3022855 IMC - CS 4on  t i s su e  b i om a rk e r s ,  
u s i n gf l a s h - f r o z e n  b a s e l i n e  a n d  p o s t t r e a tm e n t  t um o r  b i o p s i e s
 T o  a s s e s s  a n ti t um o r  a c t i v i ty  i n  b o n e ,  p e r  t h e  P r o s t a t e  C a n c e r  C l i n i c a l  T r i a l s  W o r k i n g  
G r o u p  (PCWG 2 )  (S c h e r  e t  a l .  2 0 0 8 )c r i t e r i a
5 .3 .  Gene ra l  In t roduc t ion  to  LY3022855IMC - CS4
LY 3 0 2 2 8 5 5IMC - CS 4i s  a  r e comb i n an t  hum an  m on o c l on a l  an tibody  o f  IgG 1  th a t  t a r g e t sCSF-
1R ,  a  ty r o s i n e  k i n a s e  r e c e p t o r  e x p r e s s e d  s e l e c t i v e l y  on  m a c roph ag e  and  g r anu lo cy t e  c e l l  l in e ag e s  
i n  no rm a l  i n d i v i d u a l s  a n d  o n  t um o r  c e l l s  i n  c a n c e r  (K a c i ns k i  1 9 9 5 ;  S a sm o n o  e t  a l .  2 0 0 3 ) .  
The  p r e s e n tt r i a l  w i l l  l ook  sp e c i f i c a l ly  a t  th e  immunomodu l a to ry  a c t i v i t y  o f  LY 3 0 2 2 8 5 5IMC -
CS 4i n  p a t i en t s  w i th  adv an c ed  b r e a s t  o r  p ro s t a t e  c an c e r  r e f r a c to ry  o r  in to l e r an t  to  a t  l e a s t  o n e  CC I
p r i o r  th e r apy  f o r  th e i r  c an c e r .CC I
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 120
LY3022855 (IMC -CS4)5.4. LY3022855 IMC-CS4 –Nonclinical and Clinical Experience
5.4.1. Nonclinical Pharmacokinetics of IMC- CS4
The pharmacokinet ics of LY3022855 IMC -CS4 were evaluated in mice administered 20 mg/kg 
and in cyno molgus mo nkeys at dose levels that ranged fro m 10 to 180 m g/kg. The PK of 
LY3022855 IMC -CS4 incyno molgus mo nkeys was characterized by a relat ively long serum 
half-life (t 1/2) after single (183-275 hours) or mult iple doses (158- 470 hours); these half -lives 
were substantially lo nger than that observed in CD -1 mice (110 hours). Accumulation 
(approximately 2- fold) of LY3022855 IMC -CS4 was evident after repeated once -weekly dosing 
in monkeys, suggest ing that accumulat ion may similarly  occur in humans, depen ding on the 
frequency  of dosing. The estimated volume o fdistribution of LY3022855IMC -CS4 in monkeys 
(approximately 29- 64 m L/kg) indicated that LY3022855 IMC -CS4 was not substant ially 
distributed bey ond the vasculature. In the cynomolgus mo nkey studi es,LY3022855IMC -CS4
serum  exposures were generally  proporti onal to the increases in dose from 10 to 180 m g/kg and 
no sex differences were observed.
The concentration of serum CSF -[ADDRESS_753992] dose levels (10 or 20 mg/kg). CSF-1 levels were generally  sustained 
throughout the sampling period. However, in the repeat -dose cyno molgus monkey study , the 
concentration of CSF -1 began to decrease in so me animals fro mthe low-(20 mg/kg) and 
middle -(60 m g/kg) dose groups during the recovery  period.
Formal studies to characterize the metabo lism and disposit ion of LY3022855 IMC -CS4 have not 
been conducted. As a monoclonal ant ibody , LY3022855IMC -CS4 will be largely confined to 
the ext racellular space, which is supported by  [CONTACT_574456] m numerous invest igations and is 
consistent with the PKevaluat ion of LY3022855 IMC -CS4. No formal metabolism  studies of 
LY3022855 IMC -CS4 have been performed because the catabolism of antibodies by [CONTACT_574457] s is largely understood and formal studies of the metabo lic degradation of these mo lecules 
are not warranted.
For details on the nonclinical PK of LY3022855 IMC -CS4, refer to Section [ADDRESS_753993] igator’s Brochure (IB) .
5.4.2. Nonclinical Pharmacokinetic/Pharmacodynamic Model
One of t he main pharmaco logical effect sof LY3022855IMC -CS4 proposed to underlie the 
inhibit ion of cancer progression is the deplet ion of tum or-associated macrophages.  To model 
this effect and estimate the minimum eff ective blood level required to achieve significant 
antitumor effects, cancer models established in mice were utilized.  However, since 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 121
LY3022855 (IMC -CS4)LY3022855 IMC -CS4 does not bind to murine CSF -1R, a surrogate antibody , CS7, was 
developed and utilized in order to examin e PK/pharm acodynamic relat ionships.  The binding 
affinit y of CS7 to murine CSF- 1R (dissoci ation constant [ Kd] = 0.13nM) is 6-fold greater than 
that of LY3022855 IMC -CS4 to hum an CSF -1R (K d=0.8nM).  However, comparable potencies 
of the ant ibodies were obse rved in cell -based assays of inhibit ion of CSF -1-induced 
phosphorylat ion (IC 50= 0.3nM for both antibodies), monocy te different iation (IC 50=0.3nM vs 
0.25nM for CS7 and LY3022855 IMC -CS4, respectively ), and inhibi tion of monocy te 
proliferat ion (IC 50 = 0.13 nM or 0.1nM for CS7 and LY3022855 IMC -CS4, respectively).  
Therefore, CS7 and LY3022855 IMC -CS4 were anti cipated to have similar pharmaco logical 
effects in vivo at similar concentrations.  Hence, CS7 was utilized in animal models to direct ly 
predi ct the trou gh serum LY3022855 IMC -CS4 levels necessary  to achieve rel evant efficacy  in 
human subjects .
Based on these assumpt ions, to estimate target serum concentrations for efficacy in init ial 
clinical invest igations, trough concentrations associated with efficacy w ere determined in human 
breast cancer HCC -1954 and human leukemia NKM -1 models established in mice.  
LY3022855 IMC -CS4 was evaluated i n the leukemia model established fo llowing intravenous 
(I.V.) i njecti on of  CSF -1R-expressing NKM -[ADDRESS_753994] of LY3022855IMC -CS4, as efficacy was achieved at mean 
trough concentrations down to 0.2 µg/mL. For CS7, notably higher doses and concentrations 
were required to inhibit human HCC -[ADDRESS_753995] cancer tumor growth, as a mean trough 
concentration of 425 µg/m L was associ ated wi th efficacy .
5.4.3. Clinical Pharmacokinetics of IMC- CS4
Asof 28 January  2016, the clinical experience of LY3022855 PK co mprised 27 pati ents enrolled 
in Study  JSCA (0.3 m g/kg once weekly  [QW] [n=4], 0.6 mg/kg QW [n=3], 1.25 mg/kg QW 
[n=5], 1.25 mg/kg once every  2 weeks [Q2W] [n=9], and 2.5 mg/kg QW [n=6]), and 14 patients 
enrolled in Study JSCB (1.25 mg/kg Q2W [n=9] and 1 mg/kg on Weeks 1, 2, 4, and 5 of every 
6-week cycle [n=5]).
LY3022855 in cancer patients exhibited moderate total body clearance (CL) (mean values on 
Day 1 ranged from  0.0378 to 0.0651 L/h), low volume of distribut ion at steady  state (V ss) (mean 
values on Day 1 ranged fro m 2.85 to 4.93 L), and moderate t 1/2(mean values on Day  1 ranged 
from 30.8 to 92.2 hours).
LY3022855 CL appeared to be nonlinear with respect to LY3022855 concentration, where 
higher doses of LY3022855 tended to exhibit lower CL values.  However, this apparent 
nonlinearit y was confounded by  [CONTACT_574424] (BLQ), which could artificially inflate the calculated CL at 
lower doses.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 122
LY3022855 (IMC -CS4)An apparent lack o f relationship between pat ient body  weight and LY3022 855 CL 
(Figure JSCB. 1, upper panel) resulted in an amended dose -escalat ion plan for Study  JSCA, to 
evaluate the safet y, PK, and immunogenicit y of LY3022855 using a fixed- dosing approach (that 
is, m g as opposed to mg/kg).
The clinical PK of LY3022855 are de scribed in greater detail in Section 6.1 of the IB.

I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 123
LY3022855 (IMC -CS4)Abbreviations:  N = number of patients treated; QW = once weekly; Q2W = once every 
2 weeks.
Figure JSCB. 1. Individual observed clearance versus patient body weight (upper 
panel) and LY3022855 dose (lo wer panel) for Studies JSCA  and 
JSCB.
For the ongoi ng Phase [ADDRESS_753996] been 
analyzed, wherein IMC -CS4 was administered in the fo llowing order :
Cohort 1 –2.5 mg/kg once weekly
Cohort 2 –0.3 mg/kg once weekly
Cohort 3 –0.6 mg/kg once weekly
Cohort 4 –1.25 mg/kg every 2 weeks
Cohort 5 –1.25 mg/kg once weekly
PK samples were co llected fo llowing the fi rst dose for all 5 cohorts and again following 
subsequent doses at Cy cle 1, Week 4 for Cohort 1, and at Cycle 1, Week 3 for Cohort 4.
Following single -dose administrati on of  IMC -CS4, the area under the serum concentration -time 
curve serum exposure (AUC (0-∞)), the m aximum serum  concentrati on (C max), and the trough 

I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 124
LY3022855 (IMC -CS4)concentrations (C trough) increased wi th increasing dose.  For the 1.25- mg/kg every -week dose, the 
trough concentrations fo llowing the first dose ranged fro m approximately 8 to 12 µg/mL, 
whereas for the 1.25 -mg/kg every -2-week dose, the trough concentrations fo llowing the fi rst 
dose ranged fro m approx imately 3 to 7 µg/mL.
Following m ultiple dose (fourth dose [Cy cle 1, Week 4]) of IMC- CS4 at the 2.5 -mg/kg 
every -week dosing schedule (the highest dose tested), the geometric mean clearance (at steady  
state) and exposure (AUC (0-τ)) were 0.0189 L/hr and [ZIP_CODE] hr*µg/mL, respectively.  The 
terminal eliminat ion half -life ranged from 7 to 12 days, and the accumulat ion rati os ranged from  
2.08 to 3.03.  The trough concentrations (C trough) ranged from  24.1 to 44.5 µg/mL.  However, 
these results were obtained fro m only 3 patients from one dose group (2.5 mg/kg every week).
5.4.4. Nonclinical Toxicology of IMC- CS4
A standard nonclinical toxico logy program  for advancement of a monoclonal antibody  into
clinical trials in onco logy indicat ions was conducted to assess the s afety and toxi city of
LY3022855 IMC -CS4. The nonclinical safet y assessment of LY3022855 IMC -CS4 was 
conducted in cyno molgus monkeys. This species was considered a relevant model for the 
nonclinical safet y evaluat ion ofLY3022855 IMC -CS4, based on a prelimin ary cross -species 
evaluat ion of t issue/receptor binding and/or functional in vitro pharmaco logical activi ty in 
human and cyno molgus monkey test systems and in a subsequent comprehensive t issue cross -
reactivit y study  using full panels o f monkey and human tissues. The toxicology studies 
conducted with LY3022855 IMC -CS4 included an exploratory single -dose toxi city and 
toxicokinet ic (TK) dose range -finding study  and a pi[INVESTIGATOR_22735]  4-week repeat -dose good l aboratory  
practi ce toxici ty, TK, an d immunogenici ty study  with a 6-week recovery  period. Animals were 
administered LY3022855 IMC -CS4 by I.V. infusio n, the intended clinical method of 
administration, using the dosing schedule (once weekly) in the planned init ial clinical
investigat ions of LY3022855 IMC -CS4. The pi [INVESTIGATOR_574419]. Because of an ant icipated effect of LY3022855 IMC -CS4 on 
circulat ing levels of the target ligand, CSF -1, the levels o f CSF-[ADDRESS_753997] ivity of the ant ibody . A 
thorough assessment of peripheral  blood and spleen m ononuclear cell subsets and an 
immunohistochemical analysis o fCD68+ cells (cellular marker of monocy tes/macrophages) in 
liver and spleen were a lso included to determine the effects that blockade of the CSF -[ADDRESS_753998] not been conducted.
[IP_ADDRESS]. Single -Dose Toxicity
Single-dose administration of LY3022855 IMC -CS4 at dose levels o f 10, 40, and 140 mg/kg 
administered by I.V. infusio n over a 15 -minute period was well tolerated in cyno molgus 
monkeys (2 monkeys/sex/group) during the 14 -day observat ion peri od. Sustained dose -
proporti onal exposure to LY3022855 IMC -CS4 was generally observed throughout the 14- day 
I5F - MC- JSCB(d )Phase1  Onco logy  P ro toco l Page  125
LY3022855( IMC - CS4 )o b s e r v a ti o n  p e r i od  a t  a l l  d o s e  l e v e l s  f o l l ow i n g  a dm i n i s t r a t i o n ,  w i t h  n oa p p a r e n t  s e x  d i f f e r e n c e s .  
 
 
 
 
 
 
 
 
 
S im i l a r  
e l e v a t i o n s  in  s e rume n z ym e  l e v e l s  h a v e  a l s o  b e e n  o b s e r v e d  w h e n  t r e a t i n g  w i t h  o t h e r  
p h a rm a c ol o g i c a l  ag en t st a r g e t i n g  CSF - 1R  (W ang  e t  a l .  2011 )  o r  CSF - 1  (R a d i  e t  a l .  2 0 1 1 ) .
N o  o t h e r  a d v e r s e  c l i n i c a l  s i g n s  o r  e f f e c t s  o n  f o o d  c o n s um p ti o n ,  body  w e igh t ,  h em a to l ogy ,  a n d
o rg an  w e i g h t s  w e r e  a s s o c i a t e d  w i t h  a dm i n i s t r a t i o n  o f  LY 3 0 2 2 8 5 5IMC - CS 4.
CSF- 1  s e rum  l e v e l s  i n c r e a s e d  r e l a t i v e l y  q u i c k l y  a f t e r  LY 3 0 2 2 8 5 5IMC - CS 4a dm i n i s t r a t i o n  a n d  
r em a i n e dsu s t a in ed  th roughou t  th e  14 - d a y  o b s e r v a t i on  p e r i od .  CSF- 1  w a s  n o t  d e t e c t e d  i n  a n y  
con t ro la n im a l s  a t  a n y  t i m e .  Th e  max imum  l ev e l s  o f  CSF - 1  r e a c h e dw e r e  comp a r ab l e  a c ro s s  
do s eg r o u p s ,  s u g g e s t i n g  t h a t  a  m a x im a l  p h a rm a c o d y n am i c  e f f e c t  o f  LY 3 0 2 2 8 5 5IMC - CS 4on  th i s  
p a r am e t e r  w a sa c h i e v e d  a t  e v e n  t h e  l ow e s t  d o s e  l e v e l  i n  t h e  s t u d y .
T h e  n o- o b s e r v e d - adv e r s e - e f f e c t  l ev e l  (NOAEL )  in  th i s  s tudy  w a s  c o n s i d e r e d  t o  b e
 Th is  do s e  co r r e spond ed  to  a  do s ing  D ay  1  
 
5 .4 .4 .2 .  Repea t- Dose  Tox ic i ty
I n  t h e  p i v o t a l  r e p e a t - d o s e  t o x i c i ty , TK ,  and  immunog en i c i ty  s tudy  o f  LY 3 0 2 2 8 5 5IMC - CS 4,  
d o s e s  o f  0 ,  2 0 ,6 0 ,  a n d  1 8 0  m g / k g / d o s e  LY 3 0 2 2 8 5 5IMC - CS 4w e r e  a dm i n i s t e r e d  b y  I .V .  i n f u s i on  
on c e  w e ek ly  toc y n o m ol g u s  m o n k e y s  ( 5 / s e x / g r o u p )  f o r  4  w e e k s ,  f ol l o w ed  by a  6 - w e ek  r e cov e ry 
p e r i od .  S t a n d a r d  t o x i c ol o g i c a l  and  r e l ev an t  s a f e ty  ph a rm a co l ogy( c a rd i ov a s cu l a r ,  c en t r a l  
n e rvou s[CNS ] ,  and  r e sp i r a to ry  sy s t em s )  endpo in t s  w e r e  a s s e s s ed .  A s  i n  t h es i n g l e - do s e  s tudy ,  
c i r c u l a t i n g  l e v e l s  o f  CSF - 1  w e r e  m e a su r ed .  A  t h o r o u g h  a s s e s sm e n t  o fp e r i ph e r a l  b l ood  and  
s p l e e n  m o n o n u c l e a r  c e l l  s u b s e t s  a n d  a n  imm u n o h i s t o c h em i c a l  a n a l y s i s  o fCD68+  mo n o n u c l e a r  
c e l l s  i n  l i v e r  a n d  s p l e e n  w e r e  a l s o  c o n d u c t e d .
I n t r a v e n o u s  i n f u s i o n  of  LY 3 0 2 2 8 5 5IMC - CS 4w a s  g e n er a l ly  w e l l  to l e r a t e d  a t  a l l  d o s e  l e v e l s .  
S u s t a i n e d  d o s e- p ropo r t i on a lto  s l i g h tl y - g r e a t e r- th a n - do s e - p ropo r t i on a l  in c r e a s e s  in  expo su r e  to  
LY 3 0 2 2 8 5 5IMC - CS 4w e r eg e n e r a l l y  o b s e r v e d ,  a n d  n o  s e x  d i f f e r e n c e s  i n  e x p o s u r e  w e r e  CC I
CC I
CC I
CC I
I5F - MC- JSCB(d )Phase1  Onco logy  P ro toco l Page  126
LY3022855( IMC - CS4 )app a r en t .  M od e r a t e  a c c um u l a ti o n( ap p rox im a t e ly  2 - f o l d )  o f  LY 3 0 2 2 8 5 5IMC - CS 4o c c u r r e d  a f t e r  
r e p e a t e d  a dm i n i s t r a t i o n .   
 
 
  
A s  n o t e d  i n  t h e  s i n g l e- do s e  exp lo r a to ry  s tudy ,  c i r cu l a t i n g  c o n c e n t r a t i o n s  o f  CSF - 1  i n c r e a s e d
s h o r t l y  a f t e r  LY 3 0 2 2 8 5 5IMC - CS 4a dm i n i s t r a t i o n .  CSF- 1  w a s  n o t  d e t e c t e d  i n  a n y  con t ro l  
a n im a l s .  Incon t r a s t  to  LY 3 0 2 2 8 5 5IMC - CS4 ,  t h e  c o n c e n t r a t i o n  o f  CSF - 1  d i d  no t  v a ry  w i th  do s e ,  
a s  com p a r a b l em a x im um  l e v e l s  w e r e  r e a c h e d  i n  a l l  3  d o s e  g r o u p s .  T ow a r d s  t h e  e n d  o f  t h e  
r e cov e ry  p e r i od ,CSF- 1  l e v e l s  g e n e r a l l y  d e c r e a s e d  i n  t h e  2 0 -a n d  6 0 - m g / k g  d o s e  g r o u p s ,  b u t  
r em a i n e d  e l e v a t e d  i nth e  180 - m g / k g  d o s e  g r o u p .
Th e  k ey tox i c o l o g i c a l  f ind ing s  a t t r ibu t ed  to  LY 3 0 2 2 8 5 5IMC - CS 4a dm i n i s t r a t i o n  i n  t h i s  s t u d y
w e r e  p e r i o r b i t a l  sw e l l i n g ,  i n c r e a s e s  i n  s e r um  t r a n s am i n a s e s  a s  n o t e d  i n  t h e  e x p l o r a t o r y s tudy ,
ch ang e s  in  l euko cy t e  popu l a t i o n s  (mono cy t e s ,  n eu t roph i l s ,  CD68+  mononu c l e a r  c e l l s ,  n a tu r a l
k i l l e r  [NK ]  c e l l s ) ,  a n d  t a r g e t  o r g a n  e f f e c t s  i n  l i v e r  (K u p f f e r  c e l l  h y p e r t r o p h y /hyp e rp l a s i a ) ,  sp l e en
( f o l l i cu l a r  hyp e r t rophy /d end r i t i c  c e l l  hyp e rp l a s i a ) ,  and  bon e  m a r row  (hy p e r c e l lu l a r i ty ) .  T h e
imm u n o m odu l a to rye f f e c t s  on  l euko cy t e s ,  K u p f f e r  c e l l s ,  s p l e e n ,  a n d  b o n e  m a r r ow  l i k e l y  r e f l e c t
a n  e x a g g e r a t e d  p h a rm a c o l o g i c a l  r e spon s e  to  LY 3 0 2 2 8 5 5IMC - CS 4,  po s s ib ly  a s so c i a t ed  w i th  
e l e v a t i o n s  inc i r c u l a t i n g  CSF - 1  l ev e l s  no t ed  du r ing  th e  s tudy .
E l e v a ti o n s  i n  ALT  a f t e r  th e  la s t  do s ing  o f  LY3022855IMC - CS 4w e r e  g e n e r a l l y  m i n im a l  i n  t h e  
l o w e s t  do s eg r o u p  ( 2 0  m g / k g )  a n d  m i n im a l  t o  m o d e r a t e  a t  t h e  6 0 -a n d  1 8 0 - m g / k g  d o s e  l e v e l s .  
AST  le v e l sw e r e  m in im a l ly  to  mod e r a t e ly i n c r e a s ed  a t  a l l  do s e  l e v e l s .  ALT  and  AST  r e tu rn ed  to  
b a s e l i n ei nth e  20 - m g / k g  g r o u p  a n d  t r e n d e d  t ow a r d s  b a s e l i n e  i n  t h e  6 0-a n d  1 8 0 - m g / k g  g r o u p s  
d u r i n g  t h er e c o v e r y  p e r i od ,  bu t  r em a i n e d  i n c r e a s e d  i n  s o m e  i n d i v i d u a l  a n im a l s  c o m p a r e d  w i th  
b a s e l i n e .  N oh i s t o l o g i c a l  c h a n g e s  i n  t h e  l i v e r  w e r e  n o t e d  t o  c o r r e l a t e  w i t h  t h et r a n s am i n a s e  
i n c r e a s e s ,  n o rw e r e  a n y c h a n g e s  n o t e d  i n  l i v e r  f u n c t i o n a l  p a r am e t e r s  ( t h a t  i s ,  AP,  b i l i r u b i n ,a n d  
co agu l a t i o n ) .  T h e r e f o r e ,  b a s e d  o n  t h e  sm a l l  m a g n i t u d e  o f  t h e  e l e v a ti o n s  a n d  t h e  a b s e n c e  o f
h i s to l og i c a l  o r  f u n c t i o n a l  c h a n g e s ,  t h e  i n c r e a s e s  i nALT  a n d  AST  w e r e  n o t  c o n s i d e r e d  a d v e r s e .
I n c r e a s e s  i n  c i r c u l a t i n g  w h i t e  b l o o d  c e l l s  d u e  t o  i n c r e a s e s  i n  n e u t r o p h i l s  a n d  m o n o c y t e s  w e r e
o b s e r v e d  i n  b o t h  s e x e s  a t  6 0  a n d  1 8 0  m g / k g .  F low  cy tom e t ry  a n a l y s i s  o f  s p l e e n  a n d  p e r i p h e r a l
b l o o d  r e v e a l e d  i n c r e a s e s  i n  m ono cy t e s  i n  s p l e e n  a n d  b l o o d  a t  6 0  a n d  1 8 0  m g / k g  a n d  r e d u c t i o n s
i n  s p l e n i c  NK  c e l l s  i n  a l l  LY 3 0 2 2 8 5 5IMC - CS 4- t r e a t ed  g roup s .  V a r i a b i l i ty  i n  NK  c e l l  n um b e r s  
i n  t h ep e r iph e r a l  b l ood  o f  a n im a l s  i n  a l l  d o s e  g r o u p s  ( i n c l u d i n g  c o n t r o l )  p r e c l u d e d  a s s i g n i n g  a
d e f i n i t i v e  r e l a t i o n s h i p  w i t h  LY 3 0 2 2 8 5 5IMC - CS 4t r e a tm en t .  T h e s e  c h a n g e s  i n  w h i t e  b l o o d  c e l l  CC I
coun t s ,  i nc o n j u n c t i o n  w i th  m i n im a l  r e v e r s i b l e  i n c r e a s e s  i n  s e r um  g l o b u l i n  c o n c e n t r a t i o n s  w i t h  a
c o r r e s p o n d i n g  d e c r e a s e  i n  a l b um i n  t o  g l o b u l i n  r a ti o ,  a r e  c o n s i s t e n t  w i th  t h e  p r e s e n c e  o f  a n
in f l amm a to ry  r e spon s e .  H ow e v e r ,  n o  h i s t o p a t h o l o g i c  e v i d e n c e  o f  i n f l amm a ti o n  w a s  o b s e r v e d .  
Th e  mono cy t e ,  n e u t r o p h i l ,  a n d  g l o b u l i n  c h a n g e s  w e r e  r e v e r s i b l e  b y  t h e  e n d  o f  t h e  r e c o v e r y
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 127
LY3022855 (IMC -CS4)period, while the splenic NK cell reduct ions were still apparent in some animals. These changes
were not considered adverse because o f their small magnitude.
Anatomic patho logy changes attributed to the administration of LY3022855 IMC -CS4 at the end 
of thedosing period included increased spleen weights i n females (all dose groups), which 
generally correl ated wi th splenic fo llicular hypertrophy (males at 60 and 180 mg/kg; females at 
20 and 180mg/kg), bone marrow hypercellularit y (all female dose groups, one male at 60 
mg/kg), bone marrow lympho id aggregat es (one male, one female at 180 mg/kg), and Kupffer 
cellhypertrophy /hyperplasia (primarily minimal, all male dose groups, one female at 60 mg/kg).   
Immunohistochemical analyses confirmed the presence of increased size or number of CD68+
Kupffer cells in t he liver and increased numbers of CD68+ mononuclear cells in the spleen at all
dose l evels. The CD68+ cells in the spleen were likely fo llicular dendrit ic cells. The
immunohistochemical findings in liver and spleen generally  correl ated wi th the histopath ologi c
diagnoses of Kupffer cell hypertrophy /hyperpl asia and splenic fo llicular hypertrophy . Similar
anatomic patho logy findings in spleen, liver, and bone marrow were observed after the recovery
period. These changes were not considered adverse because of their small  magnitude.
Slight to moderate periorbital swelling was observed primarily during the recovery  phase in all
LY3022855 IMC -CS4-treated groups (20, 60, and 180 mg/kg/dose). This clinical sign has been 
reported to occur in humans with another an tibody to CSF -1 (Sadis et al. 2009) and may thus 
represent a delayed response to LY3022855 IMC -CS4 in the treated monkeys. Watery  feces was 
observed only  in the 60-mg/kg/dose animals, but is considered possibly related to the 
administration of LY3022855 IMC -CS4.  These clinical signs were not considered adverse based 
on their limited impact to the overall healt h of the animal. No adverse effects were noted in 
assessments of the central nervous (neurological behavioral examinat ion), respi[INVESTIGATOR_696]  (rate), or 
cardiovascular (heart rate, blood pressure, electrocardiogram [ECG] ) systems. In addit ion, no 
evidence of an adverse reaction or intolerance attributable to LY3022855 IMC -CS4 was apparent 
at the inject ion sites after I.V. infusio n in the cyno molgus mo nkey repeat -dose toxi city studi es.
Based on the absence of any  defini tive LY3022855IMC -CS4-related adverse findings, the 
NOAEL for LY3022855 IMC -CS4 administered via 15 -minute I.V. infusio n weekly  on 4 
occasi ons was considered to be 180 m g/kg/dose. The dose corre sponded to a dosing Day 22 
mean C maxof 7985 µg/mL, C 168hrof2945 µ g/mL, and mean AUC (0-168h r)of 711340 µg·hr/mL.
5.4.5. Clinical Experience
Clinical experience wit h LY3022855 comprises 43 patients (as of 28 January 2016) who 
received the fo llowing doses I.V. in 2 ongoing Lilly -sponsored Phase 1 studies (I5F-IE-JSCA 
[JSCA] and I5F -MC-JSCB [JSCB]) :  2.5 m g/kg QW (n=6), 0.3 mg/kg QW (n=4), 0.6 mg /kg 
QW (n=3), 1.25 mg/kg Q2W (n=20), 1.25 mg/kg QW (n=5), and 1 mg/kg on Weeks 1, 2, 4, and 
5 of every  6-week cycle (n=5).   At the first human dose studied, 2.5 mg/kg QW (Study JSCA), 
which was also the highest dose administered, laboratory  abnorm alities, including Grade 2-3 
creatine kinase (CK) and Grade [ADDRESS_753999] el evations, were noted in 5 patients but were not 
classified as dose -limiting toxicit ies (DLTs) due to the lack of clinical signs or symptoms of 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 128
LY3022855 (IMC -CS4)organ toxicit y.  Because of these laboratory  abnorma lities, the protocol for Study  JSCA was 
amended and dose escalat ion was restarted at a lower dose, 0.3 mg/kg QW.
Elevated levels of CK and AST, in the absence of clinical signs or symptoms or other laboratory 
abnorm alities suggestive of end- organ damage ar e, in retrospect, believed to be 
pharmacodynamic indicators of target engagement, rather than markers of drug -related toxicit y.  
This belief is strengthened by [CONTACT_574426]. (2011), in which preclinical models support 
the hypothesis that increase s in the l evels o f serum enzymes can be the result of decreases in 
Kupffer cells, in the apparent absence of hepat ic or skeletal muscle injury.  In all cases where 
elevated enzymes were observed following LY3022855 administration in Study  JSCA, the l evels 
decreased to Grade <[ADDRESS_754000] been observed in Study JSCA:  an event of left 
ventri cular dy sfunct ion (Cohort 4, 1.25 mg/kg Q2W), an event of pan creat itis (a patient in 
Cohort 5, 1.25 mg/kg QW), an event of rhabdo myolysis (another patient in Cohort 5), and an 
event of Grade 3 CK elevat ion (Cohort 7a, 150 mg QW).  The patient with the DLT of left 
ventri cular dy sfunct ion had a baseline left ventricul ar ejection fraction (LVEF) of 35%, which 
obfuscated the relationship between LY3022855 and the DLT event; therefore, the patient was 
considered to be a suboptimal candidate for study  parti cipat ion.  The patient in Cohort 5 who 
experienced pancreat itis hada medical  history  significant for i rritable bowel  syndrome and 
gastroesophageal reflux disease (GERD), rendering the patient prone to nausea and abdo minal 
pain.  During the course of treatment in Study  JSCA, thi s pat ient’s serum levels o f lipase 
gradually increased, from 21 U/L (baseline) to 138 U/L (Cy cle 1, Week 6 [C1W6]) (C1W2 = 79 
U/L, C1W3 = 90 U/L, C1W4 = 121 U/L, C1W5 = 149 U/L).  Following the C1W3 
administration of LY3022855, the patient’s treatment with study  drug was held due to rising 
lipase l evels.  Steroi ds were not i nitiated unt il the patient presented for medical attention with 
complaints of nausea, vomit ing, and abdo minal pain on C1W6, at which t ime the patient was 
diagnosed wi th Grade 3 pancreat itis.  The symptoms improved with hospi[INVESTIGATOR_12191], supportive 
therapy , and systemic steroids.  Although this particular case resulted in a DLT, the relat ionship 
between elevated lipase and gastrointestinal symptoms is not clear, given the patient’s history  of 
irritable bowel  syndrome and GERD.
Following the occurrence of the 2 DLTs in Cohort 5 of Study JSCA, dose escalat ion was 
temporarily halted.  Subsequent PK and pharmacodynamic analyses revealed the fo llowing:
A lack of correlat ion between body  weight and LY3022855 cl earance (Figure JSCB. 1)
Interm ittent inhibit ion of CSF -1R si gnaling wi th Q2W dosing of LY3022855, as 
evidenced by [CONTACT_574427] -1 and peri pheral  CD14dimCD16brightcells by 
[CONTACT_74064] -activated cell sorting (FACS) (Figure JSCB. 2)
Sustained inhibit ion of CSF -1R signali ng wi th 2.5 mg/kg QW and 1.25 m g/kg QW 
dosing (Study  JSCA Cohorts 1 and 5, respectively) of LY3022855, as evidenced by  
[INVESTIGATOR_67132] o f both ci rculating CSF -1 and peripheral CD14dimCD16brightcells by [CONTACT_7811] (Figure 
JSCB. 2)
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 129
LY3022855 (IMC -CS4)Based on these observat ions, the protocol for Study  JSCA was amended to:  (1) examine fixed 
(non-weight-based) dosing of LY3022855 on weekly administration schedules to optimize the 
biological  effects of LY3022855 on CSF -1R inhibiti on, (2) redefine a DLT as any LY3022855 -
related AE that occurs du ring Cycle 1 and does not improve to Grade ≤2, unless stated otherwise, 
despi[INVESTIGATOR_45862], including steroids (if applicable) within 7 days o f docum ented 
occurrence , and (3) incorporate management guidelines for immune -related AEs.  Dosing in 
Study  JSCA resumed at a fixed dose of 100 mg QW, which is co mparable to 1.33 mg/kg in a 75 -
kg person and within the coefficient of variat ion in exposure (34% to 49%).  As of [ADDRESS_754001] received 100 mg QW for 6 weeks (Cy cle 1, DLT 
assessment period) without experiencing a DLT.  Of the 3 patients treated at the next higher dose 
level of 150 mg QW, 1 patient experienced a DLT of Grade 3 CK elevation associated with 
elevated serum  and urine my oglobin.

I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 130
LY3022855 (IMC -CS4)Abbreviation:  C = coh ort.
Figure JSCB.2. CD14dimCD16bright(relative percentage of CD45+HLA-DR+CD14+) in 
the blood of patients from Study JSCA .
There i s currently one IMC -CS4 study , Study  JSCA, an ongoing Phase [ADDRESS_754002] therapy  is available.  As of 22 February  2015, IMC -CS4 has been 
administered by  I.V. infusio n over 6- week cy cles to 26 pati ents in this study .  This includes:
6 pati ents dosed at the starting dose of 2.5 mg/kg weekly (Cohort 1),
4 pati ents dosed at 0.3 mg/kg weekly  (Cohort 2),
3 pati ents dosed at 0.6 mg/kg weekly  (Cohort 3),
6 pati ents dosed at 1.25 mg/kg every  2 weeks (Cohort 4),
5 pati ents dosed at 1.25 mg/kg weekly  (Cohort 5), and
2 pati ents dosed at 1.25 mg/kg every  2 weeks (expansi on cohort).
In Cohort 1 (2.5 mg/kg weekly), laboratory  findings consistent ly reported for the 6 treated 
patients included serum elevat ions of creat ine kinase (CK; also known as creatine 
phosphokinase ), AST, and LDH.  None of these findings were considered to be dose -limiting 
toxicities (DLTs), due to the lack of clinical signs and symptoms of organ toxicit y and because 
enzyme levels decreased upon discontinuation of IMC- CS4, indicat ing that this effec t was 
temporary  and reversible.  However, based on these findings, the planned dose -escalat ion 
scheme for Cohorts 2 and bey ond was revised (via dose reductions and prolonged administration 
intervals) to better characterize the IMC- CS4 dose -response effect on the m onocy te/macrophage 
system  and on vari ous serol ogic and hematol ogic param eters.
No DLTs were observed in Cohorts [ADDRESS_754003] ion (verb atim) after one dose 
of IMC -CS4; the event was considered by [CONTACT_574458] -CS4.  Because a 
DLT could not be rul ed out for this event, 2 addit ional pat ients were enrolled into Cohort 4 and 
completed the cycle without experiencing a D LT.
Five patients were subsequent ly enrolled into Cohort 5, of who m 2 devel oped DLT events:
One pat ient developed rhabdo myolysis, co mplicated by  [CONTACT_574459], after one 
dose.  No clear contribut ing or incit ing factors were ident ified other than poss ible 
dehydrat ion caused by [CONTACT_574460] 5 day s after receiving 
IMC -CS4.
One pat ient was diagnosed with pancreatit is after 3 weekly doses.  No clear incit ing 
factors coul d be ident ified other than study drug administration; however , the di agnosis 
of pancreati tis was obfuscated by  [CONTACT_28260] m edical  issues, including irritable bowel 
syndro me and baseline Grade 1 nausea.
Due to these 2 DLTs, dose escalat ion was discont inued and enrollment to a 6 -patient expansio n 
cohort (to be dosed a t 1.25 m g/kg every  2 weeks) was init iated.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 131
LY3022855 (IMC -CS4)Asof 28 January  2014 (the cutoff date for the 2014 IB for IMC -CS4), the most commo nly 
reported treatment -emergent adverse events (TEAEs) ( ≥20% patients) regardless of grade or 
relationship to IMC -CS4 were:  fatig ue (11 pati ents); hypoalbuminemia (8 patients); nausea, 
aspartate aminotransferase increased, and decreased appetite (6 patients each); cough and blood 
creatine phosphokinase increased (5 patients each); and lymphopenia, blood alkaline 
phosphatase increase d, lymphocy te count decreased, weight decreased, hypocalcemia, 
hyponatremia, and hypertensio n (4 patients each).  Six patients who received at least 1 dose of 
IMC -CS4 in Study  JSCA experienced the following Grade 3 or Grade ≥4 adverse events (AEs) 
regardl ess of relationship to IMC -CS4:  Grade [ADDRESS_754004] ion, ascites, fat igue, subcutaneous abscess, aspartate aminotransferase increased, blood 
creatine phosphokinase increased, blood alkaline phosphatase increased, ly mphocy te count 
decreased, hypokalemia, pneumothorax, and hypotensio n; and Grade ≥[ADDRESS_754005] ion 7 (Development Core Safety Information) of the IB.  Information on 
SAEs expected in the study  popul ation independent of drug exposure and that will be assessed 
by [CONTACT_240209], periodically  during the course of the study , may be found in Secti on 
6 (Effects in Humans) of the IB.
5.5. Rationale for Selection of Dose
The optimal dose and regimen schedule of LY3022855IMC -CS4 in humans are not known.  The 
protocol  will utilize 42dosages of LY3022855 IMC -CS4,where Dosages A and B are weight 
based, while Dosages C and D are non- weight based (that is, fixed), as prior data suggest that 
weight-based dosing does not affect exposure (S ection 5.4.3).   Dosage A will be 1.25 mg/kg 
administered every  2 weeks of a 6 -week cy cle, and Dosage B will be 1 mg/kg on Weeks 1, 2, 4, 
and 5 of a 6- week cy cle.Refer to Table JSCB. 1for a summary  of the LY3022855 dosages to be 
used in this study .
Table JSCB.1. Summary of LY3022855 Dosages in Study JSCB
Dosage Dose Schedule (based on a 6 -week cycle)
Dosage A (weight based dose) 1.25 mg/kg Q2W
Dosage B (weight based dose) 1 mg/kg Weeks 1, 2, 4, and 5 of a 6 -week cycle
Dosage C (non -weight based/fixed dose) 100 mg QW
Dosage D (non -weight based/fixed dose) 100 mg Q2W
Abbreviations:  QW = weekly; Q2W = ever y 2 weeks (Weeks 1, 3, and 5).
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 132
LY3022855 (IMC -CS4)The rati onale for each dosage is presented as fo llows.
Dosage A is based on the fo llowing observations from Study  JSC A:
A dosage of 1.25 mg/kg every  [ADDRESS_754006] dosage tested in Study  JSCA that 
demonstrated a si gnificant increase in the 2 ligands of CSF -1R (CSF -1,IL-34).
Results demo nstrated an acceptable clinical safet y profile of LY3022855IMC -CS4 at a 
dose of 1.25 mg/kg every 2 weeks.
Dosage B is based on the fo llowing rationale:
PK parameters from Study  JSCA revealed a 34% to 49% coefficient of variat ion in 
exposure (AUC 0-∞) for pati ents administered LY3022855IMC -CS4 at 1.25 mg/kg every  2 
weeks o r 1.25 m g/kg weekly.  Dosage B at 1 mg/kg on Weeks 1, 2, 4, and 5 of a 6 -week 
cycle will  resul t in a cumulat ive dose of 4 mg/kg every 6 weeks, which is 0.25 mg/kg 
(6.7%) greater than the cumulat ive dose per (6- week) cy cle of Dosage A (1.25 mg/kg 
every 2 weeks).  However, a 6.7% increase in exposure is wit hin the variat ion of 
exposure documented in Cohorts 4 and 5.  Thus, Dosage B is a reasonable dose and 
schedule in terms of safet y.  Addi tionally, dosing 2 consecutive weeks is expected to 
enhance inhibit ionof CSF -1R, based upon preliminary  pharm acodynamic data (CSF -1 
and IL -34) fro m Cohorts 4 and 5.  Furthermore, interruption of dosing every 3 weeks 
provi des an opportunit y for LY3022855 IMC -CS4-associ ated l aboratory  abnorm alities to 
norm alize pri or to resum ption of  dosing, as has been observed in the Phase 1 dose -
escalat ion Study  JSCA.
Dosage C rationale:
Pharmacodynamic data (Section 5.4.5) suggest that weekly administration of LY3022855 
resul ts in enhanced target engagement.  Thus, Dosage C will be implemen ted to examine 
weekly administration of LY3022855.
Dosage D rationale:
It has been observed that all pat ients who were treated with LY3022855 and experienced 
antitumor activit y (as evidenced by [CONTACT_574461] y) as of [ADDRESS_754007] 2016 
were treate d on a Q2W schedule.  Thus, Dosage D will be implemented to con tinue 
exploring Q2W dosing, but at a fixed (non -weight -based) dose.  Furthermore, the Q2W 
schedule may be preferable for qualit y of life, because the patient will require fewer 
clinic visits.
6.1. Study Population
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
re-screened if agreed upon by [CONTACT_456] .  If a patient discont inues prior to the second biopsy, 
the pati ent will be replaced.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 133
LY3022855 (IMC -CS4)6.1.1. Inclusion Criteria
[6] Have a performance status of ≤2 on the Eastern Cooperative Onco logy Group 
(ECOG) scal e.  See Attachment 8At tachm ent 6 .
[9b] Female pat ients:
arewom en of child- bearing potential who test negative for pregnancy within 
7days prior to enrollment based on a urine or serum pregnancy  test and agree 
to use a reliable method of birth control during the study  and f or [ADDRESS_754008] feeding,
10] Have an est imated li fe expectancy that, in the j udgment of the investigator ,
that will permit the patient to complete 1cycle of treatment.
6.1.2. Exclusion Criteria
14] Have symptomat ic CNS malignancy or metastasis (screening not required).
Patients wi th treated CNS metasta ses are eligible for this study  if they  are not 
currently receiving corticosteroids (to control CNS edema) and/or 
anticonvulsants , and thei r disease is asymptomat ic for at least 28days prior to 
enrollment .  Magnet ic resonance imaging (MRI) document ing disease 
stabilit y within 60 days pri or to enrollment is also required.
[16] Have any of the fo llowing cardi ovascular condi tionsa history  of and/or 
current :
a)symptom atic coronary artery disease current ly or within the past 6 months ,
b)confirmed left ventricular ejection fract ion ≤50% or any  cardiac 
insufficiency > [LOCATION_001] Heart Associat ion (NYHA) class II ,*currently 
or wi thin the past 6 months,
c)uncontrolled hypertension (>170/100 mm Hg) current ly or wit hin the past 
7 day s, or
d)serious cardi ac arrhy thmia (well -controlled atri al fibrillat ion is permitted)
currently or within the past 6 months .
6.2. Summary of Study Design
Study I5F-MC-JSCB (JSCB) i s a single -center, open -label, nonrando mized, noncontrolled 
Phase [ADDRESS_754009] infusio n, decreasing by 30 minutes 
for subsequent infusio ns, unt il administered over 30 minutes (refer to Section 7.2 for further 
details o f study  drug administrati on).  Study  JSCB is intended to explore clinical response and 
immuno logical activi ty of single-agent LY3022855 IMC -CS4 in approximately  4020 patients 
(enrolled, of who m 3616will be evaluable), by [CONTACT_574431], cy tokines, and 
immune cells .  The study  schema is shown in Figure JSCB.3.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 134
LY3022855 (IMC -CS4)Abbreviations:  Ca = cancer; LY = LY3022855 (IMC -CS4); PD = progressive disease ; 
Pts = patients.
Figure JSCB. 3. Study JSCB study design .
Enrollment will be sequent ial, starting with the assignment of patients to Dosage A 
(LY3022855 IMC- CS4, 1.25 mg/kg every  2 weeks [Q2W] of a 6-week c ycle), then the 
assignment of pat ients to Dosage B ( LY3022855 IMC-CS4, 1.0 m g/kg on Weeks 1, 2, 4, and 5 of 
a 6-week cycle) once the Dosage A cohort of the study is fully enrolled.   Once the Dosage B 
breast cancer cohort is fully enrolled, patients with bre ast cancer will be assigned by [CONTACT_574462] C (LY3022855, 100 mg QW of a 6- week cy cle) or D (LY3022855, 100 mg Q2W of a 
6-week cy cle) on an alternat ing basis unt il [ADDRESS_754010] igators will 

I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 135
LY3022855 (IMC -CS4)review clinical data to determine if enrollment of an addit ional 5 patients to each of Dosages C 
and D is warranted (refer to Section 10 for details regarding sample size).
Patients will receive Dosage A ,or Dosage B, C, or D for one 6 -week cycle or until the patient 
meets one or more criteria for study  discont inuat ion.  After 1 cycle, patients who are benefitt ing 
from study  treatm ent (that i s, no di sease progressi on or unacceptable toxicit y) may continue to 
receive study  treatment at the same dose and schedule until there is clear (confirmed) evidence of 
disease progressi on or other wi thdrawal  criteria are m et.  At the time of study co mpletion, if a 
patient conti nues to benefit from study  treatm ent, that patient may enter the continued access 
period.
Immune studies will include evaluat ions of changes in baseline over time in:  (1) peripheral 
blood immune cell subsets , as determined by [CONTACT_574433], 
andthat may include but not be limited to t he following markers : Live-Dead, CD3, CD4, CD8, 
CD14, CD16, FoxP3, PD-1, Ki-67, CTLA -4, TIM -3, LAG- 3, and ICOS, as well as (2) serum  
cytokines, as determined by [CONTACT_574434] ,and 
that may  include but not be limite d to CSF -1, IFN-γ, IL -1β, IL -2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, IL -34, and TNF -α.  Blo od sam ples f or the immuno modulatory  studies will be 
taken as described in Attachment 4 , Attachment 5, and Attachment 6 .
In addit ion, for all  patients, 2 separate tumor biopsy  procedures will be performed(attem pted):  
the first will be performed at baseline (predose), wit hin [ADDRESS_754011] a pat ient who ei ther:  
(1) di scont inues from the study  prior to the second biopsy procedure, or (2) does not have 
sufficient tumor tissue for the second biopsy  procedure and in the opi[INVESTIGATOR_3078] n of the invest igator is 
benefitt ing from study t reatment (in which case, the patient will be allowed to remain on study 
treatm ent).  In addit ion to the required blood and tumor samples previously noted, optional tumor 
biopsies and/or blood samples for bio marker research may be obtained at the invest igator’s 
discreti on in discussio n with the pati ent, such as at the time of radiographic response or treatment 
progression .
To document the immuno modulatory  activityof LY3022855IMC -CS4 treatm ent in patients with 
advanced, refractory  breast or prostate cancers ,an adequate sample size is required (refer to 
Secti on 10) .  A sufficient sample size will allow for 16 evaluable pat ients.  This sample size is 
estimated to be approximately 20 patients.  This assumes 20% of enrolled (treated) patients will 
be inevaluable .  The sam ple size i s based on the observat ion that 14 of 17 patients evaluated in 
Study  JSCA dem onstrated a m ore-than-2-fold (>100%) increase in CSF -1 levels 8 hours after 
administration of IMC -CS4.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 136
LY3022855 (IMC -CS4)6.2.1. Study Completion and End of Trial
This study willbe considered complete (that is, the sci entific evaluation will be co mplete[study
completion]) when 3616 evaluable pat ients* are attained .  “End of trial”refers to the date of the 
last vi sit or l ast scheduled proced ure for the last patient .
6.3.1. Discontinuation of Patients
The patient has confirmed evidence o f progressive disease.
oExcept ions for con tinuing wit h study  treatm ent bey ond confirmed radiographic 
progression may  be m ade on a case -by-case basis for pati ents who are believed to 
be clinical ly benefi ting from protocol  therapy  and both the iInvest igator and 
sSponsor (the CRP/ clinical research scient ist [CRS ])agree that continuing 
protocol  therapy  is in the patient’s best interest.
The patient experiences unacceptable toxicit y.
The patient exp eriences a Grade 3 or 4 infusion -related reacti on (IRR) to 
LY3022855 IMC -CS4.
7.1. Materials and Supplies
LY3022855 IMC -CS4 for Injection is supplied at 5 mg/mL strength as a solut ion dosage, 
packaged in glass vials wit h an elastomeric clo sure.  Each vial o fLY3022855 IMC -CS4 for 
Inject ion contains [ADDRESS_754012] ( 100 mg/20 -mL vial) .  Vials of LY3022855 IMC -
CS4 for Injectionshoul d be stored refrigerated at 2°C to 8°C.  The drug product is formulated to 
contain the active LY3022855 IMC -CS4 in 10mM histidine, 100mM glycine, 100mM arginine, 
and 0.01% polysorbate 80 at pH 6.0.   LY3022855 IMC-CS4 is a clear or slightly opalescent and 
colorless or slightly yellow liquid without visible particles.
LY3022855 IMC -CS4 will be administered as an I.V.infusio n. The dose is prepared and infused 
at room  temperature (23°C -27°C).  LY3022855 IMC -CS4 will be diluted in normal saline to a 
final vo lume of 250 mL.  Lilly instructi ons regarding dilut ion requirements should be fo llowed.
7.2. Study Drug A dministration
TwoFourdosages of LY3022855 IMC -CS4 will be administered in this study . Refer to 
Table JSCB. 1for a summary  of the LY3022855 dosages to be used. :  Dosage A (1.25 mg/kg 
every 2 weeks of a 6- week cy cle) and Dosage B* (1 mg/kg on Weeks 1, 2, 4, and 5 of every 6-
week cy cle)  Eligible pat ients will receive LY3022855 IMC -CS4 as an I.V. infusio n administered 
over a minimum durat ion of 30 minutes and a maximum durat ion of 4 hours, based on the known 
safet y and stabilit y of the prepared drug.  The infusion rate should not exceed 25 mg/minute.
For Dosages A and B, t The first dose of LY3022855 IMC -CS4 is dependent upon the patient’s 
baseline body  weight in kilograms.  Subsequent doses of LY3022855 IMC -CS4 must be 
recal culated if there is a ≥10% change (increase or decrease) in body  weight from baseline; 
subsequent doses may be recalculat ed if there is a <10% change (increase or decrease) in body  
weight from baseline.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 137
LY3022855 (IMC -CS4)For pati ents wi th fluid retention, the estimated dry  weight, instead of the actual body  weight, 
shoul d be used for dose cal culat ion or recal culat ion (in the setting o f substant ial fluid retention, 
the Lilly  CRP or desi gnee shoul d be consul ted regarding optimal assessment of dry  weight).
Dosages C and D are to be non -weight based (fixed dosing).
7.2.1. Dose A djustme nts and Delays
If benefitting fro m treatm ent(that i s, no di sease progressi on or other withdrawal criteria) , a 
patient who experiences a toxicitymay continue to receive LY3022855 IMC -CS4 upon 
agreem ent of  the sponsor and according to the dose reduction guidelines for thi s study  
(Table JSCB.2 Table JSCB.1 ).  For any given patient in the study , thei r dose m ay be reduced up 
to a m aximum  of [ADDRESS_754013] Reduction
A 1.0 mg/kg (Weeks 1, 2, 4, and 5) 0.6 mg/kg ( qwQW) 0.3 mg/kg ( qwQW) 0.3 mg/kg (Q2W)
B 1.25 mg/kg ( q2wQ2W ) 0.6 mg/kg ( qwQW) 0.3 mg/kg ( qwQW) 0.3 mg/kg (Q2W)
C 100 mg (QW) 75 mg (QW) 50 mg (QW) 40 mg (QW)
D 100 mg (Q2W) 75 mg (Q2W) 50 mg (Q2W) 40 mg (Q2W)
Abbreviations:  QWqw= weekly; Q2W q2w = ever y 2 weeks (Weeks 1, 3, and 5) .
In the case of the toxicit ies listed in Table JSCB.3 Table JSCB.2 , study  treatm ent m ay be held (if 
appropriate, in the opi[INVESTIGATOR_3078] n of the invest igator and upon agreem ent wi th the sponsor) for a 
maximum o f 34weeks, unt il reso lution to baseline or improvement to Grade <2.  Upon 
resol ution to baseline or improvement to Grade <2, study  treatm ent m ay be administered at a 
reduced dose (according to Table JSCB.2 Table JSCB.1 ), beginning with the next cy cle, if 
appropriate, in the opi[INVESTIGATOR_3078] n of the invest igator and upon agreement with the sponsor.  If toxicit y 
does not resolve to baseline or improve to Grade <[ADDRESS_754014] 
administered dose, stu dy treatment should be permanent ly discont inued and the patient should be 
discontinued fro m the trial.
Once a pat ient has had a dose reduction (has started a new cy cle at the reduced dose), all 
subsequent infusio nswill be at the reduced dose level; there will be no resumpt ion to pri or dose 
level(s).  Any patientexperiencing toxicit y that woul d necessi tate m ore tha n 32dose reductions 
must discont inue treatment.   Dose reductions must be confirmed by [CONTACT_456].
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 138
LY3022855 (IMC -CS4)Table JSCB. 32. Toxicities for Which Dose A djustments and Delays Apply
Grade 4 hematologic toxicity
Grade 3 hematologic toxicity lasting >7 days
Grade 3 or 4 no nhematologic toxicity.  Exceptions may be be made for the following, if agreed upon by  [CONTACT_574463]:
oGrade ≥[ADDRESS_754015] (LFT) abnormality , such as alkaline phosphatase, gamma glutamyl 
transferase (GGT), AST, and ALT, n ot suspected to be drug related
oTransient Grade ≥2 bilirubin elevation in the presence of known li ver metastases lasting ≤7 days,
oLaborato ry abnormalities that improve to Grade <2 or baseline levels within 7 days after initial 
documentation or that are deemed not clinically significant
o{note that this bullet was promoted one level during this amendment} Laboratory abnormalities 
≥Grade 3 that are deemed not clinically significant do not require dose delay
oGrade ≥3 asymptomatic elevation of CK WITHOUT elevation in serum and urine myoglobin 
does not require dose modification .
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatine kinase; 
CRP =clinical research physician.
Refer to Section [IP_ADDRESS] (Infusio n-Related Reactions) regarding dose adjust ment, delay, and 
discontinuat ion of study  treatm ent due to LY3022855 IMC -CS4 IRRs.
[IP_ADDRESS]. Infusion -Related Reactions
If a patient experiences Grade 1 IRR/allergic reactio n, the infusio n rate shoul d be decreased by 
50% for the duration of the infusio n.  In case of a Grade 2 IRR/allergic react ion, the infusio n 
must be st opped until reso lution to Grade ≤1; the infusio n may then be resumed at 50% of the 
prior infusio n rate (the duration of the infusio n shoul d not exceed 3hours).  Once the infusio n 
rate has been reduced for a Grade 1 or 2 IRR , it is recommended to m aintain the l ower infusio n 
rate for all subsequent infusio ns (prem edicat ion must be provided prior to any subsequent doses 
of LY3022855 IMC -CS4 if the patient has experienced a Grade 1 or 2 IRR).  Occurrence of a 
Grade [ADDRESS_754016] 1 hour after the end of the infusio n of LY3022855 IMC -CS4.  
This observat ion is to be done in a n area with resuscitation equipment and medicat ions necessary  
for advanced life support and cardiopulmo nary resusci tation, such as bronchodilators, 
vasopressor agents (for example, epi[INVESTIGATOR_238]), oxygen, glucocortico ids, antihistamines, and I.V. 
fluids, etc .
CAUTION:  Infusion -related reacti onsmay occur during or fo llowing LY3022855 IMC -CS4
administration.
Prem edicat ion is not recommended to be administered prior to the first infusio n of 
LY3022855 IMC -CS4.  Ho wever, if the patient experiences a Grade [ADDRESS_754017] be provided prior to any  subsequent doses of LY3022855 IMC -CS4.  The choi ce of 
prem edicat ion is to be made after discussion and agreement between the investigator and the 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 139
LY3022855 (IMC -CS4)Lilly CRP.  In such cases (Grade 1 or 2 IRRs ), administration of steroi ds shoul d be avo ided, if 
possible.   Any premedicat ion administered should be documented in the eCRF, including dose 
and route of administration.
If at any  time a patientexperiences an IRR to LY3022855 IMC -CS4, all attem pts will be made to 
obtain a blood sample for immunogenicit y analysis as close to the onset of the event as possible, 
at the resolut ion of the event, and 30 day sfollowing the event. A portion of the sample taken for 
immunogenicit y testing may be used for PK analysis, in the setting ofIRRs .
Forfurther details regarding IRRs, including characterizat ion according to CTCAE v4.0 and 
treatment gui delines, refer to the LY3022855 IMC -CS4 IB.
[IP_ADDRESS]. Other A dverse Events
Based on observations in nonclinical toxico logical studi es wi th LY302 2855IMC -CS4 and/or 
observat ions in one clinical trial wit h another monoclonal ant ibody  targeting CSF -1 (Sadi s et al . 
2009), patien ts receiving LY3022855 IMC -CS4 shoul d be cl osely  monitored f or signs indicat ive
of hepati c funct ion impairment ( for example , increases in transaminases, LDH , bilirubin, 
coagul ation disorders), inflammat ion (for example , leukocy te alterati ons, C -reactive protein), CK 
increases, and periorbital swelling.  For details, refer to the LY3022855 IMC -CS4 IB.
[IP_ADDRESS].1. Immune -Related A dverse Events (irAEs)
Symptom s occurring during or following infusio n of investigational therapy  will be defined 
according to the NCI- CTCAE, Version 4.0.
In the setting of symptoms consistent with irAEs occurring fo llowing infusio n of invest igational 
therapy, invest igators are encouraged to refer to Attachment [ADDRESS_754018] ic 
medical evaluat ions for possible non -immune -related causes of AEs.  Attachment 10 is a 
guideline for the m anagement of i rAEs; local standards m ay supersede recommendat ions when 
deem ed appropri ate by [CONTACT_093].
7.3. Method of A ssignment to Treatment
Patients who m eet all cri teria for enrollment will be assigned to receive LY3022855 IMC -CS4in 
this study .  Before each pati ent’s enrollment into the study , an eligibilit y check must be 
conducted between the invest igational site and the Lilly clinical research personnel to confirm 
that each patient meets all enrollment criteria.  Upon confirmat ion of eligibilit y,the sponsor will 
confirm the dose and ident ificat ion number assignment for each patient.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 140
LY3022855 (IMC -CS4)7.6. Treatment Compliance
LY3022855 IMC -CS4 will be administered I.V.at the invest igational site, under the di rection of  
the invest igator.  As a result, a patient’s c ompliance wi th study  drug administrati on is ensured.  
Patients shoul d attend scheduled clinic visit s and must comply  with study  criteria under thei r 
control .  Devi ation(s) fro m the prescribed dosage regimen should be recorded on the eCRF.
7.6.1. Evaluable Patients
Any pat ient who does not complete 1cycle of LY3022855IMC -CS4 treatm ent, undergo 
1baseline and 1 posttreatment tumor biopsy procedure (ie, attempted, whether the biopsy is 
successful or not), and complete immune blood studies for 1 cycle will be deemed nonevaluable 
for assessment of a dose level.
Patients who complete 1 cycle of LY3022855 IMC -CS4 treatm ent, undergo 1 baseline and 
1posttreatment tumor biopsy procedure (ie, attempted, whether the biopsy is successful or not), 
and co mplete immune blood studies for [ADDRESS_754019] been assessed in nonclinical toxico logy 
studi es and the resul ts from these studi es are detailed in the IB.  This Phase 1 study  contains 
detailed safet y monitoring that will permit further characterizat ion of the safet y profile o f 
LY3022855 IMC -CS4 in patients, bey ond that init ially characterized in Phase 1 study  JSCA .  
Study  procedures and their timing, including co llection of blood and urine samples, are described 
in the Study  Schedule ( Attachment 1).
8.1.1. Safety Data Collection and Review
The timing of all safet y evaluat ions is shown in the Study  Schedule (Attachment 1).   
Table JSCB. 4Table JSCB. 3presents a summary of AE and SAE reporting guidelines.  
Table JSCB. 4Table JSCB. 3also shows which database or sy stem  is used to store AE and SAE 
data.
8.1.2 .2. Adverse Event and Serious A dverse Event Reporting
Data on SAEs that occur before the end of trial will be stored in the col lection database and the 
Lilly S afety  System (see Attachment 7 Attachment 5 for reporting recommendat ions).
[IP_ADDRESS].1. Prior to Administration of Study Drug(s)
During screening, all AEs and SAEs (regardless of relatedness to protocol procedures) are 
collected after the patient has signed the informed consent form (ICF).  For patients who do not 
enroll in the tri al (that is, have no t received at least one dose of LY3022855 IMC -CS4), only  AEs 
and SAEs related to protocol procedures are required to be collected.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 141
LY3022855 (IMC -CS4)[IP_ADDRESS]. Summary of A E/SA E Reporting Guidelines
The AE and SAE reporting guidelines are summarized in Table JSCB.4 Table JSCB.3 .
Table JSCB. 43. Adverse Event and Serious A dverse Reporting Guidelines for 
Study JSCB
8.2. Sample Collection and Testing
Attachm ent 4 ,Attachment 5, and Attachment 6 l iststhe detailed schedule sfor sample co llections 
specifically for PK, pharmacodynamics , and immunogenicit y in this study .
Attachm ent 7 provi des a summary  of the estimated maximum number and volume o f invasive 
samples for all sampling during the study .
8.2.2. Samples for Drug Concentration Measurements 
Pharmacokinetics/Pharmacodynamics
Pharm acokinet ic and pharmacodynamic samples will be co llected as specified in the 
Pharmacokinet ic,Pharmacodynamic, and Immunogenicit y Blood S ampling Schedule 
(Attachm ent 1 ).
[IP_ADDRESS]. Pharmacokinetic Samples
At the visit s and t imes specified in the sampling schedule ( Attachment 4 , Attachment 5, and 
Attachm ent 6 ), venous blood samples of approximately [ADDRESS_754020] ion and handling of blood samples will be provided 
by [CONTACT_456].   The actual date and time o f each sam pling mustbe clearly  and accurately 
recorded.
These s amples will be analyzed at a laboratory  designated by  [CONTACT_456].  Serum concentrati ons 
of LY3022855 IMC -CS4 will be assayed using a validated ELISA method.
[IP_ADDRESS]. Pharmacodynamic Samples
The fo llowing pharmacodynamic assessments are based on the primary  study  object ive and are, 
therefore, required assessments.  Samples will be tested for changes fro m baseline over time in 
peripheral  blood immune cell subsets and in serum cy tokines to document the 
immuno modulatory  activity of LY3022855 IMC -CS4 treatm ent in patients with advanced, 
refractory  breast orprostate cancers .  Flow cy tometric analysis using an ant ibody  panel  that m ay 
include, but not be limit ed to m arkers Live -Dead, CD3, CD4, CD8, CD14, CD16, FoxP3, PD -1, 
Ki-67, CTLA -4, TIM -3, LAG -3, and ICOS will be used to evaluate T -cell and monocyte subsets 
from peripheral  blood.  In addi tion, serum  cytokine l evels will be determined by [CONTACT_574464], and may include, but not be limited to CSF -1, 
IFN-γ, IL -1β, IL -2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, IL -34, and TNF -α.
I5F - MC- JSCB(d )Phase1  Onco logy  P ro toco l Page  142
LY3022855( IMC - CS4 )R equ ir ed  s amp l e s  fo r  b i om a r k e r  r e s e a r c h  t o  b e  c o l l e c t e d  f r om  a l l  p a t i e n ts  in  th i s  s tudy  a r e th e  
f o l l o w i n g :
 b l o od  ( f o r  exp l o r a to ry  a n a l y s i s  o f  s e rum  b i om a rk e r s  th a t  m ay  b e  r e l ev an t  to  th e  
m e c h a n i sm  of  a c t i on  o f  LY 3 0 2 2 8 5 5IMC - CS 4,   
 t um o r  t i s s u e  ( f o r  e x p l o r a t o r y  a n a l y s i s  of  th e  imm u n o m odu l a to ry  e f f e c t s  o f  
LY 3 0 2 2 8 5 5IMC - CS 4a dm i n i s t r a t i o n ,  i n c l u d i n g  t h e  u n d e r s t a n d i n g  o f  t h e  
p h a rm a c o d y n am i c  e f f e c t s  o f  LY 3 0 2 2 8 5 5IMC - CS 4)
8 .2 .3 .  Samp les  fo r  Ta i lo r ing  B ioma rke rs
I n  t h e  e v e n t  o f  a n  u n e x p e c t e d  AE  o r  t h e  o b s e r v a t i o n  o f  u n u s u a l  r e s p o n s e ,  t h e  p h a rm a c o g e n e t i c  
b i om a r k e r  s am p l e s  m a y b e  g eno ty p ed  and  an a ly s i s  m ay  b e  p e r fo rm ed  to  ev a l u a t e  a  g e n e ti c  
a s so c i a t i o n  w i th  r e spon s e  to  LY 3 0 2 2 8 5 5IMC - CS 4.   T h e s e  i n v e s t i g a t i o n s  m a y  b e  l im i t e d  t o  a  
f o cu s ed  c and id a t e  g en e  s tudy  o r ,  i f  app rop r i a t e ,  g e n o m e- w id e  an a ly s i s  m ay  b e  p e r fo rm ed  to  
i d e n t i f y  r e g i o n s  o f  t h e  g e n om e  a s s o c i a t e d  w i t h  t h e  v a r i a b i l i ty  o b s e r v e d  i n  d r u g  r e s p o n s e .   T h e  
p h a rm a c o g e n e ti c  b i om a r k e r  s am p l e s  w i l l  o n l y b e  u s e d  f o r  i n v e s t i g a t i o n s  r e l a t ed  to  d i s e a s e  a n d  
d r u g  o r  c l a s s  of  d rug s  und e r  s tudy  i n  t h e  c o n t e x t  o f  t h i s  c l i n i c a l  p r o g r am .   T h e y  w i l l  n o t  b e  u s ed  
f o r  b ro ad  exp l o r a to ry  u n s p e c i f i e d  d i s e a s e  o r  p o p u l a t i o n  g e n e t i c  a n a l y s i s .
R e f e r  t o  S e c t i o n8 .2 .2 .2 ,  P h a rm a c o d y n am i c  S am p l e s ,  f o r  d e t a i l s  o f  s am p l e s  c o l l e c t e d  f o r  o t h e r  
b i om a r k e r  r e s e a r c h  t h a t  i s  p a r t  o f  th i s  s tudy .   Th e s e  o th e r  s am p l e s  m a y  b e  u s e d  f o r  r e s e a r c h  t o  
d e v e l o p  m e t h o d s ,  a s s a y s ,  p r o g n o s t i c s  a n d / o r  c om p a n i on  d i agno s t i c s  r e l a t ed  to  CSF - 1 ,  CSF - 1R ,
a n d / o r  t h e  m e c h a n i sm  o f  a c t i on  o f  s tudy  d rug s  ( LY 3 0 2 2 8 5 5IMC - CS 4) .
8 .2 .4 .  Samp les  fo r  Immunogen ic i ty  Resea rch
B lood  s am p l e s  f o r  imm u n o g e n i c i t y  t e s t ing  w i l l  b e  co l l e c t edt o  d e t e rm i n e  a n t ibody  p rodu c t i o n  
a g a i n s t  LY 3 0 2 2 8 5 5IMC - CS 4.   Imm u n o g e n i c i t y  w i l l b e  a s s e s s ed  by  a  v a l id a t ed  a s s ay  d e s ign ed  to  
d e t e c t  ADAi n  t h e  p r e s e n c e  o fLY 3 0 2 2 8 5 5IMC - CS4.   A n t i b o d i e s  m a y  b e  f u r t h e r  c h a r a c t e r i z e d  
a n d / o r  e v a l u a t e d  f o r  t h e i r  a b i l i t y  t o  n e u t r a l i z e  t h e  a c t i v i t y  o fLY 3 0 2 2 8 5 5IMC - CS 4.
I n  a d d i ti o n  to  p l a n n e d  s am p l i n g  f o r  imm u n o g e n i c i t y  t e s t ing ,  i fa t  any  t i m e  a  p a t i e n te x p e r i e n c e s  
a n  IRRto  LY 3 0 2 2 8 5 5IMC - CS 4,  a l l  a t t em p t s  w i l l  b e  m a d e  t o  o b t a i n  a  b l o o ds am p l e  f o r  
imm u n o g e n i c i t y  a n a l y s i s  a s  c l o s e  t o  t h e  o n s e t  o f  t h e  e v e n t  a s  p o s s i b l e ,  a t  t h e  r e s o l u t i o n  o f  t h e  
ev en t ,  and  30  d ay sf o l l o w ing  th e  ev en t .  A  p o r t i o n  o f  t h e  s am p l e  t a k e n  f o r  imm u n o g e n i c i ty  
t e s t i n g  m a y  b e  u s ed  fo r  PK  a n a l y s i s ,  i n  t h e  s e t t i n g  o fIRR s .
S amp l e s  m ay  b e  s to r ed  fo r  a  m ax imum  o f  15  y e a r s  f o l l o w ing  la s t  p a t i en t  v i s i t  f o r  th e  t r i a l  a t  a  
f a c i l i t y  s e l e c t ed  by  [CONTACT_3433] e  spon so r  to  en ab l e  fu r th e r  an a ly s i s  o f  immun e  r e spon s e s  to  
LY 3 0 2 2 8 5 5IMC - CS 4.   Th e  du r a t i on  a l l ow s  th e  spon so r  to  r e spond  to  r egu l a to ry  r e q u e s t s  r e l a t e d  
to  LY 3 0 2 2 8 5 5IMC - CS 4.CC I
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 143
LY3022855 (IMC -CS4)8.3. Efficacy Evaluation
Each patient’s full extent of disease will also be assessed as fo llows:
For pati ents wi th measurable disease defined by  [CONTACT_393], tum or measurements 
are to be ass essed by [CONTACT_393] 1.1 (Eisenhauer et al. 2009; Attachment 
9Attachm ent 8 ) and irRECIST ( Wolchok et al. 2009 Nishino et al . 2013 ).
10. Data A nalyses
For thi s study , approximately  [ADDRESS_754021] cancer will be treated 
at 1 of 4 dosages of LY3022855 IMC -CS4.  Of those enro lled patients, approximately 1636 
patients will  be evaluable:  [ADDRESS_754022] cancer and 6 patients 
with advanced, refractory  prostate cancer .  Refer to Secti on6.1 for the definit ion of an evaluable 
patient.
CSF-1 is the primary  pharmacodynamic bio marker documented in Study JSCA.  Serum  CSF-1 
was quant ified for 17 patients over time ;thatis, at baseline and [ADDRESS_754023] size (or Cohen’s d) is 5.81.  Consequently , the power of observing any  change 
between the eig hth hour and baseline is clo se to 1 as long as the number of samples is ≥3.
On the other handHowever , when the effect size is as small as 1 for the other unknown
pharmacodynamic markers other than CSF-1, the power is approximately 0.159 if only 3 patients 
are sam pled.
For Dosages C and D (patients with breast cancer), the sample size of [ADDRESS_754024] overall response rate (ORR) less than 20% indicates ina dequate anti tumor activit y, then at a 
one-sided t ype 1 error rate of 5%, the total sample size of 10 will provide 80% power if the true 
best ORR is 60% or higher, using a [ADDRESS_754025] stage, 5 
patients will  be enrolle d and treated on each o f Dosages C and D.  If 2 or more of the 5 patients 
on ei ther dosage (C or D) are observed to be responders by  [CONTACT_574443], an 
additional [ADDRESS_754026] ics will include the fo llowing:
Patient dem ographics will be reported.
Baseline disease characterist ics
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 144
LY3022855 (IMC -CS4)10.4. Safety A nalyses
All patients who receive at least one dose of LY3022855IMC -CS4 will be evaluated for safet y 
and toxicit y.  Adverse event terms and severit y grades will be assigned by  [CONTACT_3203] r using 
CTCAE v4.0.
10.5. Pharmacokinetic A nalyses
Pharmacokinet ic analyses will be conducted on patients who have received at least one dose of 
the study  drug and have had samples collected , and PK serum  concentrations of
LY3022855 IMC -CS4 will be determin ed.
The parameters for analysis will include but not be limited to maximum concentration (C max) 
and trough concentration (Ctrough)of LY3022855 IMC -CS4.  Addit ional analyses will be 
perform ed if warranted by  [CONTACT_33653] ,and other validated PK software programs (f or example, 
NONMEM) m ay be used if appropri ate and approved by  [CONTACT_574465] m anagement.  
The version o f any so ftware used for the analysis will be documented and the program will meet 
the Lilly  requirements of software validation.
10.6. Pharmacod ynamic A nalyses
To study  the impact of the study  drug and the dose levels on the patients, the changes from 
baseline over time in peri pheral  bloodimmune cell subsets will be documented.  The
immuno modulatory  activity of LY3022855 IMC -CS4 will be documented by [CONTACT_574466], but are n ot limit ed to: Live-Dead, CD3, CD4, CD8, CD14, CD16, FoxP3, PD -1, 
Ki-67, CTLA -4, TIM -3, LAG -3, and ICOS .  The expressio n of those markers will be quant ified 
by [CONTACT_574467].
Biomarker m easures of protein expressio n, based on flow cyto metry, MSD, and ELISA ,will be 
summarized by  [CONTACT_44835]/or dosage, based on enrolled pat ients.  Summary  stati stics may
include means, medians, corresponding standard errors, quartiles, and ran ges.  Graphics, 
including profile plots of markers over time, will be generated to explore potential patterns 
between patients.  Correlat ion analyses between biomarkers and relat ive laboratory  tests maybe 
perform ed to further explore the activit y of LY302 2855IMC -CS4.
10.7. Pharmacokinetic/Pharmacodynamic A nalyses
An exploratory  correl ative analysis o f LY3022855 IMC -CS4 PK and pharmacodynamics may be 
conducted.
10.8. Efficacy Analyses
Tumor response data will be reported using list ings and descript ive statis tics.  The ORR is 
estimated by [CONTACT_574449] a best overall response of co mplete 
response (CR) or partial response (PR).  The disease control rate (DCR) is est imated by [CONTACT_574450] a best over all response of CR, PR, or stable disease.  A 
95% exact confidence interval will be constructed to determine the level o f preci sion of the ORR 
and DCR if appropriate.  Time -to-event variables such as progression -free survival (PFS), 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 145
LY3022855 (IMC -CS4)durati on of  response, a nd overall survival (OS) will be tabulated if appropriate.  The Kaplan -
Meier m ethod (Kapl an and Meier 1958) will be used to estimate the survival curves, medians, 
and survival rates at specified time po ints, if applicable.
10.9. Interim A nalyses
Since this is a Phase 1 study , safet y data will be analyzed reviewed on an ongoing basis.
For Dosages C and D (patients with breast cancer), interim analyses will be conducted in each 
dosage to review available safety , efficacy, PK, and pharmacodynamic data after [ADDRESS_754027] patient visit.  In this case, all 
data until the data c utoff date will be used for the analysis o f safet y, efficacy , PK, and 
pharmacodynamic bio markers.   All data defined in the protocol will continue to be collected 
from patients on treatment after the data cutoff date.  These data may be reported separately, and 
the analyses on all patients including these data may not be performed.
12. References
Kaplan EL, Meier P. Nonparametric estimat ion from incomplete observat ions. J Amer Stat 
Assoc . 1958;53(282):457-481.
Nishino M, Gi obbie -Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developi[INVESTIGATOR_007] a 
commo n language for tumor response to immunotherapy: immune -related response cri teria 
using unidimensio nal measurements. Clin Cancer Res . 2013;19(14):3936- 3943.
Oken MM, Cree ch RH , Torm ey DC, Horton J , Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria of the Eastern Cooperative Oncology Ggroup .Am J Clin Oncol . 
1982;5(6):[ADDRESS_754028] ion with no signs of hepat ic 
or skel etal muscle injury . Am J Pathol. 2011;179(1):240 -247.
Wolchok JD, Hoos A, O’Day  S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, 
Nichol G, Hum phrey R, Hodi  FS. Gui delines for the evaluat ion of immune therapy activit y in 
solid tumors: immune -related response cri teria. Clin Cancer Res . 2009;15(23):7412- 7420.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 146
LY3022855 (IMC -CS4)Attachment 1. Protocol JSCB Study Schedules
Baseline and Cycle 1 A ssessments (for All Dosing Schedules)
ProcedureBaseline
Treatment Cycle 1 only CommentsRelative Day Prior 
to Day 1 of Cycle 1
≤28 ≤14 ≤7Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_754029] be signed prior to performance of any protocol -specific tests/procedures .
Medical history X
β-hCG Pregnancy test X At baseline, a urine or serum pregnancy test is required for WOCBP.  Thereafter ,
every [ADDRESS_754030] dose or according to local regulations, whichever is 
more frequent.
ECG X X X Note that in cases where ECG and blood sample collection are scheduled at the 
same time, all blood sampling should be performed prior to ECG assessment.
ECOG PS assessment X X X X X X X
Safety Assessments
Physical examination X X X X X X X Includes height (at baseline only), and thoracic, abdominal, and symptom -directed 
examination.
Vital signs and weight 
measurementX X X X X X X Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.  
Vital signs will be checked and recorded prior to each infusion of LY3022855 IMC-
CS4, midway through each infusion, at the end of each infusion, and every [ADDRESS_754031] hour following each infusion, including Cycle 1, Day 1 (also to 
be checked and recorded at nontreatment visits during Cycle 1).
Toxicity/AE assessment X X X X X X X Any preexisting toxicity should be documented, recorded, and graded (CTCAE v4.0 
grade) as a part of the baseline medical history.
AEs that are serious, considered related to study treatment or the study, or that 
caused the patient to discontinue before completing the study should be followed 
until the event is resolved, the event is no longer considered to be drug -related, the 
event becomes stable or returns to baseline, a new treatment is initiated for the 
patient, or the patient dies or is lost to follow -up.  Frequency of AEand SAE
follow -up evaluation is left to the discretion of the investigator .  Data on SAEs that 
occur before t he end of the trial will be stored in the collection database and the 
Lilly  Safety  System.
Concomitant medication 
assessmentX X X X X X X Including those medications taken within [ADDRESS_754032] dose of study 
therapy .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 147
LY3022855 (IMC -CS4)ProcedureBaseline
Treatment Cycle 1 only CommentsRelative Day Prior 
to Day 1 of Cycle 1
≤28 ≤14 ≤7Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
Laboratory Tests
HIV and viral hepatitis B 
and C screeningX* Includes HIV and hepatitis B and C, per institutional standards.
If done within [ADDRESS_754033] of care, does not 
need to be repeated.
* Should be done within [ADDRESS_754034] 12 weeks on therapy.
Coagulation X X* Evaluations performed as part of the baseline assessment do not need to be repeated 
on Cycle 1, Day 1 ,unless required in the opi[INVESTIGATOR_871] .
* Required within [ADDRESS_754035] 12 weeks on therapy , and every 2 weeks thereafter .
Urinalysis X Evaluations performed as part of the baseline assessment do not need to be repeated 
on Cycle 1, Day 1 ,unless required in the opi[INVESTIGATOR_871] .  Urinalysis 
evaluations will be performed at the beginning of each cycle (that is, approximately 
every [ADDRESS_754036] dose of study therapy).  If urine dipstick >1+ for 
protein, obtain 24 -hour urine collection for protein analysis.
Serum and urine 
myogl obinX* X* X* X* X* X* X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Tailoring biomarkers X 10 mL of blood to be drawn for future pharmacogenetic biomarker testing.
Blood sampling for PK, 
PD, IGRefer to Attachment 4 , Attachment 5, and Attachment 6 .All sampling indicated in Attachment 4 , Attachment 5, and Attachment 6 is to be 
done only after study eligibility is met.
Efficacy Assessments
Imaging studies 
(CT/MRI)X* X Radiographic assessment of tumor response should be performed prior to the start of 
a cycle so that results are available before the patient receives a new cycle of 
treatment.  If done within [ADDRESS_754037] of 
care, does not need to be repeated prior to the start of Cycle 1.
* For patients with treated CNS metastases that are eligible for this study , abaseline 
MRI documenting disease stability within 60 days prior to enrollment is required.
Bone scan X X* Breast cancer cohort :  Abaseline bone scan is required, except in the event that a 
PET scan is performed within [ADDRESS_754038] dose of study therapy that is 
negative for bone disease.  Routine bone scans during treatment are not required, 
except in the setting of bone -only disease (no lymph node, visceral, skin, or 
subcutaneous metastases), or as deemed appropriate by [CONTACT_093].
*Prostate cancer cohort :  Bone scans are required at baseline and (follow -up 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 148
LY3022855 (IMC -CS4)ProcedureBaseline
Treatment Cycle 1 only CommentsRelative Day Prior 
to Day 1 of Cycle 1
≤28 ≤14 ≤7Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
[posttreatment]) every [ADDRESS_754039] of care, does not 
need to be repeated prior to the start of C ycle 1.
Tumor core needle or 
surgical biopsyX X{2 cells 
were merged 
in this 
amendment}Required :  The first tumor biopsy will be taken (attempted) at baseline (predose), 
within 14days prior to dosing on Cycle 1, Day 1, and the second tumor biopsy will 
be taken (attempted) within 14days prior to dosing on Cycle 2, Day 1.
Optional :  In cases of disease progression, if the patient’s condition allows it, an 
optional tumor biopsy will be performed, as clinically indicated (refer to 
Section [IP_ADDRESS]).
Ad hoc tumor tissue and 
blood samplingX Optional :  Additional tumor tissue and/or blood samples for biomarker research 
may be obtained at the investigator’s discretion in discussion with the patient, such 
as at the time of radiographic response or treatment progression .  If, at any time 
during the study, tumor tissue is obtained through a core biopsy, surgical biopsy, or 
resection as routine clinical care, the sponsor requests a tissu e block or unstained 
slides for analysis of potentially relevant surrogate biomarkers.
Study Therapy Administration
Administer 
LY3022855 IMC-CS4
Weekly (on Days 1, 8, 
15, 22, 29, and 36)X X X X X X
Administer 
LY3022855 IMC-CS4
Every  2 Weeks (on Days 
1, 15, and 29 )X X X
Administer 
LY3022855 IMC-CS4 on 
Weeks 1, 2, 4, and 5 (on 
Days 1, 8, 22, and 29 )X X X X
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; CNS 
= central nervous system; CT = computed tomography; CTCAE v4.0 = Common Terminology Criteria for Adverse Events, version 4.0; ECG = electrocardiogram; ECOG PS= 
Eastern Cooperative Oncology Group perfor mance status; HIV = human immunodeficiency virus; ICF = informed consent form; IG =immunogenicity; MRI = magnetic 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 149
LY3022855 (IMC -CS4)resonance imaging; PET = positron emission tomography; PD = pharmacodynamic(s); PK =pharmacokinetic(s); SAE = serious adverse event; ULN = u pper limit of normal; 
WOCBP = women of child -bearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 150
LY3022855 (IMC -CS4)Cycle 2Assessments (for All Dosing Schedules)
ProcedureTreatment Cycle 2 only Comments
Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36 Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_754040] dose or 
according to local regulations, whichever is more frequent.
ECG X* X* Note that in cases where ECG and blood sample collection are scheduled at the same time, all blood 
sampling should be performed prior to ECG assessment.
* As clinically indicated, prior to last infusion of treatment cycle.
ECOG PS assessment X To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
Physical examination X Includes thoracic, abdomi nal, and symptom -directed examination.
Vital signs and weight 
measurementX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.  Vital signs will be 
checked and recorded prior to each infusion of LY3022855 IMC-CS4, midway through each infusion, 
at the end of each infusion, and every [ADDRESS_754041] hour following each infusion.
Toxicity/AE assessment X To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
AEs that are serious, considered related to study treatment or the study, or that caused the patient to 
discontinue before completing the study should be followed until the event is resolved, the event is no 
longer c onsidered to be drug -related, the event becomes stable or returns to baseline, a new treatment 
is initiated for the patient, or the patient dies or is lost to follow -up.  Frequency of AE and SAE 
follow -up evaluation is left to the discretion of the investi gator.  Data on SAEs that occur before the 
end of the trial will be stored in the collection database and the Lilly Safety System.
Concomitant medication 
assessmentX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on Days 1, 8, 15, 
22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, and 5 (on Days 1, 8, 22, 
and 29).
Laboratory Tests
Hematology X X X X X X Every  week for the first [ADDRESS_754042] 12 weeks on therapy , and every 2 weeks thereafter .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 151
LY3022855 (IMC -CS4)ProcedureTreatment Cycle 2 only Comments
Day 
1Day 
8Day 
15Day 
22Day 
29Day 
36 Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated otherwise .
Urinalysis X Urinalysis evaluations will be performed at the beginning of each cycle (that is, approximately every 
[ADDRESS_754043] dose of study therapy) . If urine dipstick >1+ for protein, obtain 24 -hour 
urine collection for protein analysis.
Serum and urine myoglobin X* X* X* X* X* X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Blood sampling for PK, PD, 
IGRefer to Attachment 4 , Attachment 5, and 
Attachment 6 .
Efficacy Assessments
Imaging studies (CT/MRI) X Radiographic assessment of tumor response should be performed prior to the start of a cycle so that 
results are available before the patient rece ives a new cycle of treatment.
Bone scan X* Breast cancer cohort :  Routine bone scans during treatment are not required, except in the setting of 
bone -only disease (no lymph node, visceral, skin, or subcutaneous metastases), or as deemed 
appropriate by [CONTACT_093].
*Prostate cancer cohort :  Follow -up (posttreatment) bone scans are required every 6 weeks, or as 
clinically indicate d.
Tumor assessments X Radiographic assessment of tumor response should be performed prior to the start of a cycle so that 
results are available before the patient rece ives a new cycle of treatment.
Ad hoc tumor tissue and 
blood samplingX Optional :  Additional tumor tissue and/or blood samples for biomarker research may be obtained at 
the investigator’s discretion in discussion with the patient, such as at the time of radiographic 
response or treatment progression .  If, at any time during the study, tumor tissue is obtained through a 
core biopsy, surgical biopsy, or resection as routine clinical care, the sponsor requests a tissue block 
or unstained slides for analysis of potentially relevant surrogate biomarkers.
Study Therapy Administration
Administer 
LY3022855 IMC-CS4
Weekly (on Days 1, 8, 15, 
22, 29, and 36), X X X X X X
Administer 
LY3022855 IMC-CS4
Every  2 Weeks (on Days 1, 
15, and 29X X X
Administer 
LY3022855 IMC-CS4
Weeks 1, 2, 4, and 5 (on 
Days 1, 8, 22, and 29X X X X
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; CT = 
computed tomography; ECG = electrocardiogram; ECOG PS= Eastern Cooperative Oncology Gro up performance status; IG = immunogenicity; MRI = magnetic resonance 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 152
LY3022855 (IMC -CS4)imaging; PET = positron emission tomography; PD=pharmacodynamic(s); PK =pharmacokinetic(s); SAE = serious adverse event; ULN = upper limit of normal; WOCBP = 
women of child -bearing pot ential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 153
LY3022855 (IMC -CS4)Cycle 3+Assessments (for All Dosing Schedules)
ProcedureTreatment Cycle 3 and beyond Comments
Day 1 Day 8 Day 15 Day 22 Day 2 9 Day 3 6Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_754044] dose and 
every 12 weeks thereafter, or according to local regulations, whichever is more frequent.
ECG X* X* Note that in cases where ECG and blood sample collection are scheduled at the same 
time, all blood sampling should be performed prior to ECG assessment.
* As clinically indicated, prior to last infusion of treatment cycle.
ECOG PS assessment X To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
Physical examination X Includes thoracic, abdominal, and symptom -directed examination.
Vital signs and weight 
measurementX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.  Vital 
signs will be checked and recorded prior to each infusion of LY3022855 IMC-CS4, 
midway through each infusion, at the end of each infu sion, and every [ADDRESS_754045] hour following each infusion.
Toxicity/AE assessment X To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
AEs that are serious, considered related to study treatment or the study, or that caused the 
patient to discontinue before completing the study should be followed until the event is 
resolved, the event is no longer considered to be drug -related, the event becomes stable 
or returns to baseline, a new treatment is initiated for the patient, or the patient dies or is 
lost to follow -up.  Frequency of AE and SAE follow -up evaluation is left to the 
discretion of th e investigator.  Data on SAEs that occur before the end of the trial will be 
stored in the collection database and the Lilly Safety System.
Concomitant medication 
assessmentX To be performed only on dosing days.  Dosing schedules, per protocol:  Weekly (on 
Days 1, 8, 15, 22, 29, and 36), Every 2 Weeks (on Days 1, 15, and 29), or Weeks 1, 2, 4, 
and 5 (on Days 1, 8, 22, and 29).
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 154
LY3022855 (IMC -CS4)ProcedureTreatment Cycle 3 and beyond Comments
Day 1 Day 8 Day 15 Day 22 Day 2 9 Day 3 6Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
Laboratory Tests
Hematology :
For Weekly and 
Every -2-Week 
schedulesX X X Cycle 3 and beyond:  Every 2 weeks for patients receiving treatment on the Weekly or 
Every -2-Week dosing schedule (on Days 1, 15, and 29).
For Weeks 1, 2, 4, 
and 5 scheduleX X Cycle 3 and beyond:  Every 3 weeks for patients receiving treatment Weeks 1, 2, 4, and 5 
(on Weeks 1 and 4 [that is, Days 1 and 22]).
Serum chemistry:
For Weekly and 
Every -2-Week 
schedulesX X X Cycle 3 and beyond:  Every 2 weeks for patients receiving treatment on the Weekly or 
Every -2-Week dosing schedule (on Days 1, 15, and 29).
For Weeks 1, 2, 4, 
and 5 scheduleX X Cycle 3 and beyond:  Every 3 weeks for patients receiving treatment Weeks 1, 2, 4, and 5 
(that is, on Weeks 1 and 4 [that is, Days 1 and 22]).
CEA and CA [ADDRESS_754046] cancer cohorts and if clinically applicable.
C-reactive protein
assessmentX X X Cycle 3 and beyond:  Every 2 weeks.
Urinalysis X Urinalysis evaluations will be performed at the beginning of each cycle (that is, 
approximately every [ADDRESS_754047] dose of study therapy) . If urine dipstick 
>1+ for protein, obtain 24 -hour urine collection for protein analysis.
Serum and urine 
myogl obinX* X* X* X* X* X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Blood sampling for PK, 
PD, IGRefer to Attachment 4 , Attachment 5, and Attachment 6 .
Efficacy Assessments
Imaging studies (CT/MRI) X Radiographic assessment of tumor response should be performed prior to the start of a 
cycle so that results are available before the patient receives a new cycle of treatment.
Bone scan X* Breast cancer cohort :  Routine bone scans during treatment are not required, except in 
the setting of bone -only disease (no lymph node, visceral, skin, or subcutaneous 
metastases), or as deemed appropriate by [CONTACT_093].
*Prostate cancer cohort :  Follow -up (posttreatment) bone scans are required every 6 
weeks, or as clinically indicated.
Tumor assessments X Radiographic assessment of tumor response should be performed prior to the start of a 
cycle so that results are available before the patient rece ives a new cycle of treatment.
Ad hoc tumor tissue and 
blood samplingX Optional :  Additional tumor tissue and/or blood samples for biomarker research may be 
obtained at the investigator’s discretion in discussion with the patient, such as at the time 
of radiographic response or treatment progression .  If, at any time during the study, 
tumor tissue is obtained through a core biopsy, surgical biopsy, or resection as routine 
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 155
LY3022855 (IMC -CS4)ProcedureTreatment Cycle 3 and beyond Comments
Day 1 Day 8 Day 15 Day 22 Day 2 9 Day 3 6Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±3 days ,unless indicated 
otherw ise.
clinical care, the sponsor requests a tissue block or unstained slides for analysis of 
potentially relevant surrogate biomarkers.
Study Therapy Administration
Administer 
LY3022855 IMC-CS4
Weekly (on Days 1, 8, 15, 
22, 29, and 36)X X X X X X For patients being treated on Dosage C and who are clinically benefitting, after the 
completion of Cycle 3, the dosing interval may be changed to once -every -2-week dosing 
after discussion with the sponsor.  If a patient’s dosage is changed from that of Dosage C 
(that is, weekly) to every -2-week dosing and then the patient develops progressive 
disease , the patient’s dosage may then be changed back to weekly dosing if agreed upon 
by [CONTACT_86206].
Administer 
LY3022855 IMC-CS4 
Every  2 Weeks (on Days 
1, 15, and 29 )X X X
Administer 
LY3022855 IMC-CS4 on 
Weeks 1, 2, 4, and 5 (on 
Days 1, 8, 22, and 29 )X X X X
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; CT = 
computed tomography; EC G = electrocardiogram; ECOG PS= Eastern Cooperative Oncology Group performance status; IG = immunogenicity; MRI = magnetic resonance 
imaging; PET = positron emission tomography; PD=pharmacodynamic(s); PK =pharmacokinetic(s); SAE = serious adverse event; ULN = upper limit of normal; WO CBP = 
women of child -bearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 156
LY3022855 (IMC -CS4)Follow -upAssessments (for All Dosing Schedules)
Procedure 30-Day Follow -upComments
Except forthe C ycle 1, Day 1 visit, allowable visit windows are ±[ADDRESS_754048] is required for WOCBP.
ECG X In cases where ECG and blood sample collection are scheduled at the same time, all blood sampling should be 
performed prior to ECG assessment.
ECOG PS assessment X
Physical examination X Includes thoracic, abdominal, and symptom -directed examination.
Vital signs and weight measurement X Vital signs include temperature, pulse rate, respi[INVESTIGATOR_1487], and blood pressure.
Toxicity/AE assessment X All SAEs and LY3022855 IMC-CS4-related AEs will be followed until the event is resolved, stabilized, 
returned to baseline, deemed irreversible, or otherwise explained (frequency of follow -up evaluations is left to 
the discretion of the investigator).  Data on SAEs that occur bef ore the end of the trial will be stored in the 
collection database and the Lilly Safety System.
Concomitant medication assessment X
Laboratory Tests
Hematology X
Serum chemistry X
C-reactive protein assessment X
Urinalysis X If urine dipstick > 1+ for protein, obtain 24 -hour urine collection for protein analysis.
Serum and urine myoglobin X* *As clinically indicated, if serum CK ≥2.5 × ULN.
Blood sampling for PK, PD, IG Refer to Attachment 4 , 
Attachment 5, and 
Attachment 6.
Efficacy Assessments
Tumor core needle or surgical 
biopsyX Optional :  In cases of disease progression, if the patient’s condition allows it, an optional tumor biopsy will be 
performed, as clinically indicated (refer to Section [IP_ADDRESS]) .
Abbreviations:  β -hCG = beta human chorionic gonadotropin; AE = adverse event; CK = creatine kinase; CRP = clinical research physician; ECG =electrocardiogram; 
ECOG PS= Eastern Cooperative Oncology Group performance status; IG = immunogenicity; PD =pharmacodynamic(s); PK =pharmacokinetic(s); SAE = serious adverse 
event; ULN = upper limit of normal; WOCBP = women of child -bearing potential.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 157
LY3022855 (IMC -CS4)Attachment 2. Protocol JSCB Clinical Laboratory Tests
Clinical Laboratory Tests
Hematologya
Hemoglobin
Hematocrit
Platelet s
Leukocytes (WBC) ,including differential
Neutrophils –absolute and percentage
Lymphocy tes –absolute and percentage
Monocytes –absolute and percentage
Eosinophils –absolute and percentage
Basophils –absolute and percentageClinical Chemistrya(Serum Concentrations)
Sodium
Potassium
Chloride
Bicarbonate
Magnesium
Calcium
Phospho rus
Total bilirubin
Direct bilirubin
Alkaline phosphatase
Alanine aminotran sferase (ALT)
Aspartate aminotransfera se(AST)
Gamma glutamyl transpeptidase
Albumin
Total protein
Creatinine
Blood urea nitrogen (BUN)
Uric acid
Glucose (random)
Lipase
Amylase
Creatine kinase (CK)Coagulationa
Partial thromb oplastin time (PTT)
Prothrombin time (PT)/INR
Urinalysisa
Specific gravity
pH
Protein
Glucose
Ketones
Blood
Leukocyte esterase
Serum or Urine Pregnancy TestaCardiaca
Troponin I or T
Serologiesa
HIV screening
Viral hepatitis B and C screeningIsoenzymesb
Lactate dehydrogenase (LDH)
Creatine kinase (CK)
Alkaline phosphatase
Serum Markers of Bone Metabolismb
CTX -ISerum Markers of Inflammationa
C-reactive protein
Additional tests to be performed ,as clinically 
indicated , at a routine follow -up visita
Serum myoglobin –if CK ≥2.5 × ULN
Urine myoglobin –if CK ≥2.5 × ULNSerum Tumor Markers -as clinically indicateda
CEA
CA 15 -3
Abbreviation s:  CA 15 -3 = cancer antigen 15 -3; CEA = carcinoembryonic antigen; CK = creatine kinase; HIV = 
human immunodeficiency virus; PT/INR = International Normaliz ed Ratio of prothrombin time; ULN = upper 
limit of normal; WBC = white blood cells.
aLocal or investigator -designated laboratory .
bAssay ed by [CONTACT_11007] -designated laboratory .
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 158
LY3022855 (IMC -CS4)Attachment 4. Protocol JSCB Pharmacokinetic, Pharmacodynamic, and Immunogenicity Sample Schedule for Dosages A  
and B Only
Note:  All sampling indicated in Attachment [ADDRESS_754049] 
infusionDosing Day
Cycle 1, Day 1 
(C1D1) C1D2 C1D3Dosing 
Day
C1D8Dosing 
Day
C1D15Dosing 
Day
C1D22Dosing 
Day
C1D2 9Dosing 
Day
C1D3 6
Comments(≤14 days 
of C1D1)1 hr
(±6 
min)
EOI4 hr
(±24 
min)
EOI24 hr
(±2 h r
24 min)
EOI48 hr
(±5 hr
45 min)
EOIPredose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)Predose
(±25 h r)
Pharmacokinetics X X X X X X X X The date and the time of all 
sampling must be clearly and 
accurately recorded.
Immunogenicity X X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X X PD #1= CSF-1, IL -34
PD #2 - MSKCC lab X X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X X PD #4= MSD assay for IFN -γ, 
IL-1β, IL- 2, IL -4, IL -6, IL -8, 
IL-10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X X X X FC #2= Live-Dead, CD3, CD4, 
CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and 
ICOS
Isoenzymes -Central lab X X X X X X X AP isoenzymes, total CK, CK 
isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X X X CTX -I
Troponin I or T -MSKCC 
labX X X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 159
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing 
Day
C2D1Dosing Day
C3D1 C3D2 C3D3Dosing 
Day
C3D8Dosing 
Day
C3D22
CommentsPredose
(±25 h r)Predose
(±25 h r)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 h r
24 min)
EOI48 hr
(±5 hr
45 min)
EOIPredose
(±25 h r)Predose
(±25 h r)
Pharmacokinetics X X X X X X X X The date and the time of all sampling must be 
clearly and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4= MSD assay f orIFN-γ, IL-1β, IL- 2, IL -4, 
IL-6, IL -8, IL-10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, 
Ki-67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X AP isoenzymes, total CK, CK isoenzymes, total 
LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 160
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±25 h r)
Pharmacokinetics X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *T o be done at this time point and every [ADDRESS_754050] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X PD #1= CSF-1, IL-34
PD #4 -MSKCC lab X PD #4= MSD assay f orIFN-γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cy tometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a pat ient experiences an infusion -related reaction to LY3022855 IMC-CS4, all attempts will be made to obtain a blood sample for immunogenicity analysis as 
close to the onset of the event as possible, at the resolution of the event, and 30 days following the even t.  A portion of the sample taken for immunogenicity testing may be 
used for PK analysis, in the setting of infusion -related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 161
LY3022855 (IMC -CS4)Pharmacokinetic, Pharmacodynamic, and Immunogenicity Blood Sampling Schedule for Every -2-Week Dosing
AnalysesPrior to
the first 
infusionDosing Day
Cycle 1, Day1 (C1D1) C1D2 C1D3 C1D4 C1D8
Comments(≤14 days 
of C1D1)1 hr
(±6 min)
EOI4 hr
(±24min)
EOI24 hr
(±2 hr
24min)
EOI48 hr
(±5 hr
45 min)
EOI72 hr
(±8 hr
64 min)
EOI168 hr
(±25 h r)
EOI
Pharmacokinetics X X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X X X PD #2=CBC with differential
PD #3 -MSKCC lab X X X PD #3=ALT, AST
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, 
IL-8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -
67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 162
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C1D15Dosing Day
C1D29 C1D30 C1D31 C1D32 C1D36
CommentsPredose
(±50 hr)Predose
(±50 hr)24 hr
(±2 hr
24 min)
EOI48 hr
(±5 hr
45 min)
EOI72 hr
(±8 hr
64 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X X PD #2=CBC with differential
PD #3 -MSKCC lab X* X X X PD #3=ALT, AST
* For this time point, a separate sample should not be 
collected for PD #3 assessment .  Use the serum 
chemistry sample (Attachment 1) taken at this time 
point for the PD #3 assessment.
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, 
IL-8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, 
Ki-67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 163
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C2D1Dosing Day
C3D1 C3D2 C3D3 C3D8
Comments Predose Predose1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2hr
24 min)
EOI48 hr
(±5 hr
45 min)
EOI 168hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, 
IL-8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -
67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
Troponin I or T -MSKCC 
labX
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 164
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C3D15Dosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±50 hr)Predose
(±50 hr)
Pharmacokinetics X X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *T o be done at this time point and every [ADDRESS_754051] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, 
TNFα
Flow cytometry
FC #1 -Central lab X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, 
and ICOS
Isoenzymes -Central lab X AP i soenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cy tometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a pat ient experiences an infusion -related reaction to LY3022855 IMC-CS4, all attempts will be made to obtain a blood sample for immunogenicity analysis as 
close to the onset of the event as possible, at the resolution of the event, and 30 days following the even t.  A portion of the sample taken for immunogenicity testing may be 
used for PK analysis, in the setting of infusion -related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 165
LY3022855 (IMC -CS4)Pharmacokinetic, Pharmacodynamic, and Immunogenicity Blood Sampling Schedule for Weeks 1, 2, 4, and [ADDRESS_754052] 
infusionDosing Day
Cycle 1, Day1 
(C1D1) C1D2 C1D3Dosing Day
C1D8 C1D15
Comments(≤14 days 
of C1D1)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 hr
24 min)
EOI48 hr
(± 5 hr
45 min)
EOIPredose
(±25 hr)1 hr
(±6 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X X X The date and the time of all sampling must be 
clearly and accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1=CSF- 1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X* PD #3=ALT, AST
* For this time point, a separate sample should 
not be collected for PD #3 assessment.  Use 
the serum chemistry sample (Attachment 1)
taken at this time point for the PD #3 
assessment.
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, 
IL-4, IL -6, IL -8, IL -10, IL -12p70, IL -13, 
TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, 
PD-1, Ki -67, CTLA -4, TIM -3, LAG -3, and 
ICOS
Isoenzymes -Central lab X X X X AP i soenzymes, total CK, CK isoenzymes, 
total LDH, LDH isoenzymes
Bone marker -Central lab X X CTX -I
Troponin I or T -MSKCC 
labX
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 166
LY3022855 (IMC -CS4)Week s1, 2, 4, and 5 Schedule (continued)
AnalysesDosing 
Day
C1D22Dosing 
Day
C1D29Dosing 
Day
C2D1Dosing Day
C3D1 C3D3
CommentsPredose
(±50 hr)Predose
(±25 hr)Predose
(±50 hr)Predose
(±50 hr)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI48 hr
(±5 hr
45 min)
EOI
Pharmacokinetics X X X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X X PD #1= CSF-1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #4 -MSKCC lab X X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, 
IL-10, IL -12p70, IL-13, TNFα
Flow cytometry
FC #1 -Central lab X X X X X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X X AP isoenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 167
LY3022855 (IMC -CS4)Week s1, 2, 4, and 5 Schedule (continued)
AnalysesDosing Day
C3D8 C3D15Dosing Day
C3D22Dosing Day
C5D1Dosing Day
C5D29
CommentsPredose
(±25 hr)1 hr
(±6 min)
EOI168hr
(±25 hr)
EOIPredose
(±50 hr)Predose
(±50 hr)Predose
(±25 hr)
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X* *To be done at this time point and every [ADDRESS_754053] dose .
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X X PD #4= MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, 
IL-6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X X X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, 
Ki-67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X AP isoenzymes, total CK, CK isoenzymes, total 
LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 168
LY3022855 (IMC -CS4)Week s1, 2, 4, and 5 Schedule (continued)
AnalysesDosing Day
C6D29
30-Day Follow -up
(±7 days) CommentsPredose
(±25 hr)
Pharmacokinetics X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X PD #1= CSF-1, IL -34
PD #4 -MSKCC lab X X PD #4= MSD assay for IFN -γ, IL-1β, IL-2, IL-4, IL -6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1= CD14, CD16
FC #2 -MSKCC lab X FC #2= Live-Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, and 
ICOS
Isoenzymes -Central lab X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X* *Only obtain for patients with cardiac symptoms .
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count ; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cy tometry; IFN = interferon; IL = interleukin; L DH= lactate dehydrogenase; 
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a pat ient experiences an infusion -related reaction to LY3022855 IMC-CS4, all attempts will be made to obtain a blood sample for immunogenicity analysis as 
close to the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be 
used for PK analysis, in the setting of infusion -related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 169
LY3022855 (IMC -CS4)Attachment 5. Protocol JSCB Pharmacokinetic, Pharmacodynamic, and Immunogenicity Sampling Schedule for Dosage C 
Only
Note: All sampling indicated in Attachment [ADDRESS_754054] 
infusionDosing Day
Cycle 1, Day 1 
(C1D1) C1D2Dosing 
Day
C1D8Dosing 
Day
C1D15Dosing 
Day
C1D22Dosing 
Day
C1D29Dosing 
Day
C1D36
Comments(≤14 days 
of C1D1)1 hr
(±6 
min)
EOI4 hr
(±24 
min)
EOI24 hr
(±2 hr
24 min)
EOIPredose
(±25 hr)Predose
(±25 hr)Predose
(±25 hr)Predose
(±25 hr)Predose
(±25 hr)
Pharmacokinetics X X X X X X X X The date and the time of all 
sampling must be clearly and 
accurately recorded.
Immunogenicity X X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X X PD #1=CSF- 1, IL -34
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X X PD #4=MSD assay for IFN -γ, IL-
1β, IL -2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1=CD14, CD16
FC #2 -MSKCC lab X X X X X X FC #2=Live -Dead, CD3, CD4, 
CD8, FoxP3, PD -1, Ki -67, CTLA -
4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X X X X AP isoenzymes, total CK, CK 
isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 170
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing 
Day
C2D1Dosing Day
C3D1 C3D2Dosing 
Day
C3D8Dosing 
Day
C3D22
CommentsPredose
(±25 hr)Predose
(±25 hr)1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 hr
24 min)
EOIPredose
(±25 hr)Predose
(±25 hr)
Pharmacokinetics X X X X X X X The date and the time of all sampling must be clearly 
and accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1=CSF- 1, IL -34
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4=MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, 
IL-8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X X FC #1=CD14, CD16
FC #2 -MSKCC lab X FC #2=Live -Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -
67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X AP isoenzymes, total CK, CK isoenzymes, total LDH, 
LDH isoenzymes
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 171
LY3022855 (IMC -CS4)Weekly Schedule (continued)
AnalysesDosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±25 hr)
Pharmacokinetics X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *To be done at this time point and every [ADDRESS_754055] dose.
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X PD #1=CSF- 1, IL -34
PD #4 -MSKCC lab X PD #4=MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X FC #1=CD14, CD16
FC #2 -MSKCC lab X FC #2=Live -Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X* *Only obtain for patients with cardiac symptoms.
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cytometry; IFN = interferon; IL = interleukin; L DH = lactate dehydrogenase;
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan K ettering Cancer Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a patient experiences an infusion -related reaction to LY3022855 IMC-CS4, all attempts will be made to obtain a blood sample for immunogenicity analysis as 
close to the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be 
used for PK analysis, in the setting of infusion -related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 172
LY3022855 (IMC -CS4)Attachment 6. Protocol JSCB Pharmacokinetic, Pharmacodynamic, and Immunogenicity Sampling Schedule for Dosage D 
Only
Note:  All sampling indicated in Attachment [ADDRESS_754056] 
infusionDosing Day
Cycle 1, Day1 (C1D1) C1D2 C1D8
Comments(≤14 days 
of C1D1)1hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 hr
24 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1=CSF- 1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X PD #4=MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, 
IL-12p70, IL-13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1=CD14, CD16
FC #2 -MSKCC lab X X FC #2=Live -Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -
4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 173
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C1D15Dosing Day
C1D29 C1D30 C1D36
CommentsPredose
(±50 hr)Predose
(±50 hr)24 hr
(±2 hr
24 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X PD #1=CSF -1, IL -34
PD #2 -MSKCC lab X PD #2=CBC with differential
PD #3 -MSKCC lab X* X PD #3=ALT, AST
* For this time point, a separate sample should not be collected 
for PD #3 assessment.  Use the serum chemistry sample 
(Attachment 1) taken at this time point for the PD #3 assessment.
PD #4 -MSKCC lab X X PD #4=MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -
10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1=CD14, CD16
FC #2 -MSKCC lab X X X FC #2=Live -Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 174
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C2D1Dosing Day
C3D1 C3D2 C3D8
Comments Predose Predose1 hr
(±6 min)
EOI4 hr
(±24 min)
EOI24 hr
(±2 hr
24 min)
EOI168 hr
(±25 hr)
EOI
Pharmacokinetics X X X X X X The date and the time of all sampling must be clearly and 
accurately recorded.
Immunogenicity X See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X X X PD #1=CSF- 1, IL -34
PD #2 -MSKCC lab X X PD #2=CBC with differential
PD #3 -MSKCC lab X PD #3=ALT, AST
PD #4 -MSKCC lab X X X PD #4=MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, 
IL-10, IL -12p70, IL -13, TNFα
Flow cytometry
FC #1 -Central lab X X X FC #1=CD14, CD16
FC #2 -MSKCC lab X X X FC #2=Live -Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki-67, 
CTLA -4, TIM -3, LAG -3, and ICOS
Isoenzymes -Central lab X X X X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH 
isoenzymes
Troponin I or T -MSKCC lab X
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 175
LY3022855 (IMC -CS4)Every -2-Week Schedule (continued)
AnalysesDosing Day
C3D15Dosing Day
C5D1
30-Day Follow -up
(±7 days) CommentsPredose
(±50 hr)Predose
(±50 hr)
Pharmacokinetics X X X The date and the time of all sampling must be clearly and accurately recorded.
Immunogenicity X* X *To be done at this time point and every [ADDRESS_754057] dose.
See Note at end of table.
Pharmacodynamics
PD #1 -Central lab X X PD #1=CSF- 1, IL -34
PD #4 -MSKCC lab X X PD #4=MSD assay for IFN -γ, IL-1β, IL- 2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13, 
TNFα
Flow cytometry
FC #1 -Central lab X X FC #1=CD14, CD16
FC #2 -MSKCC lab X X FC #2=Live -Dead, CD3, CD4, CD8, FoxP3, PD -1, Ki -67, CTLA -4, TIM -3, LAG -3, 
and ICOS
Isoenzymes -Central lab X AP isoenzymes, total CK, CK isoenzymes, total LDH, LDH isoenzymes
Bone marker -Central lab X CTX -I
Troponin I or T -MSKCC 
labX* *Only obtain for patients with cardiac symptoms.
Abbreviations:  ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; C = cycle; CBC = complete blood count; CK = creatine kinase; 
CSF-1 = colony -stimulating factor -1; D = day; EOI = post end of infusion; FC = flow cytometry; IFN = interferon; IL = interleukin; L DH = lactate dehydrogenase;
MSD =Meso Scale Discovery; MSKCC =Memorial Sloan Kettering Cance r Center; PD = pharmacodynamic(s); PK = pharmacokinetic(s); TNF = tumor necrosis factor.
Note:  If at any time a patient experiences an infusion -related reaction to LY3022855 , all attempts will be made to obtain a blood sample for immunogenicity analysis a s close to 
the onset of the event as possible, at the resolution of the event, and 30 days following the event.  A portion of the sample taken for immunogenicity testing may be used for PK 
analysis, in the setting of infusion- related reactions.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 176
LY3022855 (IMC -CS4)Attachment 9. Protocol JSCB Sampling Summary
The fo llowing 3 tabl es summarize the maximum number of samples (venipunctures, tissue 
biopsies), volumes for all sampling, and te sts (study qualificat ion, health mo nitoring, 
pharmacodynamics, drug concentration, tailoring bio markers, and immunogenicit y) during the
study  for each of the dosing schedules.  Estimates are provided; more samples could be required 
in the case of retests, addit ional healt h monitoring (if needed), or for patients continuing 
treatm ent bey ond the protocol -specified number of cy cles in the study .  Fewer samples may  
actually be taken (for example, patients who discont inue from the study ).
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 177
LY3022855 (IMC -CS4)Protocol JSCB Sampling Summary -Weekly Dosing Schedule (includes samples for 
Cycle 1 [only] and 30 -Day Follow -up)
PurposeSample 
TypeMaximum Amount 
per SampleMaximum 
Number SamplesMaximum Total 
Amount
Study qualification, which 
includes the following:aBlood
CBC 2 mL 1 2 mL
Chemistries 7.5 mL 1 7.5 mL
Coagulation 1.8 mL 1 1.8 mL
Health monitoring (may be more 
than 1 tube), which includes the 
following:bBlood
CBC 2 mL 7 14 mL
Chemistries 7.5 mL 7 52.5 mL
Troponin 2 mL 4 8 mL
Coagulation 1.8 mL 1 1.8 mL
Pharmacodynamics Tissue 
biopsyVaries, 5 -10 mm Up to 12 cores 120 mm
Drug concentration (PK) Blood 3 mL 9 27 mL
Tailoring biomarkers Blood 10 mL 1 10 mL
Immunogenicity Blood 10 mL 4 40 mL
Biomarkers, which includes the 
following:Blood
Cytokine analy sis 6 mL 11 66 mL
Flow cytometry 8 mL 12 96 mL
Bone markers of 
metabolism3.5 mL 4 14 mL
Isoenzy mes 5 mL + 3.5 mL 8 + [ADDRESS_754058]/ALT –MSKCC 
lab5 mL 1 5 mL
CBC –MSKCC lab 2 mL 3 6 mL
Total
[for each tissue sample type, 
rounded to nearest 10 mm]Blood
Tissue83
Up to 12 cores422 mL
120 mm
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; 
MSKCC = Memorial Sloan Kettering Cancer Center; PK = pharmacokinetic(s).
aAdditional samples may be drawn if needed for safety purposes.
bBased on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow -up, in consultation with the designated medical moni tor.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 1 78
LY3022855 (IMC -CS4)Protocol JSCB Sampling Summary –Every -2-Week Dosing Schedule (includes samples 
for Cycle 1 [only] and 30 -Day Follow -up)
PurposeSample 
TypeMaximum Amount 
per SampleMaximum 
Number SamplesMaximum Total 
Amount
Study qualification, which 
includes the following:aBlood
CBC 2 mL 1 2 mL
Chemistries 7.5 mL 1 7.5 mL
Coagulation 1.8 mL 1 1.8 mL
Health Monitoring (may be 
more than 1 tube), which 
includes the following:bBlood
CBC 2 mL 7 14 mL
Chemistries 7.5 mL 7 52.5 mL
Troponin 2 mL 3 6 mL
Coagulation 1.8 mL 1 1.8 mL
Pharmacodynamics Tissue 
biopsyVaries, 5 -10 mm Up to 12 cores 120 mm
Drug concentration (PK) Blood 3 mL 14 42 mL
Tailoring biomarkers Blood 10 mL 1 10 mL
Immunogenicity 10 mL 4 40 mL
Biomarkers, which includes the 
following:Blood
Cytokine analy sis 6 mL 12 72 mL
Flow cytometry 8 mL 13 104 mL
Bone markers of 
metabolism3.5 mL 3 10.5 mL
Isoenzy mes 5 mL + 3.5 mL 8 + [ADDRESS_754059]/ALT –MSKCC 
lab5 mL 7 35 mL
CBC –MSKCC lab 2 mL 8 16 mL
Total
[for each tissue sample type, 
rounded to nearest 10 mm]Blood
Tissue99
Up to 12 cores482 mL
120 mm
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; 
MSKCC = Memorial Sloan Kettering Cancer Center; PK = pharmacokinetic(s).
aAdditional samples may be drawn if needed for safety purposes.
bBased on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow -up, in consultation with the designated medical monitor.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 179
LY3022855 (IMC -CS4)Protocol JSCB Sampling Summary -Weeks 1, 2, 4, and 5 Dosing Schedule (includes 
samples for Cycle 1 [only] and 30 -Day Follow -up)
PurposeSample 
TypeMaximum Amount 
per SampleMaximum 
Number SamplesMaximu m Total 
Amount
Study qualification, which 
includes the following:aBlood
CBC 2 mL 1 2 mL
Chemistries 7.5 mL 1 7.5 mL
Coagulation 1.8 mL 1 1.8 mL
Health Monitoring (may be 
more than 1 tube), which 
includes the following:bBlood
CBC 2 mL 7 14 mL
Chemistries 7.5 mL 7 52.5 mL
Troponin 2 mL 3 6 mL
Coagulation 1.8 mL 1 1.8 mL
Pharmacodynamics Tissue 
biopsyVaries, 5 -10 mm Up to 12 cores 120 mm
Drug concentration (PK) Blood 3 mL 11 33 mL
Tailoring biomarkers Blood 10 mL 1 10 mL
Immunogenicity 10 mL 4 40 mL
Biomarkers, which includes the 
following:Blood
Cytokine analy sis 6 mL 12 72 mL
Flow cytometry 8 mL 12 96 mL
Bone markers of 
metabolism3.5 mL 4 14 mL
Isoenzy mes 3.5 mL + 5 mL 7 + 7 59.5 mL
CBC –MSKCC lab 2 mL 2 4 mL
Total
[for each tissue sample type, 
rounded to nearest 10 mm]Blood
Tissue81
Up to 12 cores412 mL
120 mm
Abbreviations:  CBC = complete blood count; MSKCC = Memorial Sloan Kettering Cancer Center; PK = 
pharmacokinetic(s).
aAdditional samples may be drawn if needed for safety purposes.
bBased on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow -up, in consultation with the designated medical monitor.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 180
LY3022855 (IMC -CS4)Attachment 10. Protocol JSCB Guidelines for the Management of Immune -Related A dverse Events
Guidelines for the Management of Potential Toxicities Encountered with Immuno -Oncology Agents
System Organ Clas sAdverse EventCTCAE, Version 4.0 Grade (if 
applicable) and/or Symptomsa
Treatment PlanbGrade Symptoms
Endocrine Thyr oid issues Asymptomatic, with TSH 
<0.5 × LLN or >2 × ULNContinue drug and include free T4 in subsequent cycles.
Symptomatic Continue drug.  Administer thyroid replacement.
Hypotension, altered 
mental status, headache, 
fatigueEndocrine issues aside from 
thyroid (for example, 
hypophysitis, diabetes 
mellitus)Withhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).
Resume drug when symptoms resolve and are stable on hormone 
replacement.  In case of adrenal crisis, administer stress -dose steroids.
Permanently discontinue for Grade 3 or 4.
Gastrointestinal Diarrhea, abdominal pain, 
blood in stool2 Withhold drug for 1 wk.  Administer antidiarrheal medication and check 
etiology.
Resume drug when symptoms resolve to Grade 1.  If >5 days’ duration 
despi[INVESTIGATOR_235204], begin steroids (0.5 mg/kg/d prednisone); can resume 
drug during taper when symptoms resolve to Gra de 1.
Diarrhea, ileus, perforation ≥3 Withhold drug and administer 1 -2 mg/kg/day prednisone (no steroids if 
possible perforation); discontinue drug if Grade 3 persists or Grade 4.
If >3 days despi[INVESTIGATOR_397713], add nonsteroid immunosuppressive.
Symptomatic pancreatitis 1 or 2 Withhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Can 
resume drug during taper.
≥3 Permanently discontinue drug.  Administer steroids (1 -2 mg/kg/d 
prednisone).  Can resume drug during taper.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 181
LY3022855 (IMC -CS4)System Organ Clas sAdverse EventCTCAE, Version 4.0 Grade (if 
applicable) and/or Symptomsa
Treatment PlanbGrade Symptoms
Hepatobiliary Liver abnormality AST or ALT >5 × ULN but 
≤20 × ULN
AND
total bilirubin ≤ULNDiscuss with sponsor and consider continuing protocol treatment provided 
patient remains without other evidence of liver toxicity.
AST or ALT >20 × ULN
AND
total bilirubin ≤ULNDiscuss with sponsor and consider holding protocol treatment until 
AST/ALT becomes ≤20 × ULN.
AST or ALT >5 × ULN
AND
total bilirubin >ULNWithhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Consider 
resuming protocol treatment once total bilirubin ≤ULN.
Discontinue protocol therapy permanently if bilirubin does not return to 
below the ULN within 3 wk of holding drug.
3 or 4 GGT or alkaline phosphatase Continue protocol treatment provided patient remains without other 
evidence of liver toxicity.
Musculoskeletal Muscle abnormality CK >2.5 × but ≤[ADDRESS_754060]
AND
Serum and urine myoglobin 
≤ULNDiscuss with sponsor and consider continuing protocol treatment provided 
patient remains without other evidence of muscle or renal toxicity.
CK ≥2.5 × ULN
AND
Serum and urine myoglobin 
>ULNWithhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Consider 
resuming protocol treatment once serum and urine myoglobin ≤ULN.
Discontinue protocol therapy permanently if serum and urine myoglobin 
does not return to below the ULN within 3 wk of holding drug.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 182
LY3022855 (IMC -CS4)System Organ Clas sAdverse EventCTCAE, Version 4.0 Grade (if 
applicable) and/or Symptomsa
Treatment PlanbGrade Symptoms
Nervous Weakness, paresthesia (for 
example, Guillain -Barré 
syndrome, my asthenia 
gravis)No impact on activities of 
daily  living (ADL)Withhold drug.  Resume drug when symptoms resolve.
Impact on ADL Withhold drug.  Administer appropriate medical intervention and steroids 
(1-2 mg/kg/d prednisone).  Can resume drug during taper and after 
discussion with ponsor.
Respi[INVESTIGATOR_574418], hy poxia, 
pneumonitis1 Consider to withhold drug.  Resume drug when stable.
2 Mild to moderate symptoms Withhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).  Can 
resume drug during taper.
≥3 Severe Permanently discontinue drug.  Administer steroids (1 -2 mg/kg/d 
prednisone).
If >2 days despi[INVESTIGATOR_397713], add nonsteroid immunosuppressive.
Renal and urinary Elevated creatinine, 
decreased urine output, 
blood in urine, edema1 <1.5 × baseline Continue drug.
2 to 3 >1.5 × ULN but <6 × ULN
OR
>1.5 × baselineWithhold drug.  Administer steroids (1 -2 mg/kg/d prednisone).If 
symptoms resolve to Grade ≤1, taper steroids over [ADDRESS_754061] >7 days or worsen treat with Grade 4 
recommendations .
4 >6 × ULN Permanently discontinue drug.  Administer steroids (1 -2 mg/kg/d 
prednisone).
Skin Rash, pruritus ≤50% skin affected Withhold drug. Start supportive medications for pruritus, for example, 
hydroxyzine/loratadine.  If symptoms persist or worsen after 1 wk, 
administer topi[INVESTIGATOR_143806]. Resume drug if rash improves to 
mild (localized) and steroid dose <7.5 mg.
Stevens -Johnson syndrome, 
toxic epi[INVESTIGATOR_194], 
necrosis, bullous or 
hemorrhagic lesionsPermanently discontinue drug.  Begin steroids (1 -2 mg/kg/d prednisone).
Abbreviations:  ADL = activities of daily living; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = C ommon Terminology Criteria 
for Adverse Events; I.V. = intravenous(ly); LLN = lower limit of normal; TSH = thyroid -stimulating hormone; ULN = upper limit of normal.
aIf definition of grade not specified, use CTCAE, Version 4.0 definition.
bTreatment plan should always include a thorough workup of the issue to rule out other potential etiologies.
I5F-MC-JSCB(d) Phase 1 Oncology Protocol Page 183
LY3022855 (IMC -CS4)Note:  Other steroid options can be given at equivalent doses.  For severe cases, recommend using IV steroids.  For adrenal c risis, mineralocorticoid also needs to 
be added to stress -dose IV steroids.  Also, steroids should be tapered over 1 month once sy mptoms improve to grade 1, and drug should not be restarted 
until taper over at least 1 month complete.  During steroid use, add prophylactic antibiotics for opportunistic infections.  Immunosuppressive refers to 
infliximab or cyclophosphamide.
[COMPANY_003]Leo Document ID = cd5adb38-4e12-4a02-8f9c-f35bbfa08c95
Approver:
Approval Date & Time: 09-Nov-2016 19:55:44 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 10-Nov-2016 15:51:11 GMT
Signature [CONTACT_32869]: Approved[COMPANY_003]